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Abstract 
Abdolati Ali Mohamed Alwati 
Ultrasound Assisted Processing of Solid State of Pharmaceuticals 
The application of ultrasonic energy in novel solid state pharmaceutical 
applications, including solvent free co-crystallisation and enhanced 
compressibility 
Key words: Co-crystallisation, High power ultrasound, Ultrasonic energy, 
ultrasound, Tabletability, Solvent-Free ultrasound.  
The objective of this study was to develop a new method for co-crystal 
preparation which adhered to green chemistry principles, and provided 
advantages over conventional methods. A novel, solvent-free, high-power 
ultrasound (US) technique, for preparing co-crystals from binary systems, 
was chosen as the technology which could fulfil these aims. The application 
of this technology for solid state co-crystal preparation was explored for 
ibuprofen-nicotinamide (IBU-NIC), carbamazepine-nicotinamide (CBZ-NIC) 
and carbamazepine-saccharin (CBZ-SAC) co-crystals. The effect of different 
additives and processing parameters such as power level, temperature and 
sonication time on co-crystallisation was investigated. Characterisation was 
carried out using DSC, PXRD, FTIR, Raman and HPLC. 
In addition, an NIR prediction model was developed and combined with 
multivariate analysis (PLS) and chemometric pre-treatments. It was found to 
be a robust, reliable and rapid method for the determination of co-crystal 
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purity for the IBU-NIC and CBZ-NIC pairs. Co-crystal quantification of US 
samples helped to optimise the US method. 
Finally, a model formulation of paracetamol containing 5% and 10% PEG 
8000 was ultrasonicated at maximum power with different exposure times. A 
comparison of technological and physicochemical properties of the resulting 
tablets with those of the tablets obtained using the pressing method 
evidenced significant differences. This suggested that US energy dissipation 
(mechanical and thermal effects) was the main mechanism which caused the 
PAR form I tabletability to improve. It was found that the ultrasound–
compacted tablets released the drug at a slower rate compared to pure PAR. 
This technique was shown to be useful for improving tabletability for low-
compressible drugs without the need to use a conventional tabletting 
machine. 
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CHAPTER 1 INTRODUCTION 
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1.1 General introduction 
 
According to the physical state, pharmaceutical scientists have classified 
pharmaceutical dosage forms into solids, semi solids, liquids and gaseous 
phases. Most active pharmaceutical ingredients appear in solid state form. 
Based on the order of molecular packing, the solid phase has been classified 
into:  crystalline solids which represent the most types of solids, where there 
is a regular structure that extends among the crystal and amorphous solids 
which lack distinct crystalline structure. Crystalline solids can be further 
subdivided (as shown in figure 1.1) into polymorphs, which represent 
different forms of the same molecules and multi components which consist of 
more than one type of molecules such as salts, hydrates, solvates and co-
crystals (Florence and Attwood 2011).  
 
Figure 1.1 Classifications of solids 
Many active pharmaceutical ingredients (APIs) possess poor pharmaceutical 
properties such as solubility, dissolution rate, thermal stability and 
bioavailability. This explains why less than 1% of active pharmaceutical 
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compounds appear in the market place                          . 2009; 
Ramanathan 2011). Currently inside pharmaceutical fields, co-crystallisation 
is recognised as an important technique for preparing crystalline compounds 
as an alternative to salts and polymorphs. Co-crystallisation provides an 
opportunity to improve the physico-chemical properties of an API which can 
have a significant importance in clinical applications. Many case studies have 
been reported and shown to improve solubility (Blagden et al. 2007), intrinsic 
dissolution (Lee et al. 2011), stability (Basavoju et al. 2008) and 
bioavailability (Jung et al. 2010) .  
Interest in the improvement and alteration of the physico-chemical properties 
of an API using co-crystallisation techniques has grown. Therefore 
developing and inventing suitable methods for co-crystal preparation has 
become popular. Various techniques for co-crystallisation have been used. 
Such techniques involve solvent based co-crystallisation approaches such as 
solution crystallisation (evaporation, cooling, anti-solvent), slurry 
crystallisation, sonic crystallisation, and solid based co-crystallisation 
techniques such as thermal melt based crystallisation (DSC, hot stage 
microscopy, microwave) and mechanochemical based crystallisation (neat 
grinding, solvent drop grinding). Although solution based approaches such 
as evaporation have been well studied and appear as a conventional method 
used for co-crystallisation preparation, there are some draw backs such as a 
lack of scalability (Mundhe 2013), crystallisation of individual components 
making it difficult to prepare a pure co-crystal and also requiring a large 
amount of solvent (non-green process).  
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Since the last decade, pharmaceutical scientists have focused on co-
crystallisation approaches, which are scalable, efficient, green, continuous 
and not using an external energy source. Solid state based co-crystallisation 
techniques have become more efficient and are the most established 
techniques for co-crystal formation. These include neat grinding and solvent 
drop grinding which offer  enormous capability to prepare co-crystals and 
bring compensation in regard to high yields (Bowmaker 2013). Recently our 
group has submitted a patent for solvent free continuous co-crystallisation 
(SFCC) using twin screw hot melt extrusion (Dhumal et al. 2010b). This 
technique has been successfully used for preparation of ibuprofen- 
nicotinamide co-crystals. SFCC has produced simultaneous agglomerated 
co-crystals in one step which has offered an improvement in tabletting 
properties, in addition it can decrease downstream processing and avoid 
polymorphic change to which may occur during this operation. 
Ultrasound can be defined as mechanical waves at a frequency above the 
human hearing limit. Depending on its frequency or power, ultrasound can be 
classified into 1) high frequency, low power ultrasound, 2) Low frequency, 
high power. Generally, the principal use of ultrasonic technology in industrial 
processes requires two main requests; a medium (generally liquid) and a 
vibrational energy source (transducer), which can both amplify and transfer 
vibration sound to the so-called probe or sonotrode, which is in direct contact 
with processing medium (Patist and Bates 2008).  
Recently, ultrasonic processing technology has been explored widely, 
particularly in the industrial and relevant sectors such as food industry, 
environmental, pharmaceutical and chemicals manufacturing where it may 
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exhibit an efficient, clean and green tool to improve the conventional existing 
processes.  
 In comparison with the solvent cooling and slurry sonication methods, 
Ultrasound assisted co-crystallisation from solution was succeeded in the 
preparation of non-congruently soluble co-crystal component pairs Caffeine- 
maleic acid at different molar ratios. The product resulted from solvent 
cooling and slurry sonication of mixtures of caffeine/maleic acid 2:1 co-
crystal where application of ultrasound can induce simultaneous 
supersaturation of co-crystal components in solution and produce a pure 
caffeine-maleic acid 2:1 co-crystal (Aher et al. 2010). Carbamazepine (CBZ)- 
Saccharin (SAC) co-crystals presented in two forms form I and form II, a high 
power ultrasound  with anti-solvent co-crystallisation approach appeared to 
control the polymorphism of CBZ-SAC co-crystals (Lee et al. 2015).    
In this study exploration and investigation the use of high power ultrasound 
to prepare co-crystals in the solid state. This approach has never been used 
to synthesise co-crystals i.e. all co-crystal approaches reported previously 
using a high power ultrasound were synthesised in the solution state. The 
major focus of this technology involves exploration of an alternative energy 
source and green approaches for co-crystallisation process. The present 
approach delivers a new method of developing and screening of ibuprofen, 
carbamazepine and carbamazepine dihydrate with using nicotinamide and 
saccharin as coformers.  
In the recent years, significant progress has been made to investigate the in- 
situ formation of co-crystals in a single scalable, free solvent step using a 
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melt extrusion technology. In this method, processing temperature should be 
selected close to or above the eutectic temperature of the selected co-crystal 
pairs that used for synthesis of co-crystals (Dhumal et al. 2010b; Daurio et al. 
2011; Liu et al. 2012). In 2010, Dhumal, et al found that when IBU-NIC 1:1 
was extruded at temperatures above the eutectic temperature (80°C and 
90°C) a high co-crystal purity could be obtained. Many challenges faced this 
method such as thermal degradation of high sensitive drugs. Therefore one 
of our aims in this study was to depress the processing temperature during 
the use of solvent- free ultrasonic co-crystallisation. For example use of room 
temperature as processing temperature.      
Quantification is of great importance to determine the yield of co-
crystallisation processes and the purity of product obtained. Various 
analytical solid state techniques with a combination of multivariate calibration 
tools have been used for co-crystal quantification or prediction of co-crystal 
purity such as Powder X-Ray Diffraction (PXRD), Differential Scanning 
Calorimetry (DSC), Fourier Transform Infrared (FTIR) and Raman 
Spectroscopy (Soares and Carneiro 2014). There is a considerable interest 
in developing ways to reliable predict of co-crystal using a Near Infrared 
Spectroscopy (NIR) method. Previously NIR has been used only for 
qualitative and monitoring characterisation of co-crystals (Soares and 
Carneiro 2013). The aim of this work was to develop a new method for co-
crystal quantification using a Near Infrared Spectroscopy. Relying on the 
results of this method, it can be used to optimise the processing conditions of 
screening co-crystals in solid state using the invented solvent-free ultrasound 
approach. 
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Tablets are one of the most solid dosage forms that are used widely among 
pharmaceutical dosage forms. they can be manufactured directed from the 
powder or granules using very complicated tablet press machines, but that 
material must have good compressibility to form a tablet (Mohan 2012). 
Pharmaceutical powders such as paracetamol form I and Ibuprofen 
experience plastic, elastic deformation and poor compressibility and these 
processes do not allow formation of tablet by direct compression. Poor 
compressibility can be overcome and tablets could be prepared by 
ultrasound assisted compaction (Levina et al. 2000), (Levina and Rubinstein 
2000) (Levina and Rubinstein 2002) (Fini et al. 2009).       
Another aspect, investigated in this work was the effect of ultrasound on 
poorly compressible materials such as paracetamol, whether it can form a 
good tabletability and compactability without using any compression force.  
1.2 Aims and objectives   
 
 Aims The aims of this PhD project were: 
 To overcome the challenges in the synthesis of co-crystals by 
developing a solvent-free ultrasonic technique.   
 Application of NIR for the quantification of co-crystals obtained by 
ultrasound approach.  
 To overcome the challenges in obtaining paracetamol tablet with the 
direct use of ultrasound equipment. 
 Objectives The objectives of current study were: 
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 To study the effect of variables and process parameters such as 
temperature and power rate on the product performance. 
 To study the effect of additives on ultrasound process performance in 
terms of energy propagation and temperature rise. 
 To investigate the reliability of developed NIR technique on the 
predictability and purity of the obtained co-crystal.   
 To investigate the effect and behaviour of ultrasound approach on the 
tablet properties such as dissolution, hardness, thickness, stability 
and degradation.  
 To investigate the effect of ultrasound energy on the obtained product 
in the aspect of degradation.        
1.3 Overview of thesis structure 
This thesis is organised into 9 chapters: 
Chapter 1 briefly describes the research background, aim, objectives and 
structures of the thesis.  
Chapter 2 provides an introduction to the basic principles of ultrasound, its 
mechanisms and applications. It further provides an introduction to co-
crystals as an alternative to other solid forms used in medicinal products with 
the enhancement in various physico-chemical properties of the active 
ingredient. It further explains various approaches used in the screening and 
development of these co-crystals and the challenges faced.  
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Chapter 3 briefly introduces all materials and experimental methods used. 
Method operation and development are described in detail. Characterisation 
techniques used are described in this chapter. 
Chapter 4 scrutinises the solvent-free ultrasound approach for the synthesis 
of IBU-NIC co-crystal, and its optimisation via varying different parameters 
such as processing temperature, power level, and sonication time. It 
develops an understanding of the effect of these variables on the quality of 
product by using different characterisation techniques. 
Chapter 5 explores the solvent-free approach for synthesis of CBZ-NIC co-
crystal at a processing temperature of 100°C, and different levels of applied 
power. In addition, it determines the synthesis of CBZ-NIC co-crystal at 
ambient temperature and 100% applied power level and the effect of addition 
of small amounts of water and CBZ DH on the obtained co-crystal. 
In chapter 6, the solvent-free ultrasound approach is examined for synthesis 
of CBZ-SAC form I co-crystals at ambient conditions and maximum power. 
The influence of water addition and PEG 8000 on the obtained CBZ-SAC 
form I co-crystals is also investigated.  
Chapter 7 deals with the direct use of ultrasound to assist paracetamol 
tabletability. It covers the influence of polymer addition and sonication time 
on the physical properties of paracetamol tablets.  
Chapter 8 presents a general discussion of the results presented in all 
chapters in relation to the aims and objectives.  
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Chapter 9 provides the conclusions drawn from the present work. 
Suggestions for further work in the area of use of ultrasound assisted solid 
state pharmaceuticals are also presented, followed by references and 
appendix.
  
 
 
 
 
 
 
 
CHAPTER 2 LITERATURE REVIEW AND 
BACKGROUND 
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This chapter includes an introduction to ultrasound, ultrasound principles, 
mechanisms and applications in pharmaceutical research and beyond the 
pharmaceutical field. Additionally, there is an introduction to co-crystals and 
a discussion on co-crystal definitions, screening and design, preparation 
methods and characterisation methods used. 
2.1 Ultrasound 
In recent years, there has been a growing demand for the application of 
ultrasound in many fields such as industrial and medical. This section 
provides an explanation and an overview of the basic characteristics of 
ultrasound. 
2.1.1 Basic principles of ultrasound 
Ultrasound is defined as sound waves with a frequency above the upper limit 
of human hearing. Sonic waves have frequencies ranging between 20-
20,000Hz (20 KHz), which correspond to the frequency range of the human 
hearing (table 1.1). Acoustic waves with frequencies above 20,000 Hz are 
ultrasonic, whereas waves with frequencies below 20 Hz are classified as 
infrasonic. Based on the frequency and power, acoustic sound waves can be 
classified as; 
Table 2.1 Classification of ultrasound based on frequency and power 
Type of Sound Frequency range Power 
Human Hearing (20 Hz—20 kHz) ----------------- 
High Power, low frequency ultrasound (20 kHz—100 kHz (10-1 ,    W cmˉ²) 
Low power, high frequency ultrasound (100 kHz—1 MHz)  < 1   Mw cmˉ²) 
Diagnostic ultrasound (1 MHz—10 MHz)  < 1   Mw cmˉ²) 
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Ultrasound waves have the ability to penetrate through any medium in a 
finite time as mechanical sound waves lead to vibration in any molecules, 
atoms or any medium as shown in the figure (2.1) where distortion is caused 
depending on whether a force is applied normal or parallel to the surface at 
one end the solid can resulting in producing compression or shear vibration 
respectively. There are two types of ultrasonic wave: Longitudinal (or 
Compression, dilatational, primary) waves, can be defined as waves in 
which particle motion is parallel direction of the wave propagation; 
Transverse (or shear, distortional, secondary) waves, can be defined as 
waves in which the particle motion is perpendicular to the direction of 
propagation through solid. Both waves can exist in in solid because solids 
have the rigidity that is a resistance to compressive load as well as shear, 
this property is absent in liquid and gases. However shear waves cannot be 
created in liquids and gases because of no resistance to shear in such 
media. The energy of wave is also carried with it (Saerens et al. 2014). 
 
Figure 2.1 Schematic diagrams of types of ultrasound waves (Sehmbi and Perlas 
2015)  
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 Sound is a wave caused by mechanical motion to the medium during travel 
through it. Also, the pressure vibration increases and density of medium 
decreases which leads particles within the medium to vibrate.  
 
Figure 2.2 Schematic diagram of ultrasound waves (Sehmbi and Perlas 2015) 
Properties and common characteristics of ultrasonic fields are 
explained in detail below: 
(1) Wavelength: is the length of space over which one cycle occurs, usually 
represented in millimetres (mm). Wavelength is dependent on propagation 
speed (velocity) and frequency as shown in equation 1 
W v    g h  λ) = V  ocity (V) / Frequency (F)                        (eq.1)  
Where V is wave speed (m/s) and F is frequency (Hz) 
(2) Propagation velocity of an ultrasound waves: an ultrasonic wave 
moves at a velocity (the wave velocity) that depends on the material 
properties, shape of the medium and frequency. When ultrasonic waves 
propagate through a material, it gives motion to particles. Particle motion is 
totally different from the wave motion. This particle mention is specified as 
particle velocity. Movement of sound waves through the medium is called 
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propagation and its velocity is measured in meters/second. As expressed in 
equation (1) and also in figure (2.1), the wave length and frequency are 
inversely proportional to each other. 
(3) Frequency: relates to the number of repeating events per unit time, 
which means the number of cycles that occur in one second and is 
measured in Hertz (1Hz=1/s). Frequency is one of the most essential 
parameters in ultrasound field because of its impact on resolution and its 
associated relation with the wave length, frequency is inversely related to the 
w v     g h  λ),  s  h  f  qu  c    c   s s  h  w v     g h d c   s s. 
(4) Period: the period of the wave is the time taken for one complete 
vibration cycle. Period is the second/cycle and it is inversely proportional to 
the frequency. As the frequency of a wave increases, the period of wave is 
decreases. For example, the period for 5 MHz ultrasound; 5 MHz (5 million 
Hertz) ultrasound: 1/5,000,000 = 0.0000002 = 0.2 µs. 1µs is 1 million of a 
second (0.0000001s). 
(5) Transit time: transit time is the time taken by sound waves to travel from 
one point to another point. It can be used to calculate the velocity of sound. 
Velocity = Distance / Transit time                                     (eq. 2) 
The behaviour of ultrasound waves in any specific medium can be predicted 
via the velocity and the transit time of these waves. 
(6) Acoustic impedance: it is defined as the resistance of passing of 
ultrasonic waves on the material and is used to characterise the ability of 
material to vibrate under any force applied. 
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(7) Power: the power in a field of ultrasound referrers to the total amount of 
energy being passing or applied to the samples.  
2.1.2 Anatomy of an ultrasonic system 
As shown in figure 2.3, general ultrasound equipment and equipment was 
used in this study composed form these parts: 
1-Power supply:  h s  s   so   m d  s   “g      o ”   d us d  o    p  h  
power applied constant and convert mains voltage into a resonant desired 
high frequency electrical energy to drive transducer assembly during any 
process.  
2-Piezoelectric transducer: this is also called a converter, allows the 
conversion of electrical power from ultrasonic generator to mechanical 
vibration. It has been considered as the main source of sound waves 
(Escobar-Chavez et al. 2009). Also, the transducer acts as a receiver where 
the reverse piezoelectric effect is exhibited applied mechanical force to 
   c   c       g .    h gh pow  ,    u    so  c     sduc  ’s d  m     shou d 
be less than a quarter of the sound wavelength and the total length of 
transducer is fitting to standing wave generation.  
3-Booster: this is optional and it is inserted between the transducer. It is as 
an amplifier which increases the mechanical waves. 
4-Sontrode (Horn): this is manufactured in different shapes and sizes 
according to the application that is being used. Furthermore, materials that 
are used to manufacture the sonotrode should compromise between the 
needs of ultrasonic and application. It is built from materials such as titanium 
alloy, steel, stainless steel or ceramic might be used. These materials are 
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used to deliver the generated ultrasound waves. The chosen material for 
acoustic horn should have the following characteristics; low acoustic loss, 
high dynamic fatigue stress, resistance to erosion and chemical inertness.  
The shape of the probe plays a critical role in power magnification where,  
stepped probes gives the highest amplitude magnification in comparison with 
exponential (Santos et al. 2009).     
5-Cooling oil (Chiller): this is used as refrigeration system for the probe and 
transducer and can provide an advantage to the instrument to work at high 
intensities for a practically unlimited time (Cravotto et al. 2005) 
 
Figure 2.3 Schematic diagram of high power ultrasound  
2.1.3 Types of ultrasound 
The mode of action or application for ultrasound changes as function of input 
power. Based on the applications, ultrasound can be classified as low or high 
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power. At low power, applications are used at very high frequencies, typically 
at mega-hertz. Passing low intensity ultrasound through material does not 
bring permanent changes in the structural or chemical properties, that is why 
the main use of this ultrasound is to determine and characterise the physico-
chemical properties of many biological and non-biological materials. At high 
power, ultrasound is mainly used to change the properties of materials 
passing through it. The changes caused by high intesity ultrasound are often 
constant. High intensity applications are often manufactured at low 
frequencies (Kasaai 2013). Also depending on the frequency, ultrasound can 
be classified as presented in figure 2.4. 
 
 
Figure 2.4 Frequency ranges related to ultrasound (Pilli et al. 2011) 
In general ultrasound can be broadly divided into high power and low power, 
where high power applications include high intensity focused ultrasound and 
low power applications includes low intensity ultrasound. 
2.1.4 Mechanisms of ultrasound 
In connection with its applications in various fields, it is essential to 
understand the mechanisms for different effects of ultrasound waves. An 
understanding of mechanisms will provide an opportunity to evaluate 
performances and limitations involved in its various applications. This relies 
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on the penetrated medium, where an ultrasound wave can dissipate (Kasaai 
2013) 
2.1.4.1 Mechanism of ultrasound on fluid materials 
The mechanism of action of ultrasound dissipated in fluids is not clearly 
understood, however there are several phenomena that may occur during 
subjecting ultrasound to the fluid materials. These phenomena include: 
a) Cavitation effect:  as shown in figure 2.5, cavitation is the creation of 
gaseous cavities in the fluid medium during ultrasound exposure to it, due to 
successive cycles of compression and rarefaction. Ultrasound-induced 
pressure variation inside the liquid can form the cavitation. Rapid growth and 
collapse of bubbles can be named: transient cavitation, where the slow 
oscillatory motion of bubbles is called stable cavitation. Collapse of the 
cavitational bubbles due to repetitive cycles resulting in spatially resolved 
regions of extreme excitation, pressure (1000 atm) and temperature 
(15000K) with release of shock waves, the generated shock waves can 
cause structural alteration in the medium. Performance of ultrasonic 
cavitation depends upon these parameters (frequency, intensity, solvent, 
temperature, external pressure and bubble gas) (Santos et al. 2009). Bubble 
size is inversely proportional to the frequency. Low frequency (high power) 
ultrasound generates large cavitation and consequently high temperature 
and pressure in cavitation zone, where the cavitation zone becomes smaller 
or inhibited as the frequencies increase (low power ultrasound). 
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Figure 2.5 Represented diagram of acoustic cavitation (Chowdhury and 
Viraraghavan 2009) 
b) Thermal effect: the absorbance of ultrasound can cause an increase in 
the temperature of the medium. The increase in temperature depends on the 
material absorption coefficient, where the material that possesses higher 
ultrasound absorption coefficient gains a severe thermal effect compared 
with the lower absorption coefficient materials (Escobar-Chavez et al. 2009). 
2.1.4.2 Mechanism of action on solid state materials 
Mechanical effects or mechanisms that result from particle motion are the 
main mechanisms for all applications that use high intensity ultrasonic 
energy. However, during passing ultrasonic energy through the media, many 
different mechanisms may be generated to promote the effect on the media. 
Most of these effects are related to: 
Chemical effects: the generation of heat through the medium may cause a 
chemical activity such as oxidation reactions, polymerisation, and de-
polymerisation or both have been produced during the use or exposure to 
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low frequency ultrasound waves. At exposure to low power ultrasound, all 
these chemical changes to the materials will not occur. 
Stirring: High intensity ultrasound can accelerate the random motion of 
particles in the material; this random motion may generate a violent agitation. 
Heat: As the ultrasonic energy is passed through the medium, the energy is 
lost or absorbed and transferred from one particle to another. These particles 
adapt as a conductive area and form heat to the medium. Also, a direct 
collision between particles causes a thermal conduction and leads to an 
increase in temperature of the solid samples. Shear (friction) at certain faces 
causes a higher absorption of energy. As the amplitude of ultrasonic 
vibration increases, the amount of energy converted to heat is increased. 
The increase in the temperature of the sample that is subjected to high 
power ultrasound depends on intensity or level of power input and exposure 
time or sonication time. The level of power input and sonication time have 
been found to play an important role in the synthesis of co-crystals. The 
application of sound waves drives the molecules or particles to collide or 
agitate at a high speed providing an intense, inter-particle collision and finally 
can induce effective melting at the point of collision. 
2.1.5 Applications of High Power Ultrasound 
Low frequency, high power ultrasound is a new powerful technology which is 
not only safe and environmentally friendly, but is also an efficient and 
economical technique. This new technology has been used for a variety of 
purposes, such as cleaning, extraction and crystallization within the 
pharmaceutical field.  
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2.1.5.1 Implementations in pharmaceutical and technological processes 
In the area of pharmaceuticals, the most common application of HPU mainly 
focuses on particle engineering techniques such as crystallization from 
solution, slurry (Sono- crystallisation, sonic slurry) and particle engineering 
from the melt phase (melt sonocrystallisation, ultrasound assisted melt 
extrusion). (Guo et al. 2003; Dhumal et al. 2009; Park* and Yeo 2010). 
Particle engineering under the effect of HPU can change and improve the 
primary and secondary physical properties associated with solids such as: 
a) Primary physical properties like particle size, shape, density, crystal habit 
and porosity etc. 
b) Secondary physical properties like flowability, compactability and 
compressibility.  
Particle uniformity is also particularly important in the pharmaceutical 
industry because it can directly impact the processability of the powder and 
the final product. 
Crystallisation methods are an essential part of manufacturing APIs. 
Achieving small and uniform API particles is essential for pharmaceutical 
dosage uniformity. Dry milling processes are used to reduce particle size, but 
there can be undesirable outcomes such as physical instability of the crystals 
caused by the stress applied. Large scale manufacturing of APIs cannot be 
achieved using dry milling and an extra cost related to special equipment for 
safety is also necessary. Small API particles can be obtained by the 
application of ultrasound during slurry crystallisation. In this process, an 
ultrasonic probe is operated at 20 KHz frequency with an effective energy 
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input of 100-200W for 10g of material. It has been found that crystals with an 
initial particle size of 100-200µm can be reduced to particles smaller than 
20µm using this technique. Overall, the HPU approach can significantly 
reduce the particle size of APIs whilst having no effect on the crystallinity 
(Kim et al. 2003). 
Crystal morphology can influence various physical and chemical properties 
of APIs such as flowability, packing, compaction, solubility and dissolution 
rate. A melt sonocrystallisation (MSC) process was designed by Manish et al 
for ibuprofen, where ultrasonic energy was applied to a molten state of 
ibuprofen causing a significant increase in the kinetic energy of the 
molecules and number of collisions, leading to an increased rate of 
crystallisation of the API. Different morphologies, such as hollow tubes and 
plates, during the application of ultrasound energy to the molten state of the 
API, were also observed. The results concluded that the crystal size 
decreased with an increase in US treatment time. The solubility of MSC IBU 
agglomerates was found to be significantly higher than pure IBU, because of 
the smaller crystal size. Furthermore, pure IBU is known to have a sticking 
problem to the punch during compression. This is due to surface roughness 
and large cracks between crystals. MSC IBU was proposed as an ideal 
solution to avoid sticking and to improve compressibility through smoother 
particle surfaces and  a lower number of cracks (Manish et al. 2005). 
The direct compression of tablets can be a cost effective and simple method 
to use which can also increase the stability of the API. Certain APIs which 
have poor flowability properties are difficult to directly compress, for example, 
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theophylline. This is because tablet size and weight are limited and tablets 
are at risk of capping. The application of high intensity ultrasound can 
overcome those limitations and allow for direct compression techniques to be 
used on those drugs that failed to be tableted by conventional compression 
methods. For example, high anhydrous theophylline content formulations are 
unsuitable for direct compression, ultrasound assisted compaction has been 
introduced to help produce them (Levina et al. 2000). 
Many pharmaceutical powders, such as IBU and paracetamol (PAR), during 
conventional compression techniques, can experience plastic or elastic 
deformation and can fragment into smaller particles. In 2002, a study 
conducted by Levina and Rubinstein used an ultrasound-assisted 
compaction machine operating at 20 KHz and 20-30 MPa. The simultaneous 
application of HPU with compression force was found to be better than 
applying HPU before and after the conventional compression process. It was 
found that pressure should be applied simultaneously with HPU to improve 
acoustic contact, which is required to allow ultrasound vibrations to pass 
from the horn to the material. It was also demonstrated that ultrasound-
assisted compaction was influenced by the formulation and sonication time. 
When IBU was mixed with microcrystalline cellulose (MCC), a stronger tablet 
was obtained by ultrasound-assisted compaction compared to compaction of 
IBU alone. The increase in the mechanical strength was due to HPU induced 
bonding between IBU and MCC molecules. The temperature of the tablet 
surface increased from 43°C to 60°C when the ultrasound amplitude was 
increased and sonication times were increased from 1 to 5 seconds. The 
resulting effects of HPU can cause particles rearrangement, interparticulate 
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bonding and incorporation of the API into the thermoplastic material. 
Therefore the dissolution rate can be decreased (Levina and Rubinstein 
2002).    
Dry powder inhaler formulations require drug particles with an aerodynamic 
particle size below 5µm. Particle size below 5µm provides deep lung 
deposition and good flow properties which enables accurate dose metering. 
In 2009, Dhumal et al compared an elongated crystal of Salbutamol Sulphate 
(SS) that was prepared by sonocrystallisation (SC) with a micronized spray 
drying method (SD) and without sonication. SS is a short acting B-adrenergic 
receptor agonist used for the treatment of asthma. It has been demonstrated 
in a lung simulator (cascade impactor) that the fine particle fraction (FPF) of 
the formulation increased from 16.66% for micronized SS to 31.2% for SDSS 
(achieved by spray drying of an aqueous solution of SS) and 44.2% for SD-
SCSS. The elongated crystals of SS obtained by SD-SCSS caused a 
reduction in the cohesive/adhesive forces and subsequently lead to more 
FPF deposition in the lung. In summary, the SC process was shown to be a 
rapid and simple method which could produce SS crystals suitable for 
pulmonary delivery (Dhumal et al. 2009). 
Anti-solvent processes have been widely used to crystallise pharmaceutical 
compounds, the simultaneous application of ultrasound with anti-solvent 
crystallisation of roxithromycin has had a significant effect on the 
agglomeration and crystal habit of roxithromycin when compared with the 
anti-solvent crystallisation on its own (Park* and Yeo 2010).  Agglomeration 
was decreased under the action of HPU; nucleation and the probability of 
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contact between the nuclei was also decreased. Additionally, crystals grown 
in a well-mixed condition did not agglomerate and particles with large sizes 
formed.  
Hot melt extrusion is the most widely used technique in the polymer industry. 
Many efforts have been made to develop extrusion technology for improving 
product quality. Guo et al used ultrasound-assisted extrusion for the 
dispersion of nanocomposites within a molten polymer. The ultrasound 
apparatus was constructed at the die zone and was parallel to the direction 
of the melt flow. It was demonstrated that significant changes occur to 
polymeric materials by subjecting HPU to polymer melts during the extrusion 
process (Guo et al. 2003). In addition, Isayev et al found that the application 
of HPU to polymers provided advantages such as the reduction in structural 
defects, enhancement of mechanical properties and an increase in 
crystallinity (Isayev et al. 2009). 
2.1.5.2 Application of HPU beyond pharmaceutical fields 
Introducing ultrasound as a tool for synthetic and material chemistry did not 
start until the 1980s. Since then many studies have been published. It has 
been used in various areas such as cleaning, plastic, biological cell 
disruption, water and water sewage processing (Ruecroft et al. 2005). One of 
the oldest industrial applications of power ultrasound is ultrasonic cleaning, 
where the absence of brushes with the effect of cavitation in load medium 
being the main mechanism of the cleaning procedure (Jenderka and Koch 
2006). Although, high power ultrasound would be too expensive and 
challenging to scale up, it was a viable technology to use for water treatment, 
it has been demonstrated that the decontamination of water through using 
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ultrasonic technique in conjunction with cross-flow membrane filtration is a 
feasible method (Kyllönen et al. 2006). Use of ultrasound in the food industry 
has been increasing in interest for many years. The main advantage of 
reducing the impact on nutritional content has encouraged the use of 
ultrasound combined with standard sterilisation and pasteurisation methods 
for microbe inactivation. It was reported that ultrasound-assisted thermal and 
chemical techniques had the ability to reduce numbers of many bacteria 
such as Salmonella and E.coli (Piyasena et al. 2003). Beneficial uses of 
ultrasound in food processing include sterilisation, extraction, degassing, etc.  
was mainly achieved through bubble collapse caused by cavitation and has 
been described in several reviews (Povey and Mason 1998; Chandrapala et 
al. 2012). 
2.1.6 Challenges Facing HPU Apparatus 
High power ultrasound apparatus cannot be easily generalised to meet the 
requirements of different applications and because of that, ultrasound 
apparatus have to be specially designed to suite definite application. For this 
reason HPU has been used widely at laboratory scale and there is a demand 
for simple and reliable HPU equipment for processing of large batches 
(kilograms/tones) at industrial level i.e. must be able to be scaled-up. On the 
other hand, the issues of noise irradiation and heating of ultrasonication 
should be considered in larger scale application (Shrestha et al. 2009). 
During processing of solids or blends with lower amount of solvents, the HPU 
is facing an erosion on the surface (tip) of transducer or immersion horn. 
Erosion is unavoidable will reduce the transducer life time and particle 
abraded can processing problems or contamination of products. 
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Figure 2.6 ultrasound probe erosion 
2.2 Co-crystals 
APIs appear in different forms such as solids, semisolids, liquids, and gases. 
Solid dosage forms of APIs, which consist of a single crystalline form are the 
most convenient and developed forms. The advantages of stability, 
reproducibility and amenability to purification than other forms have given the 
crystal form to be more preferred (Shan and Zaworotko 2008). Co-crystals 
are one of the solid dosage form types which have been recently developed 
and are comprised of an API and one or more co-crystal formers, where non-
covalent interaction such as hydrogen bonding, halogen bonding and ii-ii 
interaction may be present between API and co-former (Trask et al. 2005). 
Figure 2.7 shows the general scheme of co-crystallisation process. This type 
has different physicochemical properties when compared to parent drugs. 
Inside the pharmaceutical research area, there is a debate surrounding the 
 d    d f     o  of   “coc  s   ”. Th s m   s    d ff cu   fo   h  ph  m c u  c   
commu      o  g    o  wh  h       s   “coc  s   ” o  co-crystal. Although 
mos   g    w  h commo  s    m   ,   “coc  s     s a crystalline solid 
co       g mu   p   compo    s” (Childs et al. 2007). Both Dunitz and 
G u  m  h v   g   d  h    h     m shou d b  “co-c  s   ”    co trast to 
“coc  s   ”  o m      s g  of  og  h    ss of  wo compo    s (Dunitz 2003). 
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Another definition is introduced, co-crystal are formed between a molecular 
or ionic API and co-crystal former that is a solid under ambient conditions 
(Vishweshwar et al. 2006). Also, a co-crystal is defined as a crystalline 
material that is composed of two or more components, usually combined in 
stoichiometric ratio, each component existing as an atom, ionic compound or 
molecule (Childs and Hardcastle 2007). Aakeroy has presented a restrictive 
definition; a structurally homogenous material that consists of two or more 
neutral building blocks in exact stoichiometric amount and is solid under 
ambient conditions (Aakeröy et al. 2007). Bond has defined co-crystals as 
“multi component molecular crystals made from reactants that are solids 
under ambient conditions” (Bond 2007). Furthermore, Mundhe and his 
colleagues have defined co-crystals as crystalline complexes of two or more 
neutral molecular constituents, bound together in a crystal lattice through non 
covalent interaction (Mundhe 2013). 
According to the last food and drug administration (FDA) guidance, co-
crystals can be defined or classified as dissoc  b   “ PI--- xc p    ” 
molecular complexes (with the neutral guest compound being the excipient). 
In this manner, an API that has been treated with a co-crystallising excipient 
 o g           “ PI---- xc p    ” co-crystal should be treated as a drug 
product intermediate (Food and Administration 2013) 
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Figure 2.7 Representation of co-crystallisation  
Tailored properties of material through co-crystallisation 
Co-crystallisation processes as an alternative approach have demonstrated 
potential to improve a number of drug properties such as:  
A) Improved solubility of poorly soluble APIs – some recent contributions 
include carbamazepine (Chow et al. 2012; Boksa et al. 2014)  
B) Improved physical stability- Carbamazepine-saccharin co-crystals 
prepared by slurry method were physically stable and resistant to hydrate 
formation at accelerated stability conditions (Hickey et al. 2007). Co-crystals 
of Paracetamol with 5-nitroisophtalic acid was physically stable under 
accelerated stability conditions (Hiendrawan et al. 2016).   
C) Enhanced bioavailability- In terms of bioavailability, CBZ-SAC co-crystal 
was compared with CBZ marketed tablet product (Tegretol©). Represented 
co-crystal showed higher level plasma than Tegretol© in  fasted beagle dogs 
(Hickey et al. 2007). 
D) Enhanced dye and pigment- a mechanochemical co-crystallisation 
approach was observed to prepare fluorescin co-crystals involving pyridyl-
based co-crystal formers. The optical properties of (poorly soluble) colourant 
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could be changed via mechanochemical co-crystallisation. The obtained co-
crystals exhibited better thermal stability  Buč        .   13) . 
E) Enhanced photostability- Nitrofurantoin is known as a photo sensitive drug 
and exhibit rapid photoisomerisation about its C—N double bond. 
Nitrofurantoin co-crystals were exposed to 315-400 nm UV lamps and 
analysed at various time intervals. The results showed that co-crystals of 
nitrofurantoin with different co-coformers generally displayed a significant 
photostability over Nitrofurantoin itself (Vangala et al. 2012). 
F) Improved mechanical properties of poorly compressible crystalline APIs. 
Paracetamol suffers from poor mechanical properties whereas its co-crystal 
with 5-nitroisophthalic acid offered a feasible way to improve the mechanical 
properties and obtained a good tabletability of paracetamol (Hiendrawan et 
al. 2016). Co-crystals of ibuprofen and flurbiprofen with nicotinamide also 
showed better tabletability and improvement in mechanical properties in 
comparison to their respective pure APIs (Chow et al. 2012). 
2.3 Co-crystal screening and designing 
Recently pharmaceutical scientists have focused on a new solid state topic 
which is considering the design and formation of co-crystals using crystal 
engineering. The main target of co-crystal screening is to detect new 
crystalline forms of an active pharmaceutical ingredient with improved 
physical properties. Co-crystal screening protocol can be divided into three 
phases: co-crystal design; co-crystal screening and co-crystal selection. 
Pharmaceutical co-crystal design is a multi-stage process as schematically 
illustrated in figure 2.8.  The first step is to study the structure of the target 
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API molecules and find out the functional groups which can form 
intramolecular interaction, which is essential to get a desirable co-crystal 
product. The second step is to select an appropriate co-crystal coformer. A 
coformer needs to be GRAS (Generally Recognised AS Safe) 
pharmaceutically acceptable. 
 
Figure 2.8 Steps for co-crystal design and preparation 
During the design process, reliable super molecular synthons can be used to 
design only co-crystals which have a strong intramolecular interaction 
between co-crystal components. Crystal engineering can view crystals as 
super molecules i.e. assembled molecules bounded together with 
intramolecular interaction instead of covalent bonds. These interactions are 
non-covalent, non-ionic interactions, which involve hydrogen bonding and 
Vander Waalls interactions (Fabian 2009). In accordance with analysis of co-
crystal structures in the Cambridge Structural Database (CSD), hydrogen 
bonding is recognised as the most established mode of interaction among 
co-crystals (Nangia and Desiraju 1998). These studies illustrated that there 
exists a hydrogen bond motif called a synthon that take place among 
reported co-crystals. An example of these synthons is shown in (figure 2.9). 
Synthons are broken down into two categories: I) homosynthons and II) 
API Selection Coformer 
selection 
Empirical and 
theoretical 
guidance 
Co-crystal 
Screening 
Co-crystal 
Characterisation 
Co-crystal 
performance 
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hetersynthons. Homosynthons (self- association motif) are interaction 
between two of the same functional groups such as acid-acid or amide-
amide functional group (I-II), also known as homomeric interaction. 
Hetersynthons are interactions between two different functional groups and 
named as heteromeric interactions as acid-amide as (III-X). With regard to 
crystal engineering, hetersynthons are more favourable and stronger than 
homosynthons because of stronger hydrogen bonds that form between two 
different functional groups. 
 
Figure 2.9 Hydrogen bond synthon common in co-crystal structures (Good 2010) 
As shown in the figure 2.9, hetersynthons (III-X) between different functional 
moieties are important interactions in the design and structure of co-crystals 
(Good 2010) and illustrated further in figure 2.10 where, carboxylic acid and 
aromatic nitrogen can form reliable carboxylic acid-aromatic nitrogen 
supramolecular (Shattock et al. 2008). IBU-NIC co-crystals are synthesised 
through hydrogen between the carboxylic acid of IBU and the amide group of 
NIC. Statistical analysis figures of the (CSD) have shown that molecular 
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properties such as polarity, crystal packing, electrostatic charge and shape 
are essential in co-crystal design (Fabian 2009). 
 
Figure 2.10 Supramolecular Synthon : Carboxylic acid-Aromatic nitrogen 
(Shattock et al. 2008) 
In addition the selection of favourable hydrogen bonding assemblies in a 
crystal lattice was also derived by Ethers and was chosen according to the 
following rules: 
1”) all good proton donors and acceptors are used in the hydrogen bonding; 
(2) six- membered ring intramolecular hydrogen bonds form in preference to 
intramolecular hydrogen bonds; and (3) the best proton donors and 
acceptors remaining after intramolecular hydrogen bond formation form 
intermolecular hydrogen bond. According to rule (3), one of the most 
successful hydrogen bonding combinations seen for co-crystal formation is 
carboxylic acids and phenols are good hydrogen bond donors, while pyridine 
and amide carbonyl groups are good hydrogen acceptors (Aakeröy et al. 
2002). Clearly from hydrogen bond energy calculation for pairs of co-crystal, 
it has been found that the strongest hydrogen bond in this set of structure is 
the hydrogen bond between carboxylic acids and pyridine nitrogen and the 
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interaction energies are between - 70.8 and - 46.3 KJ mol-1. This means that 
acid groups are the best donors, whereas pyridine moieties are the best 
acceptors (Lemmerer et al. 2013). These results support previous 
experimental observations which have shown that the carboxylic acid- - - - 
pyridine hydrogen bond is a reliable supramolecular synthon. In addition, 
another way to predict co-crystal formation is the acid dissociation constant 
(PKa), which is one of the featured physicochemical properties of small 
mo  cu  s. ΔpK   ΔpK  = pKa (base) – pKa (acid)) between API and 
coformer is frequently utilised as a criterion to estimate whether a salt or co-
c  s    w    fo m. Wh   ΔpK  > 3, a salt is very likely to form.  Alternatively, 
when in the range 0 < ΔpK  < 3, co-crystals are more likely to be formed 
(Wang et al. 2013b). 
The next step is co-crystal screening, which is an experimental procedure to 
define whether a selected coformer is able to co-crystallise with a targeted 
API. The success of co-crystal formation also relies on experimental 
conditions such as temperature, solvent, reacting component composition 
and solubility behaviour of the reacting component in the selected solvent 
(Aitipamula et al. 2014). The purpose of co-crystal characterisation is to 
investigate the physical, chemical and crystallographic structure properties of 
formed co-crystals. Details of different co-crystal characterisation   
techniques will be given in section 3.5.  
2.4 Methods for preparation of pharmaceutical co-crystals 
Many methods have been developed for preparing co-crystals. Most of the 
synthesis methods are primary presented in the context of screening, but 
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some consideration has also given to co-crystal mechanisms and industrial 
scale up. Table 2.2 presents various methods of co-crystal preparation 
(Mohammad et al. 2011). As shown in figure (2.11) synthesis methods can 
be broadly classified into solvent and solid state based methods. Solvent 
based methods include solution crystallisation, slurry crystallisation, and 
ultrasound assisted solution crystallisation. Solid state based method are 
divided into mechanochemical methods (neat and liquid assisted grinding) 
and thermal based approaches which include hot stage microscopy, hot melt 
extrusion (HME), microwave and high power ultrasound approaches (HPU). 
Recently, co-crystal screening or preparation was conducted using non-
stoichiometric (solid addition to saturated solution of co-crystal coformer) and 
stoichiometric (evaporation and grinding) crystallisation. It has been found, 
with the respect to co-crystallisation experiments that an overall success rate 
of 85% was achieved by the non-stoichiometric approaches, while 61% of 
experiments related to stoichiometric approaches yielded co-crystals (Rahim 
et al. 2013).  
   Table 2.2 Solid and liquid based co-crystal preparation methods 
Liquid –based methods Solid-based methods 
1) Evaporation crystallisation.  
2) Slurry conversion.  
3) Reaction co-crystallisation. 
4) Cooling crystallisation.  
5) liquid-assisted grinding.  
6) Sonication.  
7) Supercritical fluid.  
8) Spray drying   
1) Melt crystallisation such as 
[hot stage microscopy and 
differential scanning calorimetry 
(DSC)].  
2) Solid state grinding.  
3) Twin-screw extrusion. 
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Figure 2.11 Co-crystal preparation methods  
2.4.1 Solvent based methods 
2.4.1.1 Solution crystallisation 
Solution crystallisation was one of the conventional methods used for the 
synthesis of co-crystals. In this procedure, crystallisation is guided by the 
degree of super saturation in solution with respect to co-crystals. In solution 
crystallisation, API and coformer in a definite stoichiometric ratio are 
dissolved in solvent. Supersaturation can be obtained via slow evaporation 
(Bruni et al. 2012). In the supersaturating region, co-crystals start to nucleate 
and crystallise out from the solution. Stoichiometric solutions consisting of 
APIs and coformers will produce co-crystals only when they have similar 
solubility in the chosen solvent. When API and coformer have a very different 
solubility, a mixture of solvents would be recommended. Using mixtures can 
bring advantages in preventing solvate formation and therefore using a 
mixture of two or three solvents has been suggested. The popularity of 
solution based approaches to prepare co-crystals is due to many advantages 
such as large, single crystals being produced giving crystal habit and surface 
 36 
 
features which are easily evaluated and absolute crystal structure 
determination is obtained. Furthermore solution crystallisation is considered 
as an effective purification step. However, there are several disadvantages 
associated with this method. One of the obstacles, a suitable solvent for all 
ingoing components must be selected before the crystallisation experiment 
starts. Unexpected solvate formation may be a problem. The incorporation of 
solvent inside the co-crystal lattice may hamper rational co-crystal design 
and formation of undesired solvate/hydrate. An additional drawback is the 
large amount of solvent was needed to prepare the co-crystal (Trask et al. 
2005; Reddy et al. 2007). 
2.4.1.2 Slurry crystallisation 
Co-crystals can be synthesised via slurry crystallisation. Slurry crystallisation 
is carried out simply by adding crystallisation solvents to solid mixtures of co-
crystal components prepared in a stoichiometric ratio (Vishweshwar et al. 
2006). Despite slurry crystallisation being a technique excessively applied to 
form pharmaceutical co-crystals, only Soares and Corneiro in 2013 have 
reported IBU-NIC co-crystals via a slurry approach with in-line monitoring by 
Raman spectroscopy and described it as a green synthesis route due to the 
use of deionised water as a solvent. The synthesis of IBU-NIC co-crystals in 
water by slurry crystallisation brings many advantages within green 
chemistry principles such as: use of safer solvent, avoiding concomitant 
formation of other crystalline forms with the obtained pure co-crystal and 
water does not generate Raman scattering using Raman spectroscopy as 
real time analysis (Soares and Carneiro 2013). 
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2.4.1.3 Ultrasound assisted crystallisation from solution (USSC)  
This technique is also termed sonic slurry or sonochemistry technique. 
Recently many efforts have been attempted to use ultrasound at a frequency 
of 20 KHz to produce co-crystals from solution/slurry (McCausland 2006; 
F  šč ć      .    9). The main mechanism attributed to create co-crystals 
from solution using ultrasound are ultrasonic waves induce cavitation in the 
solution; cavitation energy that is produced by ultrasonic waves can have an 
effect on the nucleation phenomena of a particle free solution. Within this 
mechanism, the supersaturating level can be obtained easily compared to 
conventional crystallisation, where it is difficult to achieve. Also with 
cavitation energy, a low supersaturation can induce primary nucleation by 
reducing the induction period and metastable zone width (Li et al. 2006; De 
Castro and Priego-Capote 2007). Conventional co-crystallisation approached 
such as solution; suspension/slurry and grinding were not successful in 
obtaining a pure caffeine-maleic co-crystal (Trask et al. 2005; Zhang et al. 
2007). Our research group, (Aher et al. 2010) reported ultrasound assisted 
solution crystallisation of no-congruently pair of caffeine-maleic acid pair in 
1:1, 1:2, 1:3 molar ratios. The process generated 2:1 co-crystals compared 
to a 1:1 co-crystal stoichiometry, which was attributed to molar ratio and 
simultaneous achievement of supersaturation. 
2.4.2 Solid based methods 
2.4.2.1 Mechanochemical method (Grinding) 
This is an alternative approach to the more common solution crystallisation 
approach. In addition it is green in nature as the excessive use of 
crystallisation solvent can be avoided or eliminated (Trask et al. 2004). Also, 
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mechanochemically prepared co-crystals can be obtained in quantitative 
yields and in very short reaction times i.e. the co-crystals are produced 
rapidly, without need to utilise environmentally unfriendly solvents and with a 
lower tendency for undesired solvate formation  Buč        .   13). 
Neat grinding or dry grinding is a solid state based technique and is 
performed manually via mortar and pestle or mechanically by milling the co-
crystal components together. Within this technique, the mechanism of co-
crystal formation is represented via crystal shearing of two components with 
molecular diffusion. Other mechanisms are suggested for intermediate 
formation of eutectic and intermediate formation of an amorphous phase. 
Moreover, it has been reported as way to prepare a novel pharmaceutical co-
crystal which was not easily reachable by solution crystallisation, for example 
the 1:1 co-crystals of diacetamide with acetamide, benzamide and 3, 4- 
dinitrobenzoic acid, could only prepared by grinding (Etter and Reutzel 
1991). 
Liquid assisted grinding (LAG) can also be named solvent drop grinding or 
wet grinding. Generally, liquid assisted grinding is more preferable than 
simple (neat) grinding, because it is faster and is frequently able to produce 
crystalline solid instead of amorphous materials. The LAG approach has 
been recognised as a powerful methodology to construct co-crystals in a 
rapid and quantitative manner. In addition it has been reported to be an 
efficient method of screening for co-crystal hydrates. For example, caffeine 
and citric acid was not able to form co-crystal upon neat grinding, however 
LAG with water produced a co-crystal of caffeine-citric acid (Karki et al. 2007; 
Braga et al. 2013). 
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2.4.2.2 Thermal approaches   
2.4.2.2.1 Differential Scanning Calorimetry (DSC) 
Although co-crystals have been synthesised by different methods, 
pharmaceutical scientists are focusing on how to prepare a co-crystals in a 
green, rapid and automated method. Melt crystallisation has been 
considered as a green technology and an alternative method for the 
separation and purification of materials that cannot be carried out by 
distillation or other extraction procedures (Ulrich 2004). A huge portion of 
organic binary mixtures show eutectic melting when subjected to heat 
(McNamara et al. 2006). Preparation of co-crystals via DSC is achieved by 
subjecting a binary mixture of drug and coformer to heat in a DSC pan which 
is increased past the eutectic temperature. Co-crystal formation is identified 
by the appearance of two invariant endotherms (attributed to eutectic and co-
crystal melting). It has been proven to be rapid, green (no solvent) and 
effective co-crystal screening technique, where sixteen out of twenty co-
crystals of carbamazepine, caffeine and sulfamethazine were synthesised 
(Lu et al. 2008). 
2.4.2.2.2 Hot Melt Extrusion 
Hot melt extrusion (HME) is one of the essential processing techniques used 
in the plastics industry. Currently most plastic products such as bags, pipes 
and sheets are manufactured by HME (Breitenbach 2002). In recent times 
the application of HME techniques in the pharmaceutical industry has been 
proven by a steady increase in the number of patents issued since the early 
1980s (Crowley et al. 2007). Solvent Free Continuous Co-crystallisation 
(SFCC) using HME is a continuous, green technique for co-crystal formation 
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developed by Paradkar, et al., (WO2010013035). Co-crystal formation via 
SFCC relies on the application of shear and heat in a twin screw extruder. 
The screw geometry, set screw speed and residence time control the level of 
shear. The process temperature inside HME is maintained at the melting 
point of lower melting component or eutectic point of the mixture (Dhumal et 
al. 2010a). HME offers an efficient mixing and close material packing, which 
increased the surface area of contact between the components lead to 
accelerate the non-covalent bonding between the API and coformer (Medina 
et al. 2010). The application of SFCC has been demonstrated for successful 
co-crystallisation of many pairs such as ibuprofen-nicotinamide (1:1) 
caffeine-oxalic acid (1:1), Nicotinamide-trans cinnamic acid, carbamazepine 
saccharine (1:1), theophylline-citric acid (1:1) and carbamazepine-
nicotinamide (1:1) (Daurio et al. 2011). In 2010, Dhumal, et al; successfully 
manufactured ibuprofen-nicotinamide co-crystals in an agglomerated form in 
a single step through continuous solvent free HME. They demonstrated that 
processing temperature, mixing intensity; screw geometry and screw speed 
played an important role in obtaining a pure IBU-NIC co-crystal. The co-
crystals produced at higher temperature (90°C), higher shear and lower 
screw speed were pure with no traces of un-reacted components. From all 
reported results obtained, SFFC approach for co-crystal formation can be 
considered as downstream processing, efficient, scalable and 
environmentally friendly process for the production of co-crystals which 
provides a feasible alternative to solution crystallisation approaches (Dhumal 
et al. 2010b).      
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2.4.2.2.3 Hot Stage Microscopy (HSM) 
Hot stage microscopy is one of the analytical tools used to characterise the 
physical properties of materials. The combination of microscopic properties 
and thermal analysis enable to characterise physical properties of materials 
as function of temperature and time. It is a visual technique and used in 
pharmaceutical industry to confirm transitions such as melting and 
recrystallization, which can be detected by DSC (Vitez et al. 1998). HSM is 
recognised to be an effective method in identifying behaviour of a two 
component system. Recently HSM has been applied to the preparation of co-
crystals. In this method during the application of heat, a mixture of API and 
coformer is fused together and the binary co-crystal phase is observed. The 
pharmaceutically acceptable coformer nicotinamide was screened with eight 
APIs, and  five out of eight co-crystal systems were synthesised using HSM 
method (Berry et al. 2008) 
 2.3.2.2.4 Microwave method   
Microwaves are defined as oscillating electromagnetic energy with a 
frequency range of 300 MHz-300 GHz (Leonelli and Mason 2010). The most 
used frequency in pharmaceutical microwave is 2.45GHz, which is suitable 
to convert electromagnetic energy to heat. It is an alternative energy source 
for the preparation of co-crystals. The principle mechanism of co-
crystallisation via microwave approach occurs by heat generation which 
causes the co-crystallisation process. In fact two processes take place 
concurrently, firstly a super saturated solution with respect to co-crystal 
phase form is obtained and secondly, the added solvent evaporates which 
enhances and increases supersaturation. It is concluded that process 
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solution, supersaturation and crystallisation is accelerated in a short period 
time with a limited amount of solvent. Our groups succeeded in forming 
caffeine-maleic acid co-crystal 1:1 using microwave heating. It was  found 
that microwave energy played an important role in controlling the saturation 
of the solvents at the interface of components and dielectric property of the 
solvent used (Pagire et al. 2013). A microwave reactor has been used to 
study the ability to perform co-crystallisation with caffeine-maleic acid pairs at 
1:1 and 2:1 molar ratios in the presence of selected solvents which have a 
range of dielectric properties such as methanol, water, toluene and ethyl 
acetate. It has been shown that using toluene as solvent failed to obtain any 
caf-mal co-crystals, furthermore, water and methanol solvent in a 1:1 molar 
mixture led to formation of 1:1 co-crystals and in a 2:1 molar mixture, 
produced 2:1 co-crystals with a slight amount of unreacted caffeine and 
traces of 1:1 co-crystals     
2.5 Co-crystal Characterisation Methods  
To explore new co-crystal forms or co-crystallisation processes, upmost 
significance is placed on the methods that are used for the characterisation 
of crystallisation products. Co-crystallisation is a structural assessment and 
property estimation. Various types of solid-state analytical techniques are 
capable of characterising crystal structure to evaluate their properties. These 
solid-state characterisation techniques can be classified as structural 
determination and physical property determination techniques; structural 
determination (infrared, PXRD, NIR, Raman), physical properties 
determination (DSC, TGA). All these techniques offer complimentary 
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information about the solid state properties of the examined materials 
(Römer 2008). Use of combinational techniques is highly recommended to 
accomplish a comprehensive understanding of solid-state properties. 
Distinctive information about solid-state forms is provided via each technique 
(Padrela et al. 2012).  
2.6 Summary 
In this chapter, a review was conducted on the most important publications 
within the area of ultrasound, basic principles, applications and critical review 
about pharmaceutical co-crystals ranging from the basic theory to design 
strategies, methods for preparations, their advantages and limitations. The 
review work helps understand the mechanism of ultrasound and current 
status of pharmaceutical co-crystal progress.  
  
  
 
 
 
 
 
 
 
 
CHAPTER 3 MATERIALS AND METHODS 
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This chapter provides an introduction to the materials, methods, equipments 
and softwares used for this research work. The experimental section is 
divided into two main parts; materials and methods 
3.1 Materials 
This section provides details of all materials used for this research.  
Drugs: Ibuprofen (TAJ pharmaceuticals), carbamazepine (TAJ 
pharmaceuticals), carbamazepine dihydrate (prepared in the lab), 
paracetamol (Medex). 
Co-formers: Nicotinamide and saccharin. All the co-formers were obtained 
from Sigma-Aldrich Ltd. UK. 
Polymers: Polyethylene glycol 8000 
3.2 Material profiles 
3.2.1 Drugs 
Four poorly water soluble drugs having different physicochemical properties 
and challenges were selected as model molecules for the preparation of co-
crystals using an ultrasound-assisted solid state approach. The 
physicochemical data and general information about these drugs is 
summarised in table 3.1.  
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Table 3.1 Drug profiles 
Property Ibuprofen Carbamazepine Carbamzepine.2H2O Paracetamol 
Chemical 
structure 
 
  
 
Therapeutic 
use 
Pain killer Anti-epileptic Anti-epileptic Anti-pyretic 
Molecular 
weight 
(g/mol) 
206.29 236.26 272.29 151.16 
BCS class II III III III 
Solubility 
(mg/L) 
21 17.7 15 20 
Dose (mg) 400 200 200 500 
Melting 
point (°C) 
76 175 70&175 169 
Glass 
transition 
temperatur
e (°C) 
-50 50 50 23 
Co-crystals √ √ √ √ 
Challenges Low Tg, 
Degradation, 
Low 
compressibilit
y  
Degradation, 
polymorphisms, 
Low 
compressibility 
Degradation, 
polymorphisms 
Low Tg, 
degradation
, low 
compressibi
lity  
References (Chow et al. 
2012; Gandhi 
et al. 2016) 
(Kobayashi et 
al. 2000; 
Javadzadeh et 
al. 2009) 
(Kobayashi et al. 
2000) 
(Patra et al. 
2015) 
 46 
 
3.2.2 Coformers and polymer 
Co-formers and polymers were selected on the basis of their different 
physicochemical properties. Details are given in table 3.2 
Table 3.2 Details of co-formers and polymer  
Property Nicotinamide Saccharin Poly ethylene 
glycol 8000 
Description White crystalline 
powder 
White crystalline 
powder 
White semi- 
crystalline powder 
structure 
 
 
 
Molecular 
weight 
(g/mol) 
122.12 183.18 7.000-9.000 
Melting Point 
(°C) 
128-13 226-22 59-64 
Solubility 
(mg/ml) 
1000 400 100 
References  (Chow et al. 2012) (Tomaszewska et al. 
2013) 
(Vemula and 
Katkum 2014) 
 
3.2.3 Chemicals 
The following chemicals were used throughout the experiments: 
1. De-ionised water: De-ionised water utilised for experiments was collected 
from ELGA pure lab ultra-system providing water with high purity. 
2. Analytical grade of Trifluroacetic acid (CAS number 101180937) was 
purchased from Alfa Aesar. 
3. Potassium bromide with analytical grade ≥99.9% purity (CAS number 
S44777-308) was purchased from Sigma-Aldrich, UK.  
4.  c  o         PLC g  d , ≥99.9% pu      C S  umb   1377189) w s 
purchased from Sigma-Aldrich, UK. 
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5. M  h  o   PLC g  d , ≥99.9% pu      C S  umb    7-56-1) was 
purchased from Sigma-Aldrich, UK. 
6. Orthophosphoric acid, 85% purity (CAS number 7664-38-2) was 
purchased from VWR international Ltd. 
7. Sodium hydroxide,>89% purity (CAS 13010-73-2) was purchased from 
Sigma-Aldrich. 
8. Potassium phosphate monobasic, 99% purity (CAS number 7778-77-0) 
was purchased from Sigma-Aldrich.  
3.2.4 Equipment 
Specification of all the equipment used in this research is provided in table 
below: 
     Table 3.3 Equipment specification  
Equipment Manufacturer Specifications 
US apparatus Switzerland HPU, low frequency 
DSC TA instruments, UK Q 2000 
PXRD Bruker, USA D8 powder diffractometer 
NIR spectroscopy Thermo Scientic, UK Antaris II 
FTIR spectroscopy Perkin Elmer, USA ATR Fronteir 
Raman Spectroscopy Renishaw, UK DXR Dispersive 
SEM FEI, UK Quanta 400 SEM 
Dissolution apparatus 
(USPII) 
Copley Scientific, UK USP type II paddle test 
apparatus 
UV Jasco, UK V-730 UV-visible 
HPLC Water, UK Waters e-2695, PDA-2998 
IR-Press UK Qwik-hand press 
 
Further details of the US apparatus and characterisation equipments will be 
provided in the method section.  
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3.2.5 Software  
Software used in this research for data processing are listed in Table 3.4 
      Table 3.4 Software used for analysis of results 
Software Purpose 
TA universal analysis Thermal analysis 
PowDLL converter PXRD pattern analysis 
TQ analysis software NIR spectra and Partial least square 
GRAMS/AITM Spectroscopy  
Software 
Raman spectra analysis,  
FTIR spectra analysis  
Origin  Graph and analysis 
ACD/Chem Sketch Chemical drawing software 
Picolog 32 Temperature and power measurement 
 
3.3 Methods 
This section provides a detailed explanation of experiments performed 
applying ultrasound to pharmaceutical solid state materials, including the 
process monitoring and applying characterisation techniques. In particular 
ultrasound has been explored together with poorly compressible materials 
such as paracetamol.  
3.3.1 Solvent-free ultrasound assisted pharmaceutical solid state 
materials  
Figure 3.1 shows a schematic diagram of HPU apparatus which delivers 
ultrasonic energy at the desired constant frequency. The static die cell was 
developed in-house and was effectively used for screening different co-
crystal pairs. Also, the direct use of high power ultrasound was examined to 
study its effect on poorly compressible drug without the use of any 
compression force. Further details and design of experiment is described as 
below.  
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Figure 3.1 schematic diagrams of static cell and sonotrode 
 
As shown in figure 3.1 piezoelectric transducer is the main source of sound 
waves which converted the electric power to mechanical vibration. The 
frequency was constant at 20.39 KHz and power was varied according to the 
experiments. The booster used to increase the mechanical waves, whereas 
the sonotrode utilised to deliver the generated sound waves. Water cooling 
was used to avoid heating of transducer and probe. Designed static die cell 
was used to hold the samples and to dip ultrasound prop before the 
experiment start. 
3.3.2 Process monitoring 
During the use of ultrasound apparatus, process monitoring was done by 
measuring the rise in temperature and power dissipated until the time of 
sonication. The monitoring was done by using picolog software.  
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3.3.2.1 Measurement of Power: Variations in power dissipated into the 
samples are due to the changes in acoustic-matching which results from 
acoustically-induced alterations to the material. It is therefore necessary to 
use a trapezoidal averaging technique to calculate the average power and 
total energy.  
Equation ((Y1+Y2)/2)* (C2-C1), where Y1= value of power after 1 sec. 
Y2= value of power after 2 sec, C2= time (2 sec) and C1= time (1sec) 
As a one second interval was used, C2-C1 will always account for a value 
equal to 1, therefore, changing the above equation to (Y1+Y2)/2 for each 
second interval. It was also necessary to tune the high-power ultrasound 
(HPU) acoustic drive unit using frequency and through inductive (conjugate) 
impedance matching to obtain optimum power-transfer, both acoustically and 
electrically. 
 The electrical power was measured throughout with an ACTUENERGY 
module. This unit provided both a visual digital display of real-time power, 
and transmitted a corresponding analogue voltage to enable data acquisition. 
This 10V full-scale voltage was scaled down to 67mV for sampling through a 
Picotechnology TC08-USB unit which is capable of measuring eight mixed-
signal inputs (temperature and/or voltage). The Picotechnology software 
(Picolog) was then used to sample the data via USB and PC where it could 
be displayed and analysed. 
3.3.2.2 Measurement of Temperature: Temperature changes induced by 
the HPU within the processed samples were also measured using the TC-08 
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Thermocouple Data Logger. A thermocouple was attached to the bottom of 
die cell as seen in the figure 3.3. 
 
Figure 3.2 TC-08 Thermocouple data logger 
3.4 Solvent-free ultrasound assisted co-crystallisation  
This work explored solvent-free ultrasonic approach to investigate co-crystal 
formation using different co-crystal pairs.   
3.4.1 Ibuprofen–nicotinamide co-crystal synthesis 
Ibuprofen (1.256mg) and nicotinamide (0.743mg) in a 1:1 molar ratio were 
mixed to prepare 2g of physical mixture. The mixture was poured into the 
specially designed static die cell and then the sonotrode was lowered into the 
die where the tip of the probe was in direct contact with the surface of the 
powdered physical mixture. This was held in the place by the weight of 
sonotrode assembly. The co-crystallisation process was carried out using the 
sonotrode (figure 3.3). The ultrasound is generated by a transducer, which is 
made up of a piezoelectric sandwich and is delivered from a titanium horn 
with a tip of 8mm diameter. The vertical mount and direct contact of horn to 
powdered physical mixture resulted in sound waves travelling downward and 
reflecting upward. The frequency of ultrasound waves was kept constant at 
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20.39 KHz at all different experimental conditions. The temperature of the die 
cell was controlled at different temperatures of 50°C, 60°C and 70°C. The 
electrical power used to produce HPU was fixed at different power levels of 
25%, 50%, 75% and 100% of total power.  As the power and temperature 
were increased the sonication time was reduced because at higher power 
and temperature the co-crystal formed more readily. Therefore the sonication 
times were selected based on this knowledge and were chosen to maximise 
the co-crystal concentration. Thermocouple attached to the bottom of die cell 
was used to detect the ultrasound-induced temperature rise in powdered 
materials. For the detection of the power input and ultrasound-induced 
temperature rise, picolog software was used. The details of experimental 
design of screening IBU-NIC 1:1 co-crystal using the ultrasonic approach is 
summarised in table 3.5. 
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Figure 3.3 solvent-free ultrasonic co-crystal screening apparatus 
 
 
 
 
Piezoelectric 
generator 
Chiller 
Horn 
Thermocouple 
Die cell  
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3.4.2 IBU-NIC co-crystal screening using a microwave method 
(reference method) 
IBU-NIC in a stoichiometric ratio of 1:1 was selected as a model co-crystal 
pair. Solvent mediated co-crystallisation experiments were performed using a 
microwave reactor (Monowave 300, Anton Paar Gmbh, Austria). A 1:1 molar 
mixture of IBU (0.515g) and NIC (0.304g) were mixed with 10% diluted water 
(82 µL). The mixture was then filled in a 30mL capacity glass tube. The same 
quantity was kept constant for all experiments. The temperature was set at 
80°C and the mixture was subjected to microwave heating with a holding 
time of 5 minutes followed by cooling at 40°C. The selected temperature of 
80°C was chosen because the eutectic temperature (Teu) of IBU-NIC mixture 
is 73°C. Also, 10% of diluted water was utilised because it had enhanced the 
formation of 1:1 co-crystals at low concentrations and works as a good 
microwave heating material (Pagire 2104). The obtained 1:1 pure IBU-NIC 
co-crystals were confirmed via powder X-ray diffractometry and differential 
scanning calorimetry. 
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Table 3.5 Design of experiments for IBU-NIC using solvent-free ultrasound 
approach 
Power level 
(% of total) 
Set temp (°C) Batch code Exposure time 
(sec) 
 
 
 
 
25% 
 
50°C 
A 200 
B 300 
C 400 
60°C D 400 
 
 
70°C 
R 50 
F 70 
G 90 
H 200 
I 300 
 
 
 
 
 
50% 
 
50°C 
J 50 
K 60 
L 80 
 
60°C 
M 10 
N 15 
O 20 
P 30 
 
70°C 
Q 5 
R 10 
S 15 
 
 
 
 
 
75% 
 
 
50°C 
T 5 
U 10 
V 15 
W 30 
 
60°C 
X 5 
Y 10 
70°C Z 5 
AB 10 
 
 
 
 
100% 
 
50°C 
AC 5 
AD 10 
AE 15 
 
60°C 
AF 5 
AG 10 
 
70°C 
AH 1 
AI 2 
AJ 4 
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3.4.3 Carbamazepine-nicotinamide co-crystal screening using 
ultrasound 
Ultrasonic experiments were performed by placing 2 g of solid mixture with 
an equimolar combination of model API (CBZ) and pharmaceutical co-crystal 
former (NIC) into a static cell. Then, the ultrasound probe was directly 
mounted onto the die cell. The frequency of ultrasound waves was kept 
constant at 20.39 KHz. The temperature of the die was kept constant at 
100°C. The temperature was chosen at 100°C (near eutectic point) to see 
effect of ultrasound on the co-crystal formation processed very close to 
eutectic point of physical mixture. Different levels of power were used at the 
desired sonication times. As the power level increased, the sonication time 
was reduced because at higher level of power, the co-crystal formed more 
readily. Therefore the sonication times were selected based on this 
knowledge and were chosen to maximise the co-crystal concentration. For 
the detection of the power input and ultrasound-induced temperature rise, 
picolog software was used. The detail of experimental design was described 
in table 3.6.   
Table 3.6 HPU CBZ-NIC 1:1 Processing at 100°C 
Components Set Temp (°C) Power Level 
 (% of max) 
Batch 
code 
Exposure 
Time (sec) 
 
 
 
 
 
CBZ-NIC 1:1 
PM 
 
 
 
 
 
100 
25 A 70 
B 150 
C 300 
50 D 5 
E 10 
F 20 
G 50 
75 H 5 
I 10 
J 15 
100 k 5 
L 10 
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3.4.4 CBZ-NIC co-crystal screening using ultrasound with and without 
water 
An equimolar mixture of carbamazepine (1.318g) and nicotinamide (0.681g) 
in total 2g w/w were physically mixed and poured into the die cell. Then, the 
ultrasound probe was directly mounted into the die cell. The frequency of 
ultrasound waves was kept constant at 20.39 KHz. The temperature of the 
die cell was kept constant at room temperature (20°C) and the power level 
was kept constant at 100% using three different sonication times of 20, 40 
and 60 seconds. The addition of water was to investigate whether to help 
ultrasound energy pass through, effect of co-crystal degradation and purity. 
The same experimental conditions were repeated with the addition of 5%, 
10% and 15% water to the total physical mixture of CBZ-NIC. Power input 
and ultrasound induced raise in temperature were measured using picolog 
software. Detail of experimental design shown below. 
Table 3.7 HPU CBZ-NIC 1:1 with and without water processed at room 
temperature 
Component Set Temp (°C) Power Level 
(% of Max) 
Batch 
Code 
Exposure Time 
(sec) 
CBZ-NIC 1:1 
PM 
RT 100 A 20 
B 40 
C 60 
D 80 
E 100 
CBZ-NIC-5% 
water 
RT 100 F 20 
G 40 
H 60 
CBZ-NIC-
10% water 
RT 100 I 20 
J 40 
K 60 
CBZ-NIC-
15% water 
RT 100 L 20 
M 40 
N 60 
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3.4.5 Carbamazepine dihydrate (CBZ DH)-nicotinamide co-crystal 
screening using US  
Carbamazepine dihydrate (CBZ:2H2O) containing 13.2% of water in its 
crystal lattice  was prepared by the previously reported method mentioned by 
McMahan et al., (1996) where the p-monoclinic form of carbamazepine was 
stirred in water at room temperature in 1:4 w/v proportions for 24 hours. Then 
the resultant was filtered using a vacuum pump followed by drying at room 
temperature. The synthesised carbamazepine dihydrate (CBZ DH) was 
characterised by PXRD and DSC prior to experimentation. The CBZ DH 
(1.380g) along with NIC (0.619g) as 1:1 physical mixture (total 2g w/w) was 
poured into the die cell. The ultrasound probe was then directly mounted 
onto the die cell. The frequency of ultrasound waves was kept constant at 
20.39 KHz. The temperature of the die cell was kept constant at room 
temperature (20°C) and the level of the power was kept constant at 
maximum power 100% using three different sonication times of 20, 40 and 
60 seconds as summarised in table 3.8. The power input and ultrasound 
induced temperature raise were measured using picolog software. The 
obtained mass was crushed by mortar and pestle which was characterised 
for its crystal form using powder X-ray diffractometry and differential 
scanning calorimetry.   
Table 3.8 HPU CBZDH-NIC 1:1 processing at room temperature 
Component Set Temp 
(°C) 
Power Level 
(% of max) 
Batch 
code 
Exposure Time 
(sec) 
 
CBZ DH-NIC 
1:1 
 
 
20 
 
 
100 
O 20 
P 40 
Q 60 
R 80 
S 100 
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3.4.6 CBZ-NIC co-crystallisation using solvent evaporation method 
(reference) 
CBZ-NIC co-crystals prepared by a conventional method were used for 
comparative studies and to confirm whether the US experimental method 
produced the same product as conventional methods. CBZ-NIC co-crystals 
was adopted from Shayanfar (Shayanfar et al. 2014). An equimolar weight of 
CBZ (2.633g, 0.01mol) and NIC (1.221g, 0.01mol) were dissolved in 20 ml 
absolute ethanol. The mixture was then heated at 50°C and manually stirred 
with a glass rod for 30 minutes. Finally, the solvent was evaporated giving 
the appearance of co-crystal solid residue. The solid mass obtained was left 
for 72 hours at room temperature to further remove any residual solvent and 
to obtain a dry solid mass of co-crystal. The co-crystals were crushed using a 
mortar and pestle and passed through the sieve mesh (60 mm) before 
characterisation with powder X-ray diffractometry and differential scanning 
calorimetry.    
3.4.7 Carbamazepine-Saccharine co-crystal screening using a solvent-
free ultrasonic approach 
CBZ (1.126g) was physically mixed with SAC (0.8734g) in a 1:1 molar ratio 
with total quantity of 2g. The physical mixture was then added to the die cell 
with a vertically mounted probe into the die cell. The frequency of ultrasound 
waves was kept constant at 20.39 KHz. The temperature of the die cell was 
kept constant at room temperature (20°C) and the level of the power was 
kept constant at maximum power of 100% of max using three different 
sonification times of 20, 40 and 60 seconds. To see the effect of addition of 
water and polymer on ultrasound behaviour and co-crystals formation, the 
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same experiment was repeated with the addition of 5% of water, 5% of PEG 
8000 in the physical mixture of 1:1 CBZ-SAC. The experimental detail is 
summarised in table 3.9. Picolog software was used to measure the power 
input or energy dissipation into the sample and temperature rise due to the 
ultrasound effect. The obtained mass was characterised for its crystal form 
using different analytical techniques 
Table 3.9 HPU CBZ-SAC 1:1 batches with different conditions 
Component Set Temp 
(°C) 
Power Level 
(% of max) 
Batch code Exposure Time 
(sec) 
CBZ-SAC 1:1 
PM 
RT 100 A 20 
B 40 
C 60 
CBZ-SAC-5% 
water 
RT 100 D 20 
E 40 
F 60 
CBZ-SAC-5% 
PEG 8000 
RT 100 G 20 
H 40 
I 60 
 
3.4.8 CBZ-SAC co-crystal tablets produced via solvent-free ultrasonic 
approach 
CBZ (1.126g) was physically mixed with SAC (0.8734g) in a 1:1 molar ratio 
with total quantity of 2g. The physical mixture was then added to the die cell 
with a vertically mounted probe into the dye cell. The frequency of ultrasound 
waves, temperature surrounding the dye cell and the power level was kept 
constant at 20.39 KHz, 20°C and 100%, respectively, using three different 
irradiation times of 20, 40 and 60 sec. The same experiment was repeated 
with the addition of 5% of water to the physical mixture. The tablet obtained 
was ejected from the static cell. To investigate the rate of co-crystal 
formation with and without addition of water, the top and the bottom part of 
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the tablet were examined for the molecular interactions due to the effect of 
ultrasound using Raman spectroscopy, PXRD and DSC.   
3.4.9 CBZ-SAC Co-crystals using a solution method (reference) 
CBZ-SAC form I co-crystal prepared via a solution method was used as a 
reference to investigate and compare against the results obtained by the 
ultrasound assisted technique. 
0.089 M of CBZ (21g) and SAC (16.3g) was mixed in a 500 ml capacity glass 
round bottom flask. To this, 280 ml of solvent mixture of ethanol (62.5% v/v) 
and methanol (37.5% v/v) was added. A reflux column was attached and with 
water circulation through this column at room temperature. The whole 
assembly was placed on the heater plate with temperature maintained at 
75°C. After obtaining a clear solution, heating was continued for one hour 
followed by gradual cooling to 30°C. Precipitation was observed close to 
55°C. The final precipitate was filtered through Whatman filter paper (Grade 
1) using a vacuum glass filtration assembly. The filtered solid mass was 
washed with cold methanol (5°C). Finally, the sample was air dried and 
characterised for crystal form using powder X-ray diffractometer and 
differential scanning calorimetry. 
3.5 Co-crystals characterisation techniques 
Several characterisation techniques were used to investigate the obtained 
co-crystals products produced by solvent-free ultrasonic approach.  
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3.5.1 Differential Scanning Calorimeter (DSC) 
A TA instruments Q2000 differential scanning calorimeter (Crawly, UK) was 
equipped with an RSC90 cooling unit and used to obtain DSC thermograms 
to analyse and record the heat flow of the starting materials and the 
generated crystalline products. Standard indium metal was used for 
instrumental calibration. An empty pan was used as reference. 
Approximately, 2-4mg of each sample was loaded into an aluminium pan. 
The temperature range for all the samples were selected as per the sample 
specification at a constant heating rate of 10°C/min. An inert environment 
was maintained by purging nitrogen at a flow rate of 50 ml/min. Finally, the 
melting point for each individual starting material and products obtained was 
detected by this technique. 
 
Figure 3.4 simplified differential scanning calorimetry setup 
3.5.2 Powder X-Ray Diffraction (PXRD) 
The X-ray diffractogram of the staring materials, physical mixtures and 
resultant crystalline products prepared by various methods were assessed 
using a Bruker D8 diffractometer (Coventry, UK) with an X-ray wavelength of 
0.154nm and cathode ray 40KV source with a filament emission of 40mA. All 
samples were scanned from 2 to 30 (2θ) using a 0.01° step width and 1s 
time count, while the scatter slit and receiving slit were 0.2° and 1°, 
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respectively. A silica sample holder was used where limited sample amounts 
were obtained.  
3.5.3 Near Infrared Spectroscopy (NIR) 
All the pure components of the raw materials and sonicated co-crystals were 
subjected to NIR analysis. An Antaris II NIR spectrometer (Thermo Scientific, 
UK) consisting of a halogen lamp assembly made up of quartz along with a 
fibre-optic probe and a detector (InGaAs) was used to collect off-line NIR 
spectra in diffuse reflectance mode. Each sample was placed in a standard 
glass vial and subjected to the NIR.  
 
Figure 3.5 Antaris II NIR spectrometer (Thermo Scientific, UK) 
3.5.4 Fourier Transform Infrared Spectroscopy (FT-IR) 
Selected samples were analysed by FT-IR analysis using a Perkin Elmer 
Spectrum 100 FT-IR spectrometer. A small amount of powder or 
ultrasonicated samples were placed on the diamond crystal covering it 
completely and pressed with the help of rotating vertical shift to a 
predetermined pressure confirmed by the generation of signals. Once the 
sample was placed properly, measurement was recorded. For all the 
samples, scanning scale was kept constant in the range of 600-4000 cm-1 
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with 16 scans per sample. The assembly involves an electronically stabilised 
source and detector for accurate results with high repeatability. The obtained 
spectrum was processed using GRAMS/AI software. All the ultrasonicated 
samples were analysed by FT-IR and compared with the spectrum of the 
pure drugs and their physical mixtures. 
3.5.5 Raman spectroscopy 
Raman spectra were obtained using a DXR instrument (Thermo Scientific). 
Analysis was carried out at room temperature utilising a laser wavelength of 
780nm and a laser power of 50mW. The laser was passed through an 
aperture of 50 µm slit. The estimated spot size of Raman spectra was 3.1 µm 
with an exposure time of 30 sec and 64 scans per spectra. Back-scattered 
radiation was collected for each run. The sample was placed directly onto the 
sample chamber (for tablet) or in glass vials (for starting materials). 
 
Figure 3.6 DXR Dispersive Raman 
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3.5.6 Scanning electron microscopy (SEM) 
Scanning electron microscopy was used to visualise the morphology of the 
obtained ultrasonicated products. Each powder surface was gold coated with 
the layer thickness of 30nm. SEM image was taken using an FEI Quanta 400 
scanning electron microscope under high vacuum with a voltage of 20KV 
and working distance of 10mm at various magnification levels. SEM studies 
were used to compare the reference methods with the starting materials and 
obtained products.       
3.5.7 Co-crystal quantification methods 
The ultrasonicated batches obtained from IBU-NIC and CBZ-NIC pairs were 
quantified using developed NIR calibration model to determine the purity of 
the co-crystals. It was found that the developed calibration models using NIR 
techniques were successful in the determination of the amount of co-crystal 
produced using solvent-free ultrasonic approach.     
3.5.7.1 NIR calibration model for quantifying IBU-NIC co-crystal 
As described in section 3.5.3, an Antaris II NIR spectrometer (Thermo 
Scientific, UK) in diffuse reflectance mode was used to collect the spectra of 
samples. The calibration curve for IBU-NIC system was designed using a set 
of standard samples consisting of 400mg of binary mixture of 1:1 IBU-NIC 
co-crystal (formed by microwave) and pure ibuprofen. The concentration of 
standards ranged from binary mixture containing 0 to 100% of pure ibuprofen 
at increments of 5%. Validation samples were made at the following 
concentrations: 2.5, 7.5, 12.5, 17.5, 27.5, 37.5, 52.5, 62.5, 72.5 and 92.5% of 
1:1IBU-NIC co-crystals in the binary mixture. The binary mixtures were 
mixed gently and poured into a glass vial. Each sample set was scanned five 
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times to obtain an average scan. Multi variate analysis, partial least square 
(PLS) regression, standard normal variation (SNV) pre-treatment, and 
second derivatives was used to develop and optimise the calibration model. 
This calibration model was used to predict the purity of the IBU-NIC co-
crystals produced using the solvent-free ultrasonic approach.      
3.5.7.2 NIR calibration model for quantifying CBZ-NIC co-crystal 
An Antaris II NIR spectrometer (Thermo Scientific, UK) in diffuse reflectance 
mode was used to collect the spectra of samples. A set of standards 
samples composed of binary mixture (400mg) of 1:1 CBZ-NIC co-crystal 
(solvent evaporation method) and pure carbamazepine designed to build 
calibration curve of carbamazepine-nicotinamide system. The concentration 
of standards ranged from pure CBZ (0%) to 100% 1:1 CBZ-NIC co-crystal 
with the standard made at concentration of 5% increments in between. 
Validation samples were made at the following concentration 2.5, 7.5, 12.5. 
17.5, 27.5, 37.5, 52.5, 62.5, 72.5 and 92.5% 1:1CBZ-NIC co-crystal with 
addition the remaining weight from Pure CBZ. Gentle mixing of the weight 
quantities in a glass vial using a spatula was carried out. Each standard was 
scanned five times and an average scan was taken. Multi variate analysis, 
partial least square (PLS) regression, standard normal variation (SNV) pre-
treatment and second derivatives was used to develop and optimise the 
calibration model. The obtained calibration model was used to predict co-
crystal purity of CBZ-NIC co-crystals that resulted from solvent-free 
ultrasonic approach.  
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3.5.8 Chemical stability (drug degradation) tests 
Solid state ultrasound-assisted co-crystallisation processes may cause 
degradation due to heating of and shears sensitive APIs during processing. 
Degradation of ibuprofen, carbamazepine were investigated using suitable 
HPLC methods. A water HPLC system comprising a separation module 
(waters e-2695) integrated with a degasser and photodiode array detector 
(PDA-2998) were used to perform HPLC analysis. HPLC chromatograms 
were collected at suitable wavelengths and analysed using Empower 3 
software. 
 Ibuprofen 
Ibuprofen during exposure to a high temperature over 80°C yields a 4-
isobutyle acetophenone (4-IBAP) as the main impurity and degradation 
product. Many impurities such as 2-(3-Isobutylphenyl) propanoic acid 
(Impurity A), 2-(4-Butylphenyl) propanoic acid (Impurity B), 2-(4-
Isobutylphenyl) propanamide (Impurity C), 2-(4-Methylphenyl)propanoic acid 
(Impurity D), 1-(4-Isobutylphenyl) ethanone (Impurity E).  A reported HPLC 
method was used to detect these impurities and details of this method are as 
follow; (Farmer et al. 2002) 
Column: C18 ACE 5 Hichrom with dimeter 3.0 mm, length 15 cm with 5 µm 
of packaging material and column temperature kept at 40 °C.  
Solvent system: Solvent A: MeCN/Water (36:64) acidified with 0.1 % v/v 
trifluroacetic acid  
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                           Solvent B: deionised water acidified with 0.1 % v/v 
trifluroacetic acid 
Injection volume: 10 µL; 
Flow rate: 1.5 mL/min 
Wavelengths: 214 nm 
 Carbamazepine 
The thermal degradation product of carbamazepine is known as 
iminostilbene (Naima et al. 2001). Simultaneous detection of carbamazepine 
and iminostilbene was done using a gradient developed HPLC method 
reported by (Korde 2015). The following gradient method was used for 
separation of carbamazepine and iminostilbene: organic phase varies from 2 
% to 98 % in 10 minutes and again decreased to 2 % in next 2 minutes and 
remains constant for next 2 minute. The HPLC conditions used were as 
follows: 
Column: C 18 Waters Symmetry, dimension of 4.6* 250 mm with 5 µm 
particle size of packaging material and Column temperature kept at 25 °C 
Solvent System: Solvent A: acetonitrile acidified with 0.1% v/v 
Orthophosphoric acid. 
                          Solvent B: deionised water acidified with 0.1% v/v 
Orthophosphoric acid. 
Injection volume: 10 µL; 
Flow rate: 1.2 mL/min 
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Wave lengths: 285 nm, 257 nm, 219 nm. 
3.6 Solvent-free ultrasound assisted paracetamol tabletability 
A powdered crystalline paracetamol was manually mixed with 5%, 10% w/w 
of PEG 8000 in total 2g w/w. Then poured into dye cell and probe was 
mounted vertically and immediately contact the surface of the mixed powder. 
The frequency of ultrasound waves, temperature surrounding the dye cell 
and the power level was kept constant at 20.39 KHz, 20°C and 100%, 
respectively, using two different sonication times of 20, 40 sec. The same 
experiment was repeated with using samples in total 3g w/w. Table 3.9 
summaries the experimental detail. The obtained ultrasonicated-tablet was 
scratches from the tope of surface. Picolog software was used to measure 
the power input or energy dissipation into the sample and raised temperature 
due to ultrasound effect. The tiny scratched mass was characterised for its 
crystal form using different analytical techniques. 
Table 3.10 Ultrasound solvent-free assisted paracetamol tabletability  
 
Component 
Variable parameter 
Batch 
size 
Temp 
(°C) 
PEG 
amount 
Exposure 
time(sec) 
Power level 
Paracetamol 2g RT 5% 20, 40 100% 
paracetamol 2g RT 10% 20, 40 100% 
paracetamol 3g RT 5% 20, 40 100% 
paracetamol 3g RT 10% 20, 40 100% 
3.7 IR-PRESS Method (reference) 
Conventional compressed paracetamol tablet was produced by IR-press 
method, which is normally used for preparation pressing pellets for IR 
spectroscopy. The obtained tablets via IR-press equipment (figure 3.7) used 
as reference to compare and investigate the paracetamol tablet obtained by 
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using ultrasound apparatus. A weighted paracetamol powder was mixed with 
5%, 10% of PEG 8000 in total 1g w/w, respectively. Die-set was assembled 
and the mixed powder was added. The die was put together into the Qwik-
hand press and the dye was pressed for 10 seconds with apply of 1-2 tone 
force. Pressure was released and obtained tablet was taken out after 
disassemble the die set. Dye was cleaned after finish of experiments. The 
obtained IR paracetamol tablet was characterised using different analytical 
techniques.  
  
Figure 3.7 IR press equipment used for tablet preparation 
3.8 Paracetamol characterisation techniques 
The sonicated tablets obtained from different batches were investigated 
using different characterisation techniques. The used DSC, PXRD FTIR 
spectroscopy and SEM were used as described in detail in section co-crystal 
studies (3.5.1, 3.5.2, 3.5.4 and 3.5.6).  
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3.8.1 Hardness (crushing strength) Test, Weight and Thickness 
Measurement  
A tablet hardness tester, model TBF 1000 (Copley Scientific Ltd, Nottingham, 
UK) was employed to determine the crush strength of the tablets. To perform 
this test, the tablet was placed on a platform between two precision ground 
platens (jaws), one of which was attached to the load cell and the other to a 
motor (jaw) which is provides the mechanical drive. Once the test started, the 
motorised jaw drives forward compressing the tested tablet against the fixed 
jaw until such time the tablet fractured, the motorised jaw retracted and the 
breaking force required to break the tablet from each batch was recorded. It 
was simply added a balance and standard digital micrometer (Mitutoyo, UK). 
The complete system was used for measuring tablet breaking force, weight, 
diameter and thickness. Results were expressed in kilograms-force (kgf) for 
breaking force, (g) for weight, millimetre (mm) for diameter and thickness of 
tested tablet. 
 
Figure 3.8 crushing strength, weight and thickness equipment 
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3.8.2 In-vitro drug release  
            USP II apparatus Paddle 
Drug release from direct use of HPU-assisted compressibility batches was 
studied using USP 2 dissolution test apparatus (Copley Scientific, Type NE4-
COP). Samples were analysed using a suitable UV spectrometric method. A 
calibration curve was established for the paracetamol in a phosphate buffer 
pH 5.8 from 1-10 µg/ml. obtained ultrasonicated-tablets were weigh and 
placed in dissolution vessels consisting of 900 ml of dissolution medium i.e. 
phosphate buffer pH 5.8. The paddle rotation speed was maintained at 
50rpm. The dissolution medium was kept in a thermostatically controlled 
water bath at 37°C. 5 ml samples were withdrawn at each interval time point 
(5, 15, 30, 45, 60 mins) and the same volume of the fresh corresponding 
buffer was replaced into the dissolution flask. Paracetamol content released 
in the diluted samples was analysed using UV spectrophotometer (Jasco, 
UK) and the data was processed using PCP disso software V3.  
3.8.3 Chemical stability (drug degradation) tests 
 Paracetamol 
4-amino phenol is the thermal degradation product of paracetamol. A 
reported gradient HPLC method was used for analysis, details are as follow; 
Column: C18 Waters Symmetry, dimension of 4.6* 250 mm with 5 µm 
particle size of packaging material. 
Solvent system: Solvent A: 20mM Phosphate buffer 
                           Solvent B: Acetonitrile 
Injection volume: 10 µL    
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Flow rate: 0.5 mL/min  
Wavelengths: 245nm to analyse Paracetamol, 230nm to analyse 4-
aminophenol 
Linearity range: 20-160 µg/mL   
  
 
 
 
 
 
 
 
 
CHAPTER 4 IBUPROFEN-NICOTINAMIDE CO-
CRYSTALS  
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4.1 Introduction 
This chapter explores the application of solvent-free ultrasound to generate   
co-crystals of IBU and NIC. Different parameters such as temperature, 
ultrasound power and sonication time were studied in a series of 
experiments to evaluate conditions required for formation of co-crystals and 
in order to optimise the process. The co-crystals obtained were evaluated 
using a variety of analytical techniques described in detail in chapter 3. Co-
crystals obtained using this approach were compared with co-crystals 
generated by a microwave method used to produce (reference co-crystals). 
This method has been developed in our laboratories and has not yet been 
reported for co-crystal synthesis. Different analytical solid state techniques 
were used to characterise IBU-NIC co-crystal such as FTIR, PXRD, DSC 
and Raman spectroscopy. These analytical solid state techniques combined 
with multivariate analysis were evaluated to quantify a mixture of ibuprofen-
nicotinamide co-crystals and its co-formers in order to develop a calibration 
model to determine the co-crystal purity. Out of these, Raman was the most 
reliable technique (Soares and Carneiro 2014). However, no previous work 
has utilised quantification of co-crystals using NIR. Such a study is of great 
importance to determine the fraction of unreacted precursors that were not 
converted into co-crystals during the process.  
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4.2 Crystal Structure Data 
4.2.1 Ibuprofen (CSD Refcode: IBRAC01) 
IBU is a crystalline white powder with no reported polymorph and is used as 
anti-pyritic. The unit cell belongs to P21/2 space group and shows cell 
lengths and angles as a =14.397 Å, b =7.818 Å and c =10.506 Å   d α = γ = 
90   d β = 99.7   sp c  v   . Th  crystal structure and calculated PXRD 
pattern of IBU is shown in figures 4.1 and 4.2 respectively. This form shows 
characteristic peak for IBU at 2θ = 6.1°.    
 
Figure 4.1 Crystal Structure of IBU (CSD Ref: IBRA01) 
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Figure 4.2 Calculated PXRD pattern for IBU (adapted from CSD and processed in 
Origin Pro8) 
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4.2.2 Nicotinamide (CSD Refcode: NICOAM02) 
NIC is a white crystalline powder and is an active form of vitamin B3. The 
unit cell is in P21/c and shows cell lengths and angles as: a =3.975 Å, b = 
15.632 Å and c =9.422 and α = γ = 9    d β = 99. 3    sp c  v   . Th  
crystal structure calculated PXRD of NIC are shown in figure 4.3 and 4.4 
respectively. The characteristic peak of NIC was observed at 2θ= 14.8°.  
 
Figure 4.3 Crystal structure of NIC (adapted from CSD Ref: NICOAM02) 
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Figure 4.4 Calculated PXRD patterns for NIC (adapted from CSD) 
4.2.3 Ibuprofen/nicotinamide co-crystal (CSD Refcode: SOGLAC) 
IBU-NIC co-crystals are present in a 1:1 stoichiometric ratio. The unit cell is 
P 21 with cell lengths and angles a =5.411 Å, b= 55.833 Å and c= 11.901 Å 
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and α = γ = 9    d β = 9 .  4   sp c  v   . O   u it cell is comprised of 
four-membered assemblies involving two IBU and two NIC molecules as 
shown in figure 4.5. This crystal form exhibits a hetersynthon (acid-pyridine) 
between IBU and NIC, where hydrogen bonding occurs via an amide-acid 
motif formed between NIC and IBU. The central part of each assembly is  the 
nicotinamide dimer, held together by an amide-amide motif ([ )] 
homosynthons)  F  šč ć   d Jo  s    7). The crystal structure data and 
calculated PXRD pattern for this crystal form are shown in figures 4.5 and 
4.6, respectively. The IBU-NIC co-crystal exhibits a characteristic peak at 2θ 
= 3.1°. 
 
Figure 4.5 Crystal structure of IBU-NIC co-crystal (adapted from CSD Ref: 
SOGLAC) 
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Figure 4.6 Calculated PXRD patterns for IBU-NIC Co-crystal (adapted from CSD) 
4.3 Observations 
35 batches of equimolar physical mixtures IBU-NIC (total weight 2g w/w) 
were ultrasonicated at different processing temperatures, sonication times 
and ultrasound power levels and are described in detail in table 4.1 below. At 
low US power level 25%, the samples were observed and were a compact 
tablets and with the increase processing temperature, it melted at top prop 
(figure 4.7). In figure 4.8, where higher power levels 50-100% were used, the 
samples experienced full melting, followed by solidification at room 
temperature and the colour appeared to be silver.  
Table 4.1 Experimental design of IBU-NIC processed with ultrasound at different 
power levels and temperatures settings.  
Power level 
(% of total) 
Set temp 
(°C) 
Batch 
code 
Exposure 
time(sec) 
 
 
 
 
25% 
 
50°C 
A 200 
B 300 
C 400 
60°C D 400 
 
 
70°C 
R 50 
F 70 
G 90 
H 200 
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I 300 
 
 
 
 
 
50% 
 
50°C 
J 50 
K 60 
L 80 
 
60°C 
M 10 
N 15 
O 20 
P 30 
 
70°C 
Q 5 
R 10 
S 15 
 
 
 
 
 
75% 
 
 
50°C 
T 5 
U 10 
V 15 
W 30 
 
60°C 
X 5 
Y 10 
70°C Z 5 
AB 10 
 
 
 
 
100% 
 
50°C 
AC 5 
AD 10 
AE 15 
 
60°C 
AF 5 
AG 10 
 
70°C 
AH 1 
AI 2 
AJ 4 
 
 
Figure 4.7 ultrasonicated IBU-NIC CC processed at 25% US power at different 
temperatures and sonication times 
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Figure 4.8 Ultrasonicated IBU-NIC CC processed at 50-100% US power at 
different temperatures and sonication times 
4.4 DSC results 
DSC analysis was carried out as described in section 3.5.1. Figure 4.9 
represents a general DSC result of impure and pure IBU-NIC co-crystals 
obtained during the use of solvent-free ultrasound approach at different 
process variables.  
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Figure 4.9 DSC thermograms for starting materials and ibuprofen-nicotinamide co-
crystal processed by ultrasound 
[a) IBU, b) NIC, c) IBU-NIC physical mixture (PM), d) impure ultrasonicated IBU-NIC CC, e) 
pure ultrasonicated IBU-NIC CC and f) IBU-NIC CC (reference)]. 
The above results revealed an endothermic peak at 76°C for ibuprofen 
(figure 4.9a). Nicotinamide possesses four polymorphic forms, and the 
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melting points of forms I, II, III, and IV were all seen her at 124–134, 112–
117, 107–111, and 102°C, respectively (Lin et al. 2015). 
The appearance of an endothermic peak at 131°C (figure 4.9b) indicates that 
the stable form I of NIC was used in the present study. Interestingly, the 
physical mixture (PM) of ibuprofen and nicotinamide in a 1:1 molar ratio 
depicted an endothermic peak at 72°C followed by another melting 
endotherm at 91°C. Within the PM thermogram (figure 4.9c), the first 
endothermic peak was attributed to the eutectic temperature of the physical 
mixture and this analysis was in agreement with Ulrich, 2004, which 
mentioned a large portion of organic binary mixture displaying a eutectic melt 
when heated. The second endothermic peak represented formation of IBU-
NIC 1:1 co-crystal. The thermogram of impure ultrasonicated IBU-NIC 1:1 
co-crystal (figure 4.9d) exhibited two peaks. The first peak observed at 68°C 
demonstrated the presence of un-reacted ibuprofen within the crystal lattice 
of the obtained IBU-NIC 1:1 co-crystal. A lowering IBU melting endotherm 
could be attributed to the presence of a second component NIC which acted 
as an impurity. The second endothermic peak at 91°C represents the melting 
point of IBU-NIC 1:1 co-crystal. The thermogram of the obtained pure 
ultrasonicated IBI-NIC 1:1 co-crystal (figure 4.9e) has a single endothermic 
peak at 90°C which was in agreement with DSC result of IBU-NIC co-crystal 
prepared using microwave method (reference, figure 4.7f). This shift in the 
co-crystal melting point compared to the starting materials is due to the 
interaction (hydrogen bonding between IBU and NIC) resulting in a change 
within the crystal lattice and its packing. The slight increase in the co-crystal 
melting point explains that the co-crystal attains a better thermodynamic 
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stability than ibuprofen and a subsequent higher energy is necessary to 
break the crystal lattice. The obtained results are in agreement with data 
reported in the previous literature.   
DSC results of IBU-NIC processed with 25% power at different set 
temperature and time (batches A-I) in figure 4.10 showed two endothermic 
peaks at 68°C and 91°C. This confirms that IBU-NIC co-crystals obtained at 
this lower level of power were impure. The intensity of the IBU endothermic 
peak at 67°C was decreased and the co-crystal peak at 90°C was increased 
due to an increase in its exposure to ultrasound. This observation confirms 
that the rate of conversion and interaction of IBU molecules with NIC 
molecules was enhanced by the increased exposure time and process 
temperature from 50°C to 70°C. 
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Figure 4.10 DSC thermograms of IBU-NIC processed at 25% US power at 
different temperatures and sonication times   
[A) 50°C,200s, B) 50°C,300s, C) 50°C,400s, D) 60°C,400s, E) 70°C,50s, F) 70°C,70s, G) 
70°C,90s, H) 70°C,200s and I) 70°C,300s]      
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Batches J-S represents DSC results of IBU-NIC 1:1 processed with 50% 
power at different processing temperatures are shown in figure 4.11. DSC 
thermogram batches L, P and S exhibited a single endothermic peak (91°C) 
under sonication time and process temperatures of 80, 30, 15 seconds, and 
50, 60 and 70°C, respectively. 
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Figure 4.11 DSC thermograms of IBU-NIC processed at 50% US power at 
different temperatures and sonication times   
[J) 50°C,50s, K) 50°C,60s, L) 50°C,80s, M) 60°C,10s, N) 60°C,15s, O) 60°C,20, P) 
60°C,30s, Q) 70°C,5s, R) 70°C,10s and S) 70°C,5s    
The remaining batches produced impure ultrasonicated IBU-NIC 1:1 co-
crystal, where two endothermic peaks were present. These results suggests  
that batches subjected to a higher power level of 50%, increased process 
temperature from 50 to 70°C, and reduced sonication time produce pure 
IBU-NIC 1:1 co-crystals. These DSC results and observations were similar to 
IBU-NIC 1:1 processed with 75% power level (batches T-AB, figure 4.12) 
and 100% power level (batches AC-AJ, figure 4.13) at different processing 
temperatures. Therefore, a further reduction in sonication time will be 
required with the increase in power levels and processing temperatures to 
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produce pure co-crystals, minimise the time/energy required and minimise 
degradation. 
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Figure 4.12 DSC thermograms of IBU-NIC processed at 75% US power at 
different temperatures and sonication times   
[T) 50°C,5s, U) 50°C,10s, V) 50°C,15s, W) 50°C,30s, X) 60°C,5s, Y) 60C°,10s, Z) 70°C,5s 
and AB) 70°C,10s] 
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Figure 4.13 DSC thermograms of IBU-NIC processed at 100% US power at 
different temperatures and sonication times 
[AC) 50°C,5s, AD) 50°C,10s, AE) 50°C, 15s,AF) 60°C,5s,AG) 60°C, 10s, AH) 70C,1s, AI) 
70°C,2s and AJ) 70°C,4s] 
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4.5 PXRD results                 
PXRD is a primary technique used to detect any changes that happen in the 
crystal lattice. PXRD studies for IBU-NIC were carried out as described in 
section 3.5.2. Figure 4.14 represents typical PXRD patterns of impure and 
pure IBU-NIC co-crystals obtained during the application of solvent-free 
ultrasound at different process variables. 
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Figure 4.14 PXRD patterns for starting materials, co-crystal reference and IBU-
NIC CC processed by ultrasound 
[a) IBU, b) NIC, c) IBU-NIC PM, d) impure ultrasonicated IBU-NIC CC, e) pure ultrasonicated 
IBU-NIC CC, and f) IBU-NIC CC (reference)] 
Powder X-ray diffraction for both starting materials, IBU and NIC showed 
distinguishable characteristic peaks with 2θ values of 6.0° and 14.8°, 
respectively, which is in agreement with PXRD reported for IBU and NIC in 
CSD data (figures 4.2 and 4.4).  
The PXRD diffraction of physical mixture of IBU-NIC (figure 4.14c) exhibits 
characteristic peaks for both the parent compounds. PXRD pattern of impure 
IBU-NIC 1:1 co-crystal obtained via the solvent-free ultrasound displayed two 
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characteristic peaks for co-crystal and un-reacted IBU at 2θ values of 3.1° 
and 6.0°, respectively.  
Figure 4.14 (e-f) shows PXRD patterns for the products obtained from co-
crystallisation process via solvent-free ultrasound and microwave co-
crystallisation methods. The shift in the intense peaks indicates formation of 
a new crystalline form. The products obtained from each method yielded 
identical spectra and a distinguishable characteristic peak at 3.1°. This result 
confirms that IBU-NIC 1:1 co-crystal was successfully produced from 
solvent-free ultrasound co-crystallisation and has a similar internal structure 
to IBU-NIC 1:1 co-crystal produced by the microwave co-crystallisation 
method. Although, the characteristic diffraction peak of IBU-NIC 1:1 co-
crystal obtained by two methods were observed at the same 2θ position, the 
relative integrated intensity of the diffraction peaks were reduced for  the 
microwave method at several 2θ positions. The reason behind this could be 
preferred orientation, where the distribution of crystal orientation is non-
uniform due to interaction between crystals with a particular morphology and 
a sample holder. This can lead to PXRD patterns with greater or lesser 
degree intensities about some particular orientation (McClurg and Smit 
2013). 
PXRD results of IBU-NIC processed with 25% power at different set 
temperatures are presented in figure 4.15. Batches (A-I) in figure 4.15 
showed two characteristic peaks at 2θ values of 3.1° and 6°. This confirms 
that all batches (A-I) at this level of power produced impure IBU-NIC co-
crystals which means that they contained unreacted IBU along with IBU-NIC 
co-crystals. As shown in figure 4.15, it is clearly that an increase in 
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processing temperature and sonication time increased the intensity of co-
crystal peak at 3.1° and gradually decreased the intensity of the 
characteristic ibuprofen peak at 6.0°. These observations were in agreement 
with DSC results (figure 4.10) and suggest that a longer duration of applied 
25% power ultrasound lead to an increase in the co-crystal yield. This could 
be due to the IBU and NIC molecules having a longer time to interact with 
each other under higher energy conditions forming co-crystal pair with no 
melt observed. Melting was observed while these products were subjected to 
ultrasound at higher power level of 50, 75 and 100% of total.  
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Figure 4.15 PXRD patterns of IBU-NIC processed at 25% US power at different 
temperature and sonication time 
[A) 50°C,200s, B) 50°C,300s, C) 50°C,400s, D) 60°C,400s, E) 70°C,50s, F) 70°C,70s, G) 
70°C,90s, H) 70°C,200s and I) 70°C,300s]      
PXRD patterns of IBU-NIC treated at 50% ultrasound power level (figure 
4.16) at different processing temperatures produced impure IBU:NIC 1:1 co-
crystals with higher intensity peak for co-crystal at 3.1° and lower intensity 
peak for ibuprofen at 6.0° under solvent-free ultrasound (batches J, K, M, N, 
O, Q and R). These results confirm that small amounts of unreacted 
ibuprofen were present in the samples. Therefore, a shorter exposure time 
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was required with the increase in the processing temperature to obtain pure 
co-crystals (batches L, P and S). These results were in agreement with the 
DSC results (figure 4.11). 
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Figure 4.16 PXRD patterns of IBU-NIC processed at 50% power at different 
temperatures and sonication time 
[J) 50°C,50s, K) 50°C,60s, L) 50°C,80s, M) 60°C,10s, N) 60°C,15s, O) 60°C,20, P) 
60°C,30s, Q) 70°C,5s, R) 70°C,10s and S) 70°C,5s    
Figure 4.17 depicts PXRD patterns of IBU-NIC processed at 75% power at 
temperatures of 50, 60 and 70°C. A small intensity peak at 2θ =6.1° 
represented unreacted IBU along with high intensity co-crystal peak at 2θ 
=3.1° showed in batches (T, U, V, M, N, O, Q and R). This indicated impure 
co-crystals were obtained with these batches.   
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Figure 4.17 PXRD patterns of IBU-NIC processed at 75% US power at different 
temperatures and sonication time  
[T) 50°C,5s, U) 50°C,10s, V) 50°C,15s, W) 50°C,30s, X) 60°C,5s, Y) 60C°,10s, Z) 70°C,5s 
and AB) 70°C,10s] 
Batches (W, Y and AB) presented pure co-crystals. This confirmed with 
totally disappearance of the IBU peak and appearance of a co-crystal peak 
at 3.1°. These PXRD results were similar with DSC results (figure 4.12). 
PXRD patterns for IBU-NIC co-crystal batches processed with 100% US 
power at temperatures of 50-70°C and different sonication time are shown in 
figure 4.18.  
4 6 8 10 12 14 16 18 20 22 24 26 28 30
0
4000
8000
12000
16000
In
te
n
si
ty
2 Theta (
0
)
AJ
AH
AG
AF
AE
AD
AC
AI
 
 90 
 
Figure 4.18 PXRD patterns of IBU-NIC processed at 100% US power at different 
temperatures and sonication 
[AC) 50°C,5s, AD) 50°C,10s, AE) 50°C,15s, AF) 60°C,5s, AG) 60°C,10s, AH) 70C,1s, AI) 
70°C,2s and  AJ) 70°C,4s] time  
Batches (AC, AD, AF, AH and AI) showed a small intensity peak at 2θ= 6.1°, 
indicating unreacted IBU present among IBU-NIC co-crystals. Batches (AE, 
AG and AJ) showed only one prominent peak at 2θ= 3.1°, indicating that co-
crystals formed at these conditions were pure. These results were analogous 
with DSC results (figure 4.13). It could conclude that at increased power level 
and processing temperatures, shorter sonication times were required to 
obtain pure IBU-NIC co-crystals. 
4.5 Measurement of power and temperature 
The power or energy dissipated and measured final temperature rise for 
different batches as mentioned in section 3.3.2 are described in table 4.2 
below: 
Table 4.2 Measured dissipated power and final temperature rise of IBU-NIC 
processed with ultrasound at different power levels and temperatures settings.  
Power level 
(% of max) 
Set temp 
(°C) 
Batch 
code 
Exposure 
time (sec) 
Max 
Temp(°C) 
Average 
power 
input 
(w) 
Total 
energy 
Input 
(KJ) 
 
 
 
 
25% 
 
50°C 
A 200 58 47 9.4 
B 300 56 37 11.1 
C 400 60 37 14.8 
60°C D 400 61 35 14.0 
 
 
70°C 
E 50 76 32 1.6 
F 70 77 43 3.0 
G 90 79 39 3.5 
H 200 79 41 8.2 
I 300 77 37 11.1 
 
 
 
50°C 
J 50 98 158 7.9 
K 60 104 171 10.3 
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50% 
L 80 109 200 16.0 
 
60°C 
M 10 70 112 1.1 
N 15 74 116 1.7 
O 20 81 127 2.5 
P 30 91 133 4.0 
 
70°C 
Q 5 73 106 0.5 
R 10 80 113 1.1 
S 15 90 134 2.0 
 
 
 
 
 
75% 
 
 
50°C 
T 5 52 102 0.5 
U 10 67 150 1.5 
V 15 87 184 1.3 
W 30 97 207 6.2 
 
60°C 
X 5 62 124 0.6 
Y 10 89 198 2.0 
 
70°C 
Z 5 76 144 0.7 
AB 10 91 172 0.2 
 
 
 
 
100% 
 
50°C 
AC 5 52 95 0.5 
AD 10 66 149 1.5 
AE 15 77 150 2.3 
 
60°C 
AF 5 63 95 0.5 
AG 10 76 155 1.6 
 
70°C 
AH 1 68 59 0.06 
AI 2 72 88 0.09 
AJ 4 74 100 0.1 
 
When ultrasonic energy propagates into an attenuating material such as a 
powder, absorption or energy dissipation is a mechanism that represents the 
part of ultrasonic waves converted into heat. Materials can absorb the energy 
to produce heat. An increase in the temperature may occur when the rate of 
heat production is greater than the rate of heat removal  O’B        7). This 
was observed in these results when the physical mixture of IBU-NIC was 
exposed to ultrasound waves at a frequency of 20 KHz. The average power 
input and total energy dissipated were increased as sonication time 
increases (table 4.2). As shown in the table above, when 25% power level 
was used to treat IBU-NIC1:1 physical mixture, the average power input was 
almost constant between 32-39 watts and the total energy between 1.6-
14.8KJ. In addition, with increasing processing temperature and exposure 
time, the measured final temperature increased gradually between 58-77oC. 
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As shown in figure 4.7B, sample melting was observed at the point of contact 
with the ultrasound probe (batch H and I).  
The results of IBU-NIC physical mixture treated with 50% power level 
showed that power input was high and increased with an increase in 
sonication time, which consequently lead to a rise in temperature. Although 
gradual increase of the total energy dissipation, the sudden raised 
temperature induced at this power level occurred as processing temperature 
and sonication time increases. All the measured final temperatures (batches 
J-S) were above the melting point of ibuprofen and caused melting of the 
sample (figure 4.8). This clearly demonstrates that the use of high power 
level ranging from 50 to 100% and an increase in the processing 
temperature 50-70°C helped the energy to dissipate easily, consequently, 
raising the temperature at a high rate. With the increase of power level and 
processing temperature, shorter sonication time was required to produce this 
effect.  
4.6 IBU-NIC co-crystal purity using NIR calibration model   
Measured off-line NIR spectra of ibuprofen, nicotinamide physical mixture, 
pure IBU-NIC CC obtained IBU-NIC1:1CC (reference) were used to 
determine the characteristic peaks attributed to the co-crystal. The second 
derivatives of NIR spectra of the above mentioned samples were shown in 
figure 4.19 over the spectra range (5200-4700 cm-1) wavenumbers. The 
second derivative peaks of the physical mixture were at 5045, 4975, 4855, 
and 4764 cm-1. N-H and N-H/C=O absorption from nicotinamide were 
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represented at 5045, 4975, 4855 cm-1, while, O-H/C=O absorption from 
ibuprofen were represented in 4764 cm-1. 
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Figure 4.19 Second derivatives of NIR spectra between 4700-5200 wave 
numbers: IBU, NIC, IBU-NIC PM, and IBU-NIC CC (reference)     
It is understood that hydrogen bond aids in co-crystal formation. Once the 
components bind together, vibrations are modified and peaks shift to a 
higher wave number with the appearance of new peaks observed at 5083, 
5018, 4873 and 4800 cm-1. These shifted peaks represent pure 
ultrasonicated IBU-NIC 1:1CC, IBU-NIC1:1CC (reference). These findings 
were in accordance with the study reported by Kelly et al, which 
demonstrated that NIR could be used as a real-time technique to monitor co-
crystal formation during twin screw extrusion (Kelly et al. 2012). On the other 
hand, the NIR technique was used in this research for determination IBU-NIC 
co-crystal purity. 
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A NIR calibration model was described in details in section 3.5.7.1. A PLS 
regression model was designed using a set of standard samples consisting 
of a mixture of 1:1 IBU-NIC co-crystal and pure ibuprofen. The concentration 
of the standard (pure IBU) ranging from 0% to 100% at 5% increment was 
formed by the addition of 1:1 IBU-NIC co-crystal prepared by the previously 
described microwave method. Validation samples were made at the following 
concentrations: 2.5, 7.5, 12.5, 17.5, 27.5, 37.5, 52.5, 62.5, 72.5 and 92.5%. 
A PLS model was used to predict the response of validation data set. PLS 
regression was performed using the averaged IBU-NIC calibration and 
validation samples. Nine different wave number regions were evaluated and 
eight types of chemometric pre-treatment were used. Since the regression 
was carried out using 20 calibration and 10 validation samples, using more 
than two factors would have caused over-fitting of the curves. So to keep the 
number of factors consistent, two factors were used for the PLS regression. 
Standard normal variate (SNV) pre-treatment was used to compensate for 
differences in the sample path lengths. In this study, the SNV was carried 
over the full spectra range (4000-10000 cm-1) which effectively minimised 
any scaling or off set effects that may have occurred. First and second 
derivatives (Dev) were used to improve the resolution of overlapping peaks, 
whilst, also acting as linear base line correction method. It was beneficial to 
view individual spectra in the 2nd derivative to locate important peaks which 
increase/decrease in intensity and may shift different wave numbers when 
co-crystal concentration increased. Norris smoothing technique was applied 
to derivatives to reduce the noise and improve the performance of the 
 95 
 
calibration model, whilst also, making it easier to visually interpret the 
individual spectra. 
Table 4.3 IBU-NIC models: the top ten PLS regression model in order of 
RMSEC value. 
Model Region 
(cm1) 
Chemometrics RMSEC 
(%) 
RMSEP 
(%) 
RMSEC – 
RMSEP (%) 
Corr. 
Coef. 
1 7450-7000 SNV, 2nd Dev., 
NS 
0.77 0.95 -0.18 0.9997 
2 9000-8000 SNV, 1st Dev. 0.87 1.54 -0.67 0.9996 
3 9000-8000 SNV, 2nd Dev. 0.89 1.60 -0.71 0.9996 
4 9000-8000 SNV, 1st Dev., 
SGS 
0.90 1.59 -0.69 0.9996 
5 9000-4700 SNV, 1st Dev.,  NS 0.92 1.42 -0.50 0.9995 
6 6080-6030 SNV, 1st Dev. 0.92 0.92 +0.00 0.9995 
7 6080-6030 SNV, 1st Dev., 
SGS 
0.95 0.94 +0.01 0.9995 
8 9000-8000 SNV, 2
nd
 Dev., 
SGS 
0.96 1.80 -0.84 0.9995 
9 9000-4700 SNV, 2nd Dev., 
SGS 
0.96 1.74 -0.78 0.9995 
10 10000-5400 SNV, 1st Dev., NS 0.97 1.37 -0.40 0.9995 
 
Table 4.3 shows the ten PLS regression models which exhibited the lowest 
RMSEC value. The correlation coefficient value for the models indicated that 
they were all well correlated linear models. The difference between RMSEC 
and RMSEP value were shown to give an indication of the variance between 
the calibration and validation data sets.  
Within the whole region, the wave number region of 7450-7000 cm-1, model 
1 in table 4.3 provided the smallest calibration error of 0.77% when 2nd Dev 
and NS were applied. This region provided a model with relatively low error 
values which could accurately predict the percentage yield of IBU-NIC CC in 
ultrasonicated samples, whereas, in some batches generated mixtures of 
ibuprofen and 1:1 IBU-NIC CC. This model exhibited a small RMSEP value 
of 0.95% and the difference between the RMSCE and RMSEP value was 
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only 0.18%. This small difference was a good indicator of the accuracy and 
predictability of the model.     
Model 1 is plotted in figure 4.20. Both the averaged calibration and validation 
samples are shown to compare the measured co-crystal yield to the PLS 
regression predicted co-crystal yield.  
 
Figure 4.20 IBU-NIC model: PLS regression Model 1. Using the region 7450-
7000cm-1 and chemometric 2nd Dev., SNV and Norris Smoothing (Wood et al. 
2016). 
This model had a correlation coefficient of 0.9997 and no outlying points 
were observed. The spectral and concentration factor loadings for both PLS 
factors were calculated. The first factor used 99.1% spectral information and 
99.7% concentration information. The second factor used 0.5% spectral and 
0.2% concentration information.  
Figure 4.21 illustrates the 2nd DEV. NIR spectral region; 7450-7000 cm-1 
(model1) depicts clear and predictable differences between each spectrum. 
Selected concentrations were chosen to explain the peak shifting and 
general differences between each co-crystal concentration (IBU, 25%CC, 
50%CC, 75%CC and 100%CC). The majority of the observed bands in this 
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range showed an increase in the absorbance intensity as 1:1 IBU-NIC CC 
concentration decreased from 100% co-crystal to 0% (pure ibuprofen). 
 
Figure 4.21 IBU-NIC model: 2nd derivatives NIR spectra over the region 7450-
7000 cm-1 with Norris smoothing of ibuprofen and the calibration samples with 25, 
50, 75 and 100% 1:1 IBU-NIC CC (Wood, et al. 2016) 
It was difficult to identify individual bands within the NIR spectra because 
most of these were overtone or combination bands. The hydrogen bonding 
involved in the formation of IBU-NIC CC may have caused some of the 
observed band shifting. The most significant shift observed in the region was 
from 7108 cm-1 to 7128 cm-1. Two other shifts were seen from 7070 cm-1 to 
7081cm-1 and from 7367 cm-1 to 7378 cm-1. 
4.6.1 Quantification of IBU-NIC co-crystal yield using NIR calibration 
model 
Quantification is of great importance to determine the yield of co-
crystallisation process and the purity of product obtained. A developed NIR 
calibration model was successful in determining the percentage yield of co-
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crystals of 1:1 IBU-NIC CC obtained under the effect of different US power 
levels, times and processing temperatures.  
 
Figure 4.22 % IBU-NIC CC at applied 25% power level using NIR method 
Figure 4.22 shows the total amount of IBU-NIC co-crystal obtained from the 
solvent-free co-crystallisation method at applied power levels of 25% at 
different processing temperatures using the NIR calibration model. These 
NIR results were correlated well with previously presented qualitative DSC 
and PXRD results. At a processing temperature of 50°C and exposure time 
of 200s, 300s and 400sec, the predicted yield of co-crystal using NIR 
calibration model was 54, 57 and 60%, respectively. Although longer 
exposure time was utilised, the quantity of the obtained co-crystal did not 
reach above 60%, which means that 40% of unreacted ibuprofen did not 
convert into co-crystal. Also, the amount of obtained co-crystal was 61% at a 
processing temperature of 60°C and exposure time of 400s. The yield of 
IBU-NIC co-crystal at processing temperature, 70°C with sonication times: 
50s, 70s, 90s, 200s and 300s was 64, 74, 83, 94 and 95%, respectively. 
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From these results, it is confirmed that the quantity of co-crystals obtained 
increased with an increase in exposure time.  The increase of processing 
temperature to 70°C, an exposure time of 50s was enough to produce similar 
yield of co-crystal compared to lower processing temperature (50°C) and 
longer exposure time (400s), which was 64 and 60%, respectively. This 
confirms that temperature is an essential parameter which can assist in 
dissipating ultrasound energy easily, thereby producing a higher amount of 
co-crystal in a shorter sonication time.  
Figure 4.23 shows prediction of ultrasonicated IBU-NIC co-crystal 
concentration at 50% of applied power level at different processing 
temperatures using NIR calibration model.           
 
Figure 4.23 % IBU-NIC CC at applied 50% power level using NIR method 
As shown in figure 4.23, at a processing temperature of 50°C and sonication 
times of 50, 60 and 80 sec at 50% power level produced IBU-NIC co-crystal 
yield of 93, 94 and 98%, respectively. Thus, longer sonication time of 80s 
was required to obtain almost pure IBU-NIC co-crystal. The predicted yield of 
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IBU-NIC CC at processing temperature of 60°C and exposure time of 10, 15, 
20 and 30 sec was 79, 82, 95 and 98%, respectively. Therefore, the 
sonication time required to obtain almost pure co-crystal was 30 seconds. 
While using a processing temperature of 70°C with sonication times of 5, 10 
and 15 sec, the predicted IBU-NIC CC yield was 76, 90 and 98%, 
respectively. It was found that the rate of conversion of physical mixture to 
IBU-NIC co-crystal was high while using shorter sonication times. Moreover, 
with the increase in the processing temperatures (50, 60 and 70°C), 
sonication time was decreased (80, 30 and 15 seconds), respectively to 
obtain a highly pure co-crystal.  
The figure below represents the prediction of ultrasonicated IBU-NIC CC at 
applied power of 75% at various processing temperatures using NIR 
calibration model.  
 
Figure 4.24 % IBU-NIC CC at applied 75% power level using NIR method 
When IBU-NIC PM at different processing temperatures 50, 60 and 70°C 
was subjected to 75% of power level for 5 seconds, the measured IBU-NIC 
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co-crystal concentration was 50, 55 and 60%, respectively. The amount of 
physical mixture converted into co-crystal increased gradually with the 
increase in processing temperature. At an exposure time of 10 sec, the 
predicted IBU-NIC CC concentration was similar to the samples processed at 
50 and 60°C (i.e. 90%), but the prediction for sample processed at 70°C was 
98% (almost phase pure co-crystal). At 50 and 60°C, sonication times of 15 
and 20 sec obtained almost pure IBU-NIC co-crystals, i.e., 98 and 99% 
respectively. 
Figure 4.25 represents the prediction of ultrasonicated IBU-NIC CC at 
applied 100% power level and various processed temperatures of 50, 60 and 
70°C using the NIR calibration model. 
 
Figure 4.25 % IBU-NIC CC at applied 100% power level using NIR method 
 At 100% power level, the predicted concentration of IBU-NIC CC at processed 
temperature of 50°C and exposure times: 5, 10 and 15 sec was 85, 82 and 98%, 
respectively. Whereas, at applied temperature of 60°C and sonication times: 5 and 
10 sec; the measured IBU-NIC CC concentration was 83 and 98%, respectively. At  
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the highest processing temperature of 70°C, the shortest sonication times was 
required to obtain the highest concentration of IBU-NIC CC, i.e. at 1, 2 and 
4sec, produced 93, 94 and 99% pure co-crystals, respectively. Hence, high 
power level and temperature required a shorter sonication time to produce 
almost pure IBU-NIC CC, since, all the physical mixture was converted into 
co-crystals and no unreacted compound was present in the sample. No 
significant difference was observed in the quantity of IBU-NIC CC obtained at 
75 and 100% of applied power level, especially at temperatures: 50 and 
60°C with sonication times of 5 and 10 sec. Therefore, it has been illustrated 
that NIR calibration model findings were in accordance with PXRD and DSC 
results.     
4.7 Degradation analysis  
The estimation of ibuprofen impurities in ultrasonicated processed samples 
(batches A to AJ) were performed using a HPLC reported method (Farmer et 
al. 2002). The ultrasonic process involves the use of maximum power 100% 
to force complete conversion to the co-crystal which may cause high 
localised temperature which can cause degradation. In this study, some 
ultrasonicated IBU-NIC co-crystals obtained, exhibited a change in colour 
(silver colour) which could be due to the metallic influence of release of some 
metals from the sonotrode or static cell, or degradation of the product. 4-
IBAP is one of the main impurities of ibuprofen (peak4, figure 4.26) as well 
as other degradation products shown in figure 4.26. Each indicated peak 
represents a type of impurity which could be within the starting material, 
ibuprofen. The highest peak depicted at the retention time of 12 minute 
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represents ibuprofen. All ultrasonicated products were subjected to this 
developed method in order to determine whether these samples contained 
ibuprofen degraded products. As shown in figure 4.27, the only peak eluted 
relates to ibuprofen at 12.8 minutes. This suggests that IBU-NIC co-crystals 
did not contain any degraded products. Therefore, it can be reasonably 
assumed that solvent-free ultrasonic method is a safe method for co-crystal 
synthesis. 
 
1) 2-(4-Methylphenyl) propanoic acid, 2) 2-(4-Isobtylphenyl) propanamide, 3) 
Benzophenone, 4) 2-(3-Isobutylphenyl) propanoic acid, 5) Ibuprofen, 6) 2-(4-
Butylphenyl) propanoic acid, 7) 1-(4-Isobutylphenyl) ethanon 
 
Figure 4.26 Adopted HPLC method for determination of ibuprofen and related 
impurities    
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Figure 4.27 Chromatogram showing separation of ibuprofen  
4.8 SEM Analysis 
SEM provides a high resolution image required to evaluate the size and 
shape of nanometer scale particles. The SEM images of ibuprofen, 
nicotinamide, IBU-NIC 1:1 CC obtained by ultrasound and microwave 
methods are given in figure 4.28. Ibuprofen crystals exhibited a distinctive 
needle shaped structure which is in accordance to the previous studies 
(Zalte Amar Gangadhar* and Bhanudas 2014). Nicotinamide crystals 
showed spherical clusters with rough surfaces. Pure ultrasonicated IBU-NIC 
1:1 co-crystals at different conditions depicted a change in crystal habit i.e., 
development of a homogenous aggregate of fine needle shaped crystals 
were observed. SEM images of IBU-NIC1:1 co-crystals prepared by the 
microwave method were similar and crystals appeared as homogenously 
aggregated needle particles. Therefore, it was confirmed that the mechanism 
of co-crystal formation using a microwave irradiation is similar to ultrasound 
at high level of power (50, 75 and 100% of total), where the nucleation of co-
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crystals resulted from the solidification of the melt of the starting 
components. The difference in environmental conditions of crystal growth 
from one process to another can normally cause a variation in their crystal 
habit, forming crystals with different external shapes but the same internal 
structure (Singh et al. 2014). 
 
Figure 4.28 SEM images of A) IBU 300x, B) NIC 300x, C) Ultrasonicated IBU-
NIC1:1CC 200x and D) IBU-NIC1:1 CC reference 200x 
4.9 Process optimisation 
In this study, solvent-free ultrasonic approach was utilised for the synthesis 
of IBU-NIC 1:1 co-crystals using variable parameters such as processing 
temperature, sonication time and levels of applied power. Different 
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characterisation techniques were used to optimise the processing 
parameters in order to obtain the pure IBU-NIC 1:1 co-crystal and improve its 
yield. The results of these characterisation techniques were comparable and 
complementary to each other. Table 4.4, figure 4.29 and figure 4.30 illustrate 
the optimum condition of solvent-free ultrasonic approach, where pure 1:1 
IBU-NIC co-crystal was achieved. 
Table 4.4 Optimum conditions of solvent-free ultrasound co-crystal approach 
Component Power level (% of max) Set Temp 
(°C) 
Exposure Time 
(sec) 
 
 
 
 
IBU-NIC PM 1:1 
 
50 
50 80 
60 30 
70 15 
 
75 
50 30 
60 10 
70 10 
 
100 
50 10 
60 10 
70 4 
 
40 50 60 70 80 90 100 110
-10
-8
-6
-4
-2
0
2
4
6
8
H
ea
t f
lo
w
 (W
/g
)
Temperature (
0
C)
I
H
G
F
E
D
C
B
A
J
 
 107 
 
Figure 4.29 DSC thermogram of pure IBU-NIC CC produced by solvent-free 
ultrasonic approach 
[A) IBU-NIC CC (reference), pure ultrasonicated IBU-NIC CC at different conditions B) 
50°C,80s,50%, C) 60°C,30s,50%, D) 70°C,15s,50%, E) 50°C,30s,75%, F) 60°C,10s-75%, 
G) 70°C,10s,75%, H) 50°C,15s,100%, I) 60°C,10s,100% and J) 70°C,4s,100% power)] 
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Figure 4.30 PXRD patterns of pure IBU-NIC CC produced by solvent-free 
ultrasonic approach 
[A IBU, pure ultrasonicated IBU-NIC CC at different conditions: B) 50°C,80s,50%, C) 
60°C,30s,50%, D) 70°C,15s,50%, E) 50°C,30s,75%, F) 60°C,10s,75%, G) 70°C,10s,75%, 
H) 50°C,15s,100%, I) 60°C,10s,100% and J) 70°C,4s,100% power)] 
4.10 Mechanism of co-crystal formation 
4.10.1 At low level of power, 25%  
Dhumal, et al., 2010 demonstrated that co-crystal formation via hot melt 
extrusion required temperatures higher than the eutectic point of the 
extrudate. However, her IBU-NIC 1:1 co-crystals were successfully produced 
at temperatures lower than the eutectic point using solvent-free ultrasound at 
low level of power 25%. This level of the ultrasound energy was not enough 
to raise the temperature above the eutectic point; therefore, no melting 
transition was observed. Also, measured temperature confirmed that the 
generated temperature (60°C) was lower than the eutectic point (72°C). 
Localised heating due to ultrasound could have caused melting or diffusion 
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at the interface leading to formation of co-crystal phase at a low energy level. 
It has also been reported that the ultrasound-assisted technique succeeded 
in combining two or more different APIs or API and an excipient via solution 
atomisation and sonication process (Pitchayajittipong et al. 2009). The pre-
blend sample prior to ultrasonication, containing stoichiometric equivalents of 
the two starting materials, did not show any conversion to the co-crystals. 
This shows that ultrasound mechanical action provided by ultrasound waves 
is critical for co-crystal formation. The probable mechanism of ultrasonic co-
crystallisation is due to enhanced diffusion at drug-coformer interface caused 
by localised heating. Longer exposure times with an increase in the 
processing temperature were desirable to maximise the degree of co-crystal 
formation. This finding is in agreement with the results observed in HME 
AMG 517-sorbic acid system where high yield of co-crystal was achieved at 
a longer residence time, low screw speed and temperature inside barrel 
should not above the eutectic point (Medina et al. 2010; Daurio et al. 2014).  
 
Figure 4.31 Schematic diagram for IBU-NIC co-crystals processed at low power 
level 25% 
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4.10.2 At high level of power, 50-100% 
Ultrasound waves propagate into the medium via a series of compression 
and rarefaction waves called mechanical waves (Doicrycz and Suslick 1990). 
At high power level, high temperature achieved causes phase change. The 
propagation of ultrasound energy to the melt phase is faster and number of 
collision between the drug and coformer molecules increases significantly 
resulting in formation of co-crystals at faster rate. IBU and NIC form eutectic 
which has melting point 73°C. The collision of IBU and NIC molecules in the 
eutectic phase may be responsible for the formation of faster and more 
percentage of co-crystal.    
 
 
Figure 4.32 Schematic diagram for IBU-NIC co-crystals processed at high power 
level (50-100%) 
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4.11 Summary  
A solvent-free ultrasonic approach was found to be able of synthesis of IBU-
NIC co-crystals. Variable parameters were used such as processing 
temperature, sonication time and level of applied power. Different 
characterisation techniques were used to optimise the processing 
parameters in order to obtain the pure IBU-NIC 1:1 co-crystals and improve 
its yield. The results obtained from different analytical techniques were 
complementary to each other such as DSC, PXRD and NIR quantification 
using a calibration model. They were used to optimise the solvent-free 
ultrasonic approach for the synthesis of IBU-NIC co-crystals. It was found 
that with the increase of high power and temperature applied, a shorter 
sonication time and less total energy dissipated was required to produce 
pure IBU-NIC CC. Pure co-crystal was obtained when all of the physical 
mixture was converted into co-crystals and no unreacted components were 
present in the sample. The degradation of the samples was analysed using 
HPLC and no degradation was found to occur. The solvent-free ultrasonic 
approach can be considered to be efficient and an environmentally friendly 
process for the production of IBU-NIC co-crystals.    
  
 
 
 
 
 
 
 
CHAPTER 5 CARBAMZEPINE-NICOTINAMIDE CO-
CRYSTAL 
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5.1 Introduction 
Carbamazepine-nicotinamide co-crystal has been extensively chosen as a 
model co-crystal system. Carbamazepine possesses a supramolecular 
carboxamide synthon, which has a tendency to form H-bonds with 
nicotinamide and thus readily co-crystallises. CBZ-NIC co-crystal appears in 
two polymorphic forms termed form I and form II and the stable form is form I 
which melts around 159°C. It has been generated via different techniques 
such spray drying, liquid assisted grinding, neat grinding, cryo-milling, 
solvent evaporation and solution crystallisation (Rahman et al. 2011; Patil et 
al. 2014). Polymorphic form II was identified by polymer mediated nucleation 
and growth from solution (Porter III et al. 2008) as well as by melt-quenching 
form I co-crystal (Seefeldt et al. 2007).      
This chapter will explore the application of the solvent-free ultrasound 
approach on the synthesis of co-crystals of carbamazepine and 
carbamazepine dihydrate. Carbamazepine exhibits low solubility and high 
permeability and belongs to the BSC class II drug category (Zakeri-Milani et 
al. 2009). It is a very challenging API as it exists in four different polymorphic 
forms and readily converts into solvate and dihydrate when exposed to 
organic solvents and water respectively. The CBZ used in this study was 
polymorph III. This h s b    us d         m    of    h  m  ’s d s  s  
(Kobayashi et al. 2000; Shayanfar et al. 2014). The first part of this study will 
use a processing temperature near to the eutectic temperature of the 
physical mixture of CBZ: NIC (100°C) and apply different levels of power and 
sonication times. The second part will use ambient processing temperature 
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and an applied maximum power. The effect of those processing variables on 
1:1 molar ratio of CBZ-NIC solid state will be examined together with addition 
of a small quantity of water 5, 10, 15%. Finally, the effect of ultrasound on 
carbamazepine dihydrate-nicotinamide physical mixture will be explored.  
5.2 Crystal structure data 
5.2.1 Carbamazepine, anhydrous form III (CSD Ref: CBMZPN10) 
Carbamazepine (CBZ) is present in four different polymorphic forms: two 
monoclinic, one triclinic and one trigonal. The most thermodynamically stable 
polymorph at room temperature is P- monoclinic form (form III). Polymorph 
form IV is a C-lattice monoclinic form which is an enantiotropic pair to p- 
monoclinic form. Form I (triclinic) exists after high temperature modification, 
whereas, the least stable form, trigonal form II undergoes fast transformation. 
Molecular confirmation and hydrogen bonding patterns were similar between 
all forms, and the difference only lies in the pattern of  (8) carboxamide 
dimer units (formed via hydrogen bonding between carboxamide donor and 
carbonyl acceptor).  The unit cell of form III is in P21/n space group with cell 
length: a=7.53(1), b 11.15(2), c 15.47(2) and angle β = 116.2(1) (Grzesiak et 
al. 2003; Harris et al. 2005). The crystal structure and calculated PXRD 
pattern is shown in figures 5.1 and 5.2, respectively. This form shows 
characteristic peaks at 2θ = 12.93° and 2θ = 15.1°  
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Figure 5.1 Crystal structure of CBZ form III (CSD Ref: CBMZPN10)  
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Figure 5.2 PXRD pattern of CBZ Form III (adapted from CSD Ref: CBMZPN10) 
5.2.2 Carbamzepine dihydrate (CSD Ref: FEFNOT02) 
The dihydrate form is proven to be a monoclinic form and is obtained from P- 
monoclinic (form III) with space group P 21/c and unit cell dimensions: a = 
1 . 7  ) Å, b =  8.7  5) Å, c = 4.83 1) Å   d β = 1 3.45 . Th   s mm    c 
unit encompasses one CBZ molecule and two water molecules (figure 5.3). 
The structure is similar to anhydrous carbamazepine where dimers of CBZ 
are linked via pairs of hydrogen bonds at N-H...O alongside a hydrogen bond 
network between amino group and water molecules forming double layers. 
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This results in an outside layer of hydrophobic CBZ with hydrophilic water 
molecules present at the core forming channels (figure 5.4) (Harris et al. 
2005). The PXRD pattern for CBZ dihydrate is shown in figure 5.5. 
 
Figure 5.3 Crystal structure of CBZ dihydrate (CSD Ref: FEFNOT02) 
 
Figure 5.4 CBZ dihydrate hydrogen- bonded network arrangement with stacks of 
CBZ molecules (Harris et al. 2005) 
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Figure 5.5 PXRD pattern for CBZ dihydrate (CSD Ref: FEFNOT02). 
5.2.3 CBZ: NIC 1:1 CC (CSD Ref: UNEZES) 
The unit cell of CBZ: NIC 1:1 co-crystal (figure 5.6) relates to P21/n space 
group with a=5.096(<1) Å, b=17.595(3) Å, c=19.647 18) Å,   d   g  s: α= 
90.00, β= 90.92(<1),   d γ= 90.00 (CSD Ref: UNEZES). The crystal 
structure is shown in figure 5.6. The calculated PXRD pattern of this form 
shows a characteristic peak at 2θ = 6.7°, 8.9°, 10.3° and 20.5° (figure 5.7). 
 
 
Figure 5.6 Crystal structure of CBZ: NIC 1:1 CC attained from CSD Ref: UNEZES 
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Figure 5.7 PXRD patterns of CBZ-NIC1:1 CC (obtained from CSD Ref: UNEZES)  
5.3 CBZ-NIC processed at 100°C with different power levels 
The method used to prepare ultrasonicated CBZ-NIC CC processed at 
100°C at various levels of power was described in detail in section 3.4.3.  
5.3.1 DSC results 
DSC analysis was carried out as described in section 3.5.1. Figure 5.8 
represents a typical DSC result of impure and pure CBZ-NIC co-crystals 
obtained during solvent-free ultrasonication at 100°C at different power 
levels. The thermograms for CBZ form III shows two melting endotherms at 
175°C and at 191°C, which is explained by polymorphic transformation of 
recrystallised CBZ form III to form I. NIC exhibited a sharp endothermic 
melting  peaks at 131°C.  CBZ-NIC physical mixture produced endothermic 
peaks at 125°C and 159°C are linked to the melting of NIC and co-crystal 
generated by melt fusion phenomena, respectively. The endothermic peak at 
155°C may be due to melting of the remaining CBZ. These results were in 
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agreement with the earlier reported thermal behaviour (Seefeldt et al. 2007; 
Chieng et al. 2009).    
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Figure 5.8 DSC thermograms for starting materials and CBZ-NIC co-crystal 
processed by ultrasound 
a) CBZ, b) NIC, c) CBZ-NIC PM, d) Impure ultrasonicated CBZ-NIC CC, e) Pure 
ultrasonicated CBZ-NIC CC, f) CBZ-NIC CC (reference) 
Impure ultrasonicated CBZ-NIC co-crystal (figure 5.8,d) showed two 
endothermic peaks at 125°C and 159°C. The first endothermic peak 
represents the eutectic of unreacted physical mixture and the second peak 
relates to the co-crystal. The presence of a small endothermic peak at 155°C 
may be due to remaining CBZ. Both pure ultrasonicated and reference CBZ-
NIC co-crystal exhibited a single endothermic peak at 160°C and 162°C, 
respectively. A slight shift in the endothermic peak of pure ultrasonicated 
CBZ-NIC co-crystal could be due to the degradation caused by ultrasound. 
Those peaks were different from the melting point of the staring material 
indicative of co-crystal formation (Rahman et al. 2011). 
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Figure 5.9 represents DSC thermograms of CBZ-NIC processed with 25% 
power at 100°C with different exposure times, batches (A-C).  
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Figure 5.9 DSC thermograms for CBZ-NIC CC processed at 100°C and 25% 
power 
[Processed at various exposure times A) 70, B) 150 and C) 300sec] 
As shown above, DSC thermograms of batches A-C exposed to different 
exposure times of 70, 150, and 300 sec produced two endothermic peaks at 
125°C and at 159.9°C. This confirms that all the batches at this level of 
power generated impure CBZ-NIC co-crystals. The presence of small 
endothermic peaks at 155°C may be due to remaining CBZ. With the 
increase in exposure time, the intensity of the first peak was observed to 
decrease, causing a corresponding increase in co-crystal peak intensity.  
DSC thermograms of CBZ-NIC co-crystals processed with 50% power at a 
processing temperature of 100°C and various exposure times are shown in 
figure 5.10, batches (D-G). The obtained CBZ-NIC co-crystal exposed to 5 
sec exposure time had two endothermic peaks at 125°C and 159°C. With the 
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increase in exposure time to 10 sec (batch E), a small endothermic peak was 
observed around 125°C followed by a high intensity peak at 159°C. This 
indicates the conversion of CBZ-NIC physical mixture into co-crystal.      
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Figure 5.10 DSC thermograms of CBZ-NIC CC processed at 100°C and 50% 
power 
[Processed at various exposure times D) 5, E) 10, F) 20 and G) 50sec] 
Beyond the above exposure time, i.e., 20 and 50 sec (batches D and E), a 
sharp single endothermic peak at 159°C was observed. This peak was 
different from the melting point of starting materials and their equimolar 
physical mixture indicating the formation of a new crystalline phase (CBZ-
NIC CC). 
DSC thermograms in figure 5.11 represents CBZ-NIC co-crystals obtained at 
applied power of 75% and processing temperature of 100°C. At this level of 
power with a 5 sec sonication time, the thermal behaviour of the obtained 
sample (batch H) showed two endothermic peaks at 125°C and 159°C. A 
single endothermic peak was observed in the batch I, where 10 sec of 
 120 
 
sonication time was applied. Above 10 sec sonication time (batch J), both 
broad exothermic and endothermic peaks were observed at 60-80°C and 
159.9°C, respectively. This explains that the solvent-free ultrasonic method 
for synthesis of CBZ-NIC CC at these conditions yielded a mixture of 
amorphous and crystalline form. 
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Figure 5.11 DSC thermograms of CBZ-NIC CC processed at 100°C and 75% 
power 
[Processed at various exposure times, H) 5, I) 10 and J) 15 sec] 
DSC thermograms of CBZ-NIC co-crystals at applied power of 100% and at a 
processing temperature of 100°C are shown below: 
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Figure 5.12 DSC thermograms of CBZ-NIC CC processed at 100°C and 100% 
power 
[Processed at various exposure times K) 5 and L) 10 sec] 
When CBZ-NIC physical mixture was exposed to 5 sec of sonication time, 
two endothermic peaks were observed at 125°C and 160°C followed by a 
single endothermic peak at 155°C. This confirmed that CBZ-NIC CC was not 
a pure form where the first endothermic peak exhibited the melting of NIC 
with unreacted CBZ which progressively melts and dissolves at higher 
temperature forming CBZ-NIC co-crystal at 160°C. At an exposure time of 10 
sec, a single endothermic peak was observed at 160°C which belongs to 
CBZ-NIC co-crystal form I. 
5.3.2 PXRD Results 
PXRD studies for CBZ-NIC pairs were carried out as described in section 
3.5.2. The solvent-free ultrasonic approach was successfully utilised for the 
generation of CBZ-NIC CC form I. The overlay of PXRD scans of impure and 
pure ultrasonicated CBZ-NIC co-crystal and reference CBZ-NIC CC are 
shown in figure 5.13. The diffractogram of CBZ form III, NIC and their 
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respective physical mixture were also shown for comparison. Figure 5.13, (a) 
shows that pure anhydrous CBZ form III has characteristic peaks at 2θ = 
12.9°, 15.1° and 15.6°, identical to those of CSD (figure 5.2). NIC (b) shows 
the characteristic diffraction peak at 2θ= 14.8°. Their physical mixture (c) 
encompass the peaks of CBZ and NIC which was at 2θ = 14.8°, 15.1° and 
15.6°, as indicated by arrows. 
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Figure 5.13 PXRD patterns of starting materials, co-crystal references and CBZ-
NIC CC processed by ultrasound 
[a) CBZ, b) NIC, c) CBZ-NIC PM, d) Impure ultrasonicated CBZ-NIC CC, e) Pure 
ultrasonicated CBZ-NIC CC, f) CBZ-NIC CC reference] 
The diffractogram of an impure ultrasonicated CBZ-NIC CC (d) showed 
characteristic peaks at 2θ = 6.6°, 8.9°, 10.3°, 20.5°, 14.8°, 15.1° and 15.6°. 
These peaks represent pure CBZ-NIC CC and unreacted physical mixture.  
Both pure CBZ-NIC CC prepared by ultrasound and the reference method (e 
and f) showed similar characteristic peaks at 2θ = 6.6°, 8.9°, 10.3° and 20.5°. 
The new peaks also resembled the calculated diffractogram of CBZ-NIC co-
crystal structure reported in the CSD figure 5.7 (reference code UNEZES).  
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PXRD results of CBZ-NIC CC processed with 25% power at a set 
temperature of 100°C as shown in figure 5.14, batches (A-C) depict 
characteristic peaks at 2θ = 6.6°, 8.9°, 10.3°, 20.5°, 14.8°, 15.1° and 15.6°. 
Although the exposure time was increased from 70 to 300 sec, the 
characteristic peaks representing unreacted NIC and/ or CBZ at 2θ = 14.8°, 
15.1° were still present, which indicates that the obtained CBZ-NIC CC was 
not in pure form.  
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Figure 5.14 PXRD patterns of CBZ-NIC processed at 100°C and 25% power  
[Exposure times A) 50, B) 150 and C) 300sec] 
In figure 5.15, the obtained CBZ-NIC co-crystals at 50% power was exposed 
to different exposure times of 5, 10, 20 and 50 sec (Batches D-G). A 
prominent peak for unreacted NIC at 14.8° was observed in the diffractogram 
at 5 sec (Batch D), which may have resulted in low intensity peaks for CBZ-
NIC co-crystal. With the increase in exposure time (Batches E-G), peaks 
representing unreacted NIC and CBZ disappeared completely, thereby, 
increasing the relative intensity of  the peaks exhibiting CBZ-NIC CC form I 
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at 2θ = 6.6°, 8.9°, 10.3°, 20.5°. It was observed that 20 sec of exposure time 
was enough to generate pure co-crystal. 
6 8 10 12 14 16 18 20 22 24 26 28 30
0
400
800
1200
1600
In
te
ns
ity
2 Theta (
0
)
G
F
E
D
 
Figure 5.15 PXRD patterns of CBZ-NIC processed at 100°C and 50% power  
[Exposure times D) 5, E) 10, F) 20 and G) 50sec] 
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Figure 5.16 PXRD patterns of CBZ-NIC processed at 100°C and 75% power 
[Exposure times H) 5, I) 10 and J) 15sec] 
Figure 5.16 represents PXRD patterns of CBZ-NIC co-crystals processed at 
100°C with 75% power at sonication times of 5, 10 and 15 sec (Batches H-J). 
A prominent peak for unreacted NIC at 14.8° (indicated by an arrow, figure 
5.16) was observed in the case of diffractogram at 5sec (Batch H), which 
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may have resulted in low intensity peaks for CBZ-NIC co-crystal. With the 
increase in exposure time (5 and 10 sec, Batches I and J), peaks 
representing unreacted NIC disappeared completely, thereby, increasing the 
relative intensity of the peaks exhibiting pure CBZ-NIC CC form I. Figure 
5.17 depicts PXRD patterns of CBZ-NIC co-crystals processed at 100°C with 
100% power at sonication times of 5 and 10 sec (Batches K and L).       
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Figure 5.17 PXRD patterns of CBZ-NIC processed at 100°C and 100% power 
[Exposure times H) 5, I) 10 and J) 15sec] 
As shown above, the PXRD pattern of batch K (5 sec exposed time) showed 
a prominent peak of unreacted NIC at 2θ =14.8° (indicated arrow) and low 
intensity peaks for CBZ-NIC co-crystal at 2θ = 6.6°, 8.9°, 10.3°, 20.5°. At 10 
sec exposure time (batch L), peaks representing unreacted NIC disappeared 
completely and peaks representing CBZ-NIC co-crystal form I were 
prominent. This indicated that pure CBZ-NIC co-crystal was obtained.  
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5.3.3 Measurement of power and temperature  
The method used for measurement of power dissipation and final 
temperature rise due to the absorption of ultrasound energy was described in 
detail in section 3.3.2. 
Table 5.1 Measured dissipated power and final temperature of CBZ-NIC processed 
at 100°C with using different power levels. 
Component Power 
level 
Set 
Temp 
(°C) 
Batch 
code 
Exposure 
time (sec) 
Max 
Temp 
(0C) 
Average 
Power 
input 
(W) 
Total 
Energy 
Input 
(KJ) 
 
 
 
 
 
CBZ:NIC 
1:1 PM 
 
25% 
 
 
 
 
 
100 
A 70 104 50 0.3 
B 150 110 40 6.0 
C 300 110 35 11.0 
 
50% 
D 5 104 130 0.6 
E 10 110 154 1.5 
F 20 150 200 4.0 
G 50 162 220 11.0 
 
75% 
H 5 105 120 0.6 
I 10 110 158 1.6 
J 15 143 220 3.3 
100% K 5 105 130 0.6 
L 10 112 156 1.6 
 
As shown in the table above, when 25% power level was used to treat CBZ-
NIC PM (batches A-C) at different exposure times of 70, 150 and 300 sec, 
although, the total energy dissipated increased with the increase of 
sonication times, the  average power input was almost similar (35-50W) and 
the ultrasound-induced temperature was nearly the same (104-110°C). The 
samples formed a compact tablet and no melt was observed at the point of 
contact with the ultrasound probe. This confirms that a 25% power level of 
ultrasound produced energy propagating through the sample which was less 
violent.  
 127 
 
The results of CBZ-NIC PM treated with 50% power (Batches D-G) showed a 
higher average power input (130-220W) and higher total energy input (0.6-
11KJ) which increased with an increase in sonication time. The final 
measured temperature at 5 and 10 sec of sonication times was 104 and 
110°C respectively, which was below the melting point of NIC. In this case, 
no overall melting was observed, but partial melting took place at the contact 
point between the powder and the tip of the ultrasound probe. Beyond this 
time at 20 and 50 sec (Batches F and G), the final temperature recorded 
were 150 and 162°C, respectively. This temperature elevation was higher 
than the melting point of NIC; confirmed by the complete melting of the 
sample. Thus, the use of high power level (50-100%) and processing 
temperature of 100°C close to the eutectic point of the PM caused the 
magnitude of the vibration in sonotrode to be high at these conditions. This 
clearly demonstrates the propagation of highly intense vibrations dissipating 
energy resulting in a steep rise in temperature after 10 sec exposure time. 
Hence, a shorter sonication time produced this effect. These results 
demonstrate that the use of high power level of ultrasound assists eutectic-
mediated co-crystallisation in two steps: firstly, it provides intense sound 
wave propagation and molecular collision, exposing the two reactant surface 
for eutectic formation and secondly, it enhances co-crystal formation through 
induce crystal nucleation in the eutectic phase. The nucleation of this co-
crystal phase results in subsequent solidification of the entire melt to form 
solid co-crystals (Chadwick et al. 2007).  
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5.3.4 CBZ-NIC co-crystal purity using NIR calibration model 
The NIR calibration model is described in detail in section 3.5.6.2. A PLS 
regression model was designed using a set of standard samples consisting 
of a mixture of 1:1 CBZ-NIC co-crystal and pure carbamazepine. The 
concentration of the standard (pure CBZ) ranging from 0% to 100% at 5% 
increments was formed by the addition of 1:1 CBZ-NIC co-crystal prepared 
by the evaporation method. Validation samples were made at the following 
concentrations: 2.5, 7.5, 12.5, 17.5, 27.5, 37.5, 52.5, 62.5, 72.5 and 92.5%. 
A PLS model was used to predict the response of a validation data set. PLS 
regression was performed using the averaged CBZ-NIC calibration and 
validation samples. Nine different wave number regions were evaluated and 
eight types of chemometric pre-treatment were used. Standard normal 
variate (SNV) pre-treatment was used to compensate for differences in the 
sample path lengths and two factors were used for PLS regression. First and 
second derivatives (Dev) were used to improve the resolution of overlapping 
peaks, whilst, also acting as linear base line correction method. 
Table 5.2 Ten PLS regression models using different regions and different 
levels of chemometrics 
Model Region(cm
-1
) Chemometrics RMSEC 
(%) 
RMSEP 
(%) 
RMSEC – 
RMSEP (%) 
Corr. 
Coef. 
1 9000-8500 SNV, 2nd Dev. 1.18 4.26 -3.08 0.9992 
2 9000-8500 SNV, 2nd Dev., 
SGS 
1.23 3.53 -2.30 0.9992 
3 10000-9646 SNV, 2nd Dev. 1.51 5.49 -3.98 0.9988 
4 10000-9646 SNV, 1st Dev., 
SGS 
1.54 4.00 -2.46 0.9987 
5 10000-9646 SNV, 1st Dev. 1.55 3.92 -2.37 0.9987 
6 10000-9646 SNV, 2nd Dev., 
SGS 
1.63 4.73 -3.10 0.9985 
7 10000-5400 SNV, 2nd Dev. 2.23 3.07 -0.84 0.9973 
8 9000-8500 SNV, 1st Dev. 2.28 3.32 -1.04 0.9972 
9 9000-8500 SNV, 1st Dev., 
SGS 
2.30 3.32 -1.02 0.9971 
10 9000-8500 SNV, 2nd Dev., Ns 2.32 3.33 -1.01 0.9971 
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Table 5.2 shows the ten PLS regression models in order of RMSEC values. 
According to the correlation coefficient values, the models were well 
correlated with linear models. The wavenumber region of 9000-8500 cm-1 
provided the first and second smallest calibration errors of 1.18% (Model 1) 
and 1.23% (Model 2). This region provided a model with relatively low error 
values which could accurately predict the percentage yield of 1:1 CBZ-NIC 
CC in samples where there was a mixture of carbamazepine and the 1:1 CC. 
The best overall performing model was determined to be Model 2. Model 2 
was chosen because it exhibited a small RMSEP value of 3.53% compared 
to 4.26% for Model 1. The difference between the RMSEC and RMSEP 
value was only -2.3% for Model 2 where as it was significantly larger for 
Model 1, -3.08%.  
Model 2 is plotted in figure 5.18, both averaged calibration and validation 
samples are shown to compare the measured co-crystal yield to PLS 
regression predicted co-crystal yield. 
 
Figure 5.18 CBZ-NIC model: PLS regression model 2. Using the region 9000-
8500cm-1 and chemometric 2nd Dev., SNV and SG Smoothing (Wood et al. 2016) 
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This model had a correlation coefficient of 0.9992. An outlying point was 
observed for the validation sample 52.55 CBZ-NIC CC yield. The first factor 
used 95.1% spectral information and 99.4% concentration information. The 
second factor used 0.6% spectral and 0.4% concentration information. 
It was beneficial to view individual spectral in the 2nd derivative to emphasise 
important peaks which increase/decrease in intensity and may shift different 
wave numbers when co-crystal concentration increased. The 2nd Dev. NIR 
spectral region, 9000-8500cm-1, used for Model 2 is shown in figure 5.19.  
The majority of the observed bands in this region exhibited an increase in 
absorbance intensity as the 1:1 CBZ-NIC CC concentration was decreased 
from 100% to 0% (pure carbamazepine). It may be possible that the 
hydrogen bonding involved in forming the 1:1 CBZ-NIC CC may have caused 
some of the observed band shifting. The band shifting for this system was 
more subtle compared to the ibuprofen-nicotinamide system. The most 
significant observed shift was from 8690cm-1 to 8705cm-1. The most 
prominent band associated with the co-crystal in this region was situated at 
8751cm-1. 
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Figure 5.19 CBZ-NIC model:  2nd derivative NIR spectra over the region 9000-
8500cm-1 with SG smoothing of carbamazepine and the calibration samples with 25, 
50, 75 and 100% 1:1 CBZ-NIC co-crystal (Wood et al. 2016). 
The 2nd Dev. 1:1 CBZ-NIC spectra used to create the models were relatively 
complex and exhibited more subtle differences between each co-crystal 
concentration. The complex 1:1 CBZ-NIC spectra could have been caused 
by the different arrangement of hydrogen bonding associated with the co-
crystal. This complexity could have impacted the PLS regression and may 
have caused higher error values for the selected 1:1 CBZ-NIC model. 
 132 
 
 
Figure 5.20 % CBZ-NIC CC at processing temperature 100°C with different 
applied power using NIR method 
The figure 5.20 shows the total amount of CBZ-NIC co-crystal obtained using 
the solvent-free ultrasound method at a processing temperature of 100°C 
with different levels of power using the NIR calibration model. These NIR 
results were reflected in previously presented DSC and PXRD results. At 
25% of power and exposure times of 70, 150, 300 sec, the predicted yield of 
co-crystal using NIR calibration model was 58, 65 and 75%, respectively. 
Although longer exposure time was utilised, the quantity of the obtained co-
crystal did not reach above 75%, which indicates non-conversion of 25% of 
CBZ into co-crystal. Hence, co-crystals obtained were impure. The co-crystal 
yield of samples (D, H and K) subjected to 5 sec at different power levels of 
50, 75 and 100% was 66, 71 and 71 %, respectively. At 10 sec exposure 
time, the co-crystal yield was 100% for samples (J-L) with applied power of 
75 and 100%. When 50% power was applied beyond 15 sec exposure time, 
the co-crystal yield was 100% (F-G) i.e. pure form. From these results, we 
can conclude that the application of ultrasound at high levels of power with 
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processing temperatures close to the eutectic point required shorter 
sonication times to produce pure CBZ-NIC co-crystals.        
5.3.5 Chemical stability 
The use of the solvent-free ultrasonic approach, at a processing temperature 
of 100°C, induced degradation in the sample, as observed by the change in 
its colour. An earlier report observed yellow degradant produced while 
forming CBZ co-crystals at temperatures much below 170°C using HME 
technique (Joshi 2012). Knowing the thermal instability and high melting 
point of CBZ along with the degradation of its co-crystals, it was considered 
important to perform degradation tests on the ultrasound samples generated. 
The degradation process under the application of ultrasound could be due to 
an additional steep rise in the temperature caused by the localised heat 
generated by probe which exceeding the set temperature. Within the United 
States Pharmacopeia (USP) standards for drug preparations and chemical 
substances, the limit set for CBZ related impurities is not more than 0.2% 
(Convention 2015). The impurity inspected during this study was a CBZ 
degradation product, iminostilbene. The degradation into iminostilbene of the 
ultrasonicated product was examined using the HPLC method described in 
detail in section 3.5.7. A calibration curve was constructed to determine the 
degraded product as shown in figure 5.21. 
 134 
 
 
Figure 5.21 Calibration curve for iminostilbene concentration against the peak 
area obtained from HPLC analysis. 
 
Figure 5.22 Chromatogram for CBZ and iminostilbene showing peak elution at 8 
and 11.2 minutes, respectively. 
As shown in figure 5.22, a HPLC method for the separation and identification 
of the CBZ and iminostilbene peak was developed with two well separated 
peaks at retention times of 8 and 11.2 mins, respectively. The average 
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iminostilbene impurity in each sample was calculated after calculating their 
peak area. 
Table 5.3 Degradation results: Percentage iminostilbene in ultrasonicated CBZ-
NIC CC processed at 100°C with different levels of power 
Component Power 
level (% 
of max) 
Set 
Temp 
(°C) 
Batch 
code 
Exposure 
time 
(sec) 
Iminostilbene 
(%) 
Standard 
Deviation 
SD 
 
 
 
 
 
CBZ-NIC  
 
25% 
 
 
 
 
 
100 
A 70 0.00472 0.000004 
B 150 0.00489 0.000018 
C 300 0.00567 0.000009 
 
50% 
D 5 0.00504 0.000007 
E 10 0.00583 0.000009 
F 20 0.01973 0.000033 
G 50 0.02495 0.001512 
 
75% 
H 5 0.00492 0.000017 
I 10 0.00600 0.000071 
J 15 0.00781 0.000018 
100% K 5 0.00515 0.000008 
L 10 0.00614 0.000002 
 
The HPLC results show the presence of iminostilbene in all ultrasonicated 
CBZ-NIC batches which increased with increase in exposure time and power 
applied. Considering the HPLC results in table 5.3, the entire analysed 
samples presented a relatively small amount of iminostilbene. The observed 
% impurities were significantly below the standard level given by USP 
(0.2%). The % impurity observed was highest in co-crystals obtained with an 
applied power of 50% at an exposure time of 50 sec. These results were in 
accordance with a previously reported study, where parameters such as a 
high temperature, high exposure time and microwave irradiation elevated 
degradation levels in microwave-assisted co-crystallisation process (Pagire 
et al. 2013). 
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5.3.6 SEM results 
Scanning electron microscopy (SEM) was utilised to support the existing 
results. It was viewed as a useful technique to observe particle morphology 
information including particle size. In this section, SEM was used for 
analysing pure CBZ, NIC, CBZ-NIC physical mixture 1:1, CBZ-NIC co-
crystals (reference) prepared by the solution method and for analysing 
selected CBZ-NIC ultrasonicated samples produced at a processing 
temperature of100°C with different sonication times (figure 5.23). 
SEM images of pure CBZ and NIC are shown in (figure 5.23A, B) at 100X 
and 200 X magnifications respectively. The CBZ and NIC particles ranged 
from 50um to 400um in diameter. Figure 5.23C and D represented the SEM 
images for CBZ-NIC physical mixture 1:1. In the 200X image (C) the CBZ 
and NIC particles can be observed next to one another. Under further 
magnification 2000X (sample 5.23D), CBZ particles can be seen coating the 
NIC particle surface  
 
 
 
B A 
B 
 137 
 
         
Figure 5.23 SEM images for ultrasonicated CBZ-NIC co-crystals processed at 
100°C and different power levels 
A) CBZ, 100X, B) NIC, 200X, C) CBZ-NIC PM, 200X, D) CBZ-NIC PM, 2000X, E) CBZ-NIC 
CC, 3000X (reference), CBZ-NIC CC processed at 100°C with different power levels, F) 
300s-25% power, 2000X, G) 50s-50% power, 2000X and H) 10s-75% power, 2000X. 
Figure 5.23E displays the SEM image of the 1:1 pure co-crystal made using 
the solvent evaporation method described in section 3.4.6. The co-crystal is 
shown at 3000X magnification. From solution, the co-crystals grew with 
needle shaped morphology. SEM images of selected ultrasonicated samples 
at different conditions samples F, G and H were magnified at 2000X. Both 
H G 
F E 
D 
C D E F 
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hollow co-crystal needles and solid needle shaped crystals were observed 
and were generally shorter than the co-crystal needles produced using 
solution evaporation in figure 5.23E. These differences in size of crystal 
needles may be due to the different power levels and exposure times. 
Crystals may have experienced more growth than those which formed early 
during the ultrasonication.  
5.4 CBZ-NIC processed at ambient temperature with 
application of 100% power  
In this section, results are presented to the effect of maximum power level 
applied at ambient condition on an equimolar mixture of CBZ and NIC and 
with the addition of 5, 10 and 15% of water, and 1:1 physical mixture of CBZ 
DH-NIC; all constituting a total weight of 2g w/w.  
5.4.1 Observations 
Different batches of equimolar physical mixture of CBZ-NIC with a total 
weight of 2g (w/w) were subjected to 100% US power at room temperature. 
Figure 5.24 shows the ultrasound behaviour on some of the CBZ-NIC co-
crystals batches exposed to 100% power at different sonication times. At 60 
sec of subjecting CBZ-NIC 1:1 physical mixture (figure 5.24A), the sample 
was melted and colour changed to yellow. When CBZ-NIC PM-15% water 
(figure 5.24B) was subjected to ultrasound for 20 sec, a compact tablet was 
formed; however, as sonication time increased to 60 sec and added 5% and 
15% water was to the physical mixture, the ultrasound energy dissipated 
readily   and formed holes in the tablet due to cavitation (figure 5.24C and D). 
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Figure 5.24 ultrasound behaviour on CBZ-NIC co-crystals 
CBZ-NIC co-crystal batches obtained at A) 60s, B) 20s-15% water, C) 60s-55 water, D) 60s-
15% water 
5.4.2 DSC Results 
DSC analysis was carried out as described in section 3.5.1. Figure 5.25 
represents results of CBZ-NIC co-crystals obtained using maximum 
ultrasound power at ambient temperature. 
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Figure 5.25 DSC thermograms of CBZ-NIC processed at RT with 100% applied 
power 
A B C 
D 
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[CBZ-NIC PM, obtained CBZ-NIC CC at A) 20sec, B) 40sec, C) 60sec, D) 80sec and  E) 
100sec] 
The physical mixture of CBZ and NIC in a 1:1 molar ratio depicted two 
endothermic peaks. The first peak reflected the melting of NIC at 125°C, 
followed by subsequent melting of CBZ dissolving in the melt of NIC giving 
rise to a co-crystal peak around 159°C (Liu et al. 2012). DSC thermograms 
for CBZ-NIC co-crystal obtained at different sonication times of 20, 40 and 60 
and 80 sec showed two endothermic peaks at 125°C and 159°C, 
respectively. The intensity of the co-crystal endothermic peaks increased as 
the sonication time increased. This observation suggests that the rate of 
conversion and interaction of CBZ with NIC molecules was enhanced with 
the increase of exposure time. The DSC thermogram of sample produced at 
100 sec of exposure time (batch E) showed a broad exothermic peak at 50-
80°C and single endothermic peaks at 159°C. This demonstrates that the co-
crystals at this exposure time were pure with partial amorphisation. Longer 
exposure time and high ultrasound energy can induce intensive inter-
molecular collision where particles may generate friction between the 
particles and the die wall, causing partial amorphisation (Pazesh et al. 2013). 
This result was in agreement with a previously reported study, where  an 
ultrasound-assisted tabletting machine for compaction of a mixture of 
ketoprofen with polymer caused a partial amorphisation of ketoprofen with 
ultrasound energy at high exposure time (Sancin et al. 1999). For this 
reason, ultrasound treatment of CBZ-NIC in the presence of a minute 
amount of water at ambient temperature and maximum power was carried 
out to explore the formation of co-crystals suppressing amorphisation. This 
 141 
 
was further used to investigate any degradation in the presence of water and 
its implication on ultrasound energy propagation.  
Figure 5.26 represents the DSC thermograms of CBZ-NIC CC obtained by 
ultrasound processed at RT at maximum power with addition of 5% water 
(figure 5.26A), 10% water (figure 5.26B) and 15% water (figure 5.26C) at 
different sonication times of 20, 40 and 60 sec. 
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Figure 5.26 DSC thermograms of CBZ-NIC processed at RT with 100% power and 
addition of A) 5% water, B) 10% water and C) 15% water 
It was observed that all batches shown in figure 5.26A with addition of 5% 
water (F-H) exhibited two endothermic peaks at 125°C and 159°C 
respectively, which correspond to the eutectic point of the physical mixture 
and melting point of the co-crystal. The co-crystals obtained with exposure 
times of 20, 40 and 60 sec were not pure. Batch F at 20 sec of exposure time 
produced a broad endothermic peak between 60°C and 80°C which 
corresponds to the loss of water. With increase in exposure time, the 
ultrasounds dehydrated the amount of water present in sample and therefore 
did not generate a broad water peak for batches G and H. In figure 5.26B, 
DSC thermograms of batch I exhibited two endothermic peaks at 125°C and 
159°C which relates to the eutectic point and co-crystal melt. Further 
exposure time of 40 and 60 sec (batches J and K) exhibited a single 
endothermic peak at 159°C which corresponds to the melting point of CBZ-
NIC co-crystal form I. For batches with 15 % water (L, M and N) at all 
exposure times showed a broad endothermic peak between 60°C and 80°C 
due to loss of water followed by single a single endothermic peak at 159°C. 
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This confirms that the co-crystals generated were a hydrated CBZ-NIC co-
crystal form I and the increase in ultrasound exposure time with the addition 
of 15% water was not sufficient to dehydrate the obtained co-crystal.  
Figure 5.27 represents DSC thermograms of CBZ DH-NIC CC obtained at 
room temperature with application of maximum level of power under different 
sonication times.  
The DSC thermogram of batch (O) which was exposed to 20 sec of 
ultrasound shows a broad endothermic peak over the temperature range 
between 50-80°C, attributed to the dehydration of water. The endothermic 
peak at 125°C represents either the eutectic mixture temperature or 
unreacted NIC, followed by a co-crystal peak at 159°C. This result confirms 
that CBZ-NIC co-crystal obtained at 20 sec was a hydrate form and hence, 
impure. DSC thermograms of batches P, Q and R exposed to 40, 60 and 80 
sec showed similar results with two endothermic peaks at 124°C and 159°C. 
Therefore, the absence of a broad endothermic peak for water was observed 
at higher sonication times i.e. at higher ultrasound exposure.    
40 60 80 100 120 140 160 180 200
-8
-7
-6
-5
-4
-3
-2
-1
0
1
2
3
4
5
6
7
8
H
ea
t F
lo
w
 (W
/g
)
Temperature (
0
C)
159
0
C
124
0
C
S
R
Q
P
O
 
 
 144 
 
Figure 5.27 DSC thermograms of CBZDH-NIC processed at RT with applied of 
100% Power 
[CBZ DH_NIC PM1:1 treated at O) 20 sec, P) 40 sec, Q) 60sec, R) 80 sec and S) 100 sec] 
At 100 sec of exposure time (batch S), DSC thermogram exhibited a single 
endothermic peak at 159°C, representing pure co-crystal peak.  
5.4.3 PXRD Results 
PXRD analysis was carried out as described in section 3.5.2. Figure 5.28 
depict PXRD patterns of obtained CBZ-NIC CC processed at RT under 
100% power level at different sonication times.  
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Figure 5.28 PXRD patterns of CBZ-NIC processed at RT with 100% power at 
different sonication times 
[CBZ-NIC PM, CBZ-NIC PM treated at A) 20sec, B) 40sec, C) 60sec, D) 80sec and E) 
100sec, CBZ-NIC CC (reference)] 
 The PXRD pattern of CBZ-NIC PM encompassed peaks of CBZ and NIC 
and showed unique characteristic peaks (figure 5.28, indicated by arrows) at 
14.8° and 15.3°, identical to previous reports (Rahman et al. 2011). PXRD 
patterns of CBZ-NIC CC subjected to 20, 40, 60 and 80 sec (batches A, B, C 
and D), produced pronounced CBZ-NIC co-crystals peak at 6.8, 8.9 10.3 and 
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20.2 respectively, with the presence of unreacted physical mixture (figure 
5.28 indicated by arrows). This result is in agreement with the DSC results 
(figure 5.25). The diffractogram obtained at 100 sec (Batch E) produced 
characteristic peaks attributed to CBZ-NIC co-crystal pure form; identical to 
CBZ-NIC co-crystal produced by the reference method. However, these 
peaks were diffused and of low intensity. This suggests that the obtained co-
crystal at this point was partially amorphised.        
Figure 5.29 shows PXRD patterns of CBZ-NIC CC obtained by ultrasound 
processed at RT, exposed to 100% power with the addition of 5% water 
(figure 5.29A), 10% water (figure 5.29B) and 15% water (figure 5.29C), at 
different sonication times (20, 40 and 60 sec). In figure 5.29A, the 
diffractogram of CBZ-NIC physical mixture with 5% water depicts 
characteristic peaks of CBZ-NIC PM (indicated by arrows) along with co-
crystal peaks at 2θ values of 6.8°, 8.9° 10.3° and 20.2°. This may suggest 
the role of water in co-crystal formation as demonstrated in a study where 
moisture uptake generated a liquid medium for dissolution of the reactant, 
and subsequent co-crystal nucleation and growth (Jayasankar et al. 2006; 
Jayasankar et al. 2007). Although the intensity of characteristic peaks of CBZ 
and NIC (indicated by arrows) decreased, the peak intensity of co-crystal 
increased with increase in exposure time from 20 to 60s (Batch F, G and H). 
Therefore, all batches showed impure co-crystal patterns in agreement with 
the DSC results (figure 5.26A). This suggests that the amount of water 
added was not enough to generate pure CBZ-NIC co-crystal at the above 
conditions. In figure 5.29B, 10% of water was added to CBZ-NIC physical 
mixture before it was subjected to ultrasound. The sample with 20 sec of 
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exposure time (batch I) showed pronounced  characteristic peaks of the co-
c  s        θ v  u s of  .8°, 8.9° 1 .3°   d   . °. A low intensity peak around 
14.8 (indicated by an arrow) corresponds to unreacted NIC. Beyond 20 
second exposure time, i.e. 40 and 60 sec batches (J and K) showed unique 
characteristic peaks of co-crystal which were identical to the characteristic 
peaks of the reference CBZ-NIC CC. A study using a co-grinding method 
demonstrated water as a potential plasticiser which enhanced the molecular 
diffusion and the rate of co-crystallisation at ambient conditions and gave an 
additional freedom to molecules at various interfaces; enhancing the 
molecular collision, and  allowing formation of co-crystal seeds (Shan et al. 
2002). These results confirm that samples with 10% water under ultrasound 
can enhance the rate of co-crystal formation and produce pure co-crystal 
form I above 20 seconds of exposure time. Furthermore, the presence of 
water as a plasticiser lowers the Tg and enhances the molecular mobility 
(Jayasankar et al. 2006) of the starting material forming co-crystals at 
exposure times below 80 sec, thereby, inhibiting amorphisation.  
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Figure 5.29 PXRD patterns for CBZ-NIC processed at RT with applied of 100% 
power and addition of A) 5% water, B) 10%water, C) 15% water    
Figure 5.29C showed PXRD patterns of CBZ-NIC CC processed at ambient 
temperature and maximum applied power with the addition of 15% water. A 
diffractogram of CBZ-NIC physically mixed with 15% water showed 
characteristic peaks of physical mixture at 14.8° and 15.3° along with 
emerging characteristic peaks of co-crystal. This proves that the manual 
physical mixture of starting materials in the presence of water induced or 
initiated co-crystal formation. The diffractogram of sample obtained at an 
exposure time of 20 sec (batch L) depicted low intensity characteristic peaks 
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at 14.8, 15.3, and high intensity peaks corresponding to co-crystal formation. 
Exposure times of 40 and 60 sec (M and N batch) diminished the physical 
mixture peaks at 14.8 and 15.3, followed by co-crystal peak. Moreover, the 
appearance of a unique characteristic peak at 12.3 confirmed the presence 
of water explaining the presence of the hydrated form of co-crystal. This 
peak was absent in the diffractogram of dehydrated or dry CNZ-NIC CC form 
I (CSD and X-ray of CBZ-NIC CC reference, figures 5.7 and  5.29C, 
respectively).  
Figure 5.30 represents PXRD patterns of CBZ DH-NIC processed at ambient 
temperature with 100% applied power at different sonication times.  CBZ DH 
showed a strong structure orientation with peaks at 9.0° and 12.18 and 
remained until all water of hydration was removed (Harris et al. 2005; Khoo 
et al. 2013). The diffractogram of samples obtained at exposure times of 20, 
40, 60, 80 sec (batches O, P, Q and R, respectively) showed a prominent 
characteristic peak for CBZ-NIC CC with low intensity NIC peak at 14.8° 
(indicated by an arrow). This confirms the presence of unreacted NIC in the 
obtained co-crystal; confirming finding of DSC results in figure 5.27.      
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Figure 5.30 PXRD patterns of CBZ DH-NIC processed at RT with 100% power at 
different sonication times 
[CBZ DH, obtained CBZ DH-NIC CC at O) 20sec, P) 40sec, Q) 60sec, R) 80sec and S) 
100sec] 
 
 At exposure time of 100 sec (batch S), the low intensity NIC peak diminished 
with the appearance of prominent peaks of CBZ-NIC Co-crystal form I 
identical to the diffractogram of CBZ-NIC CC (reference) and DSC results 
(figure 5.27).  
5.4.4 Measurement of power and temperature 
Ultrasound energy dissipation and final temperature rise due to the 
absorption of ultrasound energy was measured by the method described in 
section 3.3.2. 
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Table 5.4 Measured dissipated power and final temperature of CBZ-NIC, CBZ-NIC 
5, 10, 15% water and CBZ DH-NIC processed at RT and 100% power at different 
sonication times 
Component Set 
Temp 
(°C) 
Power 
Level 
(% of 
max) 
Batch 
code 
Exposure 
Time 
(sec) 
Max 
Temp 
(°C) 
Average 
Power 
Input (W) 
Total 
Energy 
Input 
(KJ) 
CBZ-NIC1:1 
PM 
 
 
 
 
 
 
 
 
RT 
 
 
 
 
 
 
 
 
 
100% 
A 20 22 87 1.7 
B 40 32 107 4 
C 60 63 127 7.6 
D 80 74 137 11 
E 100 84 160 16 
CBZ-
NIC_5% 
water 
F 20 23 108 2.2 
G 40 29 125 5 
H 60 44 140 8.4 
CBZ-
NIC_10% 
water 
I 20 22 116 2.3 
J 40 28 125 5 
K 60 52 138 8.3 
CBZ-
NIC_15% 
water 
L 20 24 128 2.6 
M 40 45 155 6.2 
N 60 57 160 9.6 
CBZ DH-
NIC 1:1 PM 
O 20 20 90 1.8 
P 40 24 97 3.9 
Q 60 31 108 6.5 
R 80 39 120 9.6 
S 100 42 145 14.5 
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The results showed that ultrasound-induced temperature rise in solid pairs 
CBZ-NIC batches from A to E was higher as compared to other batches. 
Also, the average power input and the total energy dissipation were higher 
as compared to other batches. This may be due to the closely arranged solid 
molecules dissipating the energy at a high speed causing inter-molecular 
collisions and hence, a rise in temperature. A report issued by Gould 
suggested that there was a linear relationship between the heat transfer rate 
and the sound amplitude while using water as medium in sloid–liquid 
interface (Gould 1966). This phenomena is in agreement with the results 
obtained using 5, 10 and 15% of water added to CBZ-NIC where water 
further helped in the dissipation of the power applied, increasing the heat 
transfer rate consequently. Therefore, batches H, K and M subjected to 
ultrasound for 60 sec showed a rise in temperature of 44°C, 52°C and 57°C, 
respectively. In the case of CBZ DH, strongly bound water molecules are 
present in the crystal lattice  and appears as less dense crystals (Harris et al. 
2005). The water molecules in the crystal lattice space out the CBZ 
molecules apart from each other, therefore, the power input and the total 
energy dissipated less and reduced the molecular collision; lowering the 
power and rise in temperature as illustrated in batches P to S compared to 
batches A to E.  
5.4.5 Determination of % purity of co-crystal using NIR method 
The NIR calibration model was described in detail in section 3.5.6.2. PLS 
regression model 2 in the region 9000-8500 cm-1, chemometric 2nd Dev., 
SNV and SG smoothing was utilised to determine the purity or predict the 
yield of CBZ-NIC co-crystal from batches  A to S (figure 5.18). This model 
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exhibited a correlation coefficient of 0.9992, and a small RMSEP value of 
3.53%, and the difference between the RMSEC and RMSEP value was only 
-2.3%. Figure 5.31 shows the total amount of CBZ-NIC co-crystal obtained 
for: a) equimolar mixture of CBZ and NIC alone; b) with addition of 5%, 10, 
and 15% water; c) and d) CBZ DH and NIC mixture processed at ambient 
temperature and applied power of 100%. These NIR results were reflected in 
previously presented DSC and PXRD results and hence, prove that the NIR 
calibration model was feasible for determining the purity of the co-crystals. 
When the equimolar mixture of CBZ-NIC in solid state was ultrasonicated 
(figure 5.31 red columns), the amount of CBZ-NIC co-crystal generated 
increased gradually as sonication time increased. The highest percentage 
yield of the co-crystal was observed at an exposure time of 80 sec, where a 
visual melting of the sample was noticed. This concludes that the NIC 
melting helped dissolve CBZ molecules and further aid in its co-
crystallisation. Water-assisted ultrasonication of equimolar mixture of CBZ 
and NIC readily produced quantitative yield of co-crystals, i.e. 94% within 20 
sec. Co-crystal formation was high for CBZ DH, and in mixtures with water at 
a sonication time of 20 sec, followed by anhydrous CBZ III.   
 153 
 
 
Figure 5.31 % CBZ-NIC CC processed at ambient temperature with applied of 
100% power using NIR calibration model  
5.4.6 Chemical stability 
The use of solvent-free ultrasonic approach processed at room temperature 
and 100% power did not produce any changes in colour. The localised 
temperature generated from the tip of the probe may cause changes in 
chemical structure; therefore it was seemed to perform degradation on 
ultrasound samples generated at different conditions. The impurity inspected 
during this study is a CBZ degradation product, iminostilbene. The 
degradation into iminostilbene of the ultrasonicated product was examined 
using the HPLC method which was described in detail in section 3.5.7.  A 
calibration curve was constructed to determine the degraded product as 
shown in figure 5.21. 
Table 5.5 Degradation results: Percentage iminostilbene in ultrasonicated 
CBZ-NIC, CBZ-NIC with addition of 5, 10 and 15% water, and CBZ DH-NIC 
processed at RT with applied 100% power at different sonication times.  
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Component Batch 
code 
Set 
Temp 
(°C) 
Exposure 
Time 
(sec) 
Power 
level  
(% of 
max) 
Iminostilbene 
(%) 
SD 
 
CBZ-NIC1:1 
PM 
A  
 
 
 
 
 
 
 
 
 
RT 
 
20  
 
          
 
 
 
 
 
 
 
100 
 
 
 
0.0000 0.0000 
B 40 0.0056 3.0808 
C 60 0.0095 7.1885 
D 80 0.0137 0.0001 
E 100 0.0224 0.0023 
CBZ-NIC_5% 
water 
F 20 0.0046 4.5641 
G 40 0.0048 1.0497 
H 60 0.0055 6.0475 
CBZ-
NIC_10% 
water 
I 20 0.0000 0.0000 
J 40 0.0046 5.1347 
K 60 0.0047 1.9968 
CBZ-
NIC_15% 
water 
L 20 0.0043 0.0000 
M 40 0.0046 2.0538 
N 60 0.0047 2.9667 
CBZ DH-NIC 
1:1 PM 
O 20 0.0051 3.0808 
P 40 0.0043 0.0000 
Q 60 0.0046 3.0808 
R 80 0.0049 7.8732 
S 100 0.0051 6.6180 
 
The HPLC results show the presence of iminostilbene in ultrasonicated CBZ-
NIC mixture without the addition of water, (batches A to E). The degradant 
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amount increased with increase in exposure time, with batch E producing 
amounts above the USP standards (i.e. >0.2%). This suggests that localised 
heat temperature resulted from the application of maximum power may have 
increased the extent of degradation, particularly as sonication time 
increased. Furthermore, the presence of amorphous content in batch E also 
enhances the extent of degradation (figure 5.25). It was found that 
amorphous forms tend to degrade at higher rates than the crystalline forms. 
This could be due to an increase in the specific surface area and molecular 
mobility which therefore reduces the activation energy (Shah et al. 2014). 
The presence of iminostilbene in ultrasonicated CBZ-NIC with addition of 5, 
10, 15% water, and CBZDH-NIC batches were almost similar at different 
sonication times with degradant content below the USP standard limits.  
5.4.6 SEM results 
SEM images for the for the ultrasonicated CBZ-NIC co-crystals using 
physical mixtures alone, with addition of water and added CBZDH are shown 
in figure 5.32.  
 
A B 
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Figure 5.32 SEM images for CBZ-NIC co-crystals processed with and without 
addition of water. 
A) CBZ-NIC-RT-80s, 100x, B)  CBZ-NIC-RT-80s, 500x, C) CBZ-NIC-60s-10% water, 100x, 
D) CBZ-NIC-60s-10% water, 200x, E) CBZ DH, 1000x and F) CBZ DH-NIC-80s, 2000x. 
The morphology of CBZ-NIC co-crystals obtained at different conditions were 
different. Crystal morphology of the co-crystals obtained at 80 sec exposure 
time without addition of water (figure 5.32A, 100x, B 500x) exhibited 
agglomerated particles. With the addition of 10% water and exposure to 60 
sec of ultrasound (figures 5.32C,D magnified at 100x and 200x), the crystal 
morphology consisted of aggregated needles with some showing hollow 
cores. CBZ DH crystals, magnified at 1000x (figure 5.32D) were observed as 
long needles (typical DH morphology) (Tian et al. 2006), while the crystal 
morphology of the co-crystals obtained at 80 sec exposure (figure 5.32E, 
2000x) showed a needle-like morphology, however some needles exhibited 
hollow cores. 
C D 
D E 
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5.5 Summary 
To summarise the results of this chapter, the solvent-free ultrasonic 
approach was succeeded in producing of CBZ-NIC co-crystal polymorph I. 
Pure CBZ-NIC co-crystal processed at 100°C and different levels of power 
was mainly dependent on level of power and sonication times. For example 
at 100% power, 10 sec was required to produce pure CBZ-NIC co-crystals. 
Temperature rise and power input were increased as level of power and 
sonication time increased. Longer exposure of CBZ-NIC processed at RT to 
100% power produced CBZ-NIC co-crystal with partial amorphisation. 
Addition of 5%, 10% and 15% of water played an important role to overcome 
amorphisation and degradation, which enhanced co-crystal formation. A 
developed NIR calibration model succeeded in determining the purity of 
CBZ-NIC co-crystals obtained at different conditions. The utilised 
characterisation techniques DSC, PXRD and quantitative NIR produced 
complementary results. The degradation study suggested that degradation of 
carbamazepine was minimal and the ultrasonicated samples would meet the 
FDA standard if made in tablet form. Overall this entire chapter highlighted 
the potential of the ultrasound technology in the pharmaceutical sector. 
Pharmaceutical co-crystals were successfully manufactured using this 
technology and this study helped to provide information on the effect of 
different parameters on co-crystallisation. 
   
  
 
 
 
 
 
 
 
 
 
CHAPTER 6 CARBAMZEPINE-SACCHARIN CO-
CRYSTAL
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6.1 Introduction 
This chapter describes the formation of co-crystals of carbamazepine (CBZ) 
and saccharin (SAC) via the solvent-free ultrasonic approach. CBZ forms a 
complex with SAC and has been extensively studied as a co-crystal to 
overcome the problem of solubility, polymorphism, scale-up and solvate 
formation. The CBZ-SAC co-crystal pair is challenging as it appears in two 
polymorphic forms, form I and form II (Porter III et al. 2008). Different  
methods for  forming  CBZ-SAC co-crystals have been demonstrated such 
as solution, slurry, grinding and sonic slurry (Tomaszewska et al. 2013).  A 
solvent-free approach using a twin-screw extruder for the scale-up of CBZ-
SAC 1:1 co-crystal lead to its degradation and polymorphic transformation 
under high temperature conditions (Joshi 2012). Therefore, this compound is 
also susceptible to degradation and requires controlled manufacture storage. 
In this study we investigated co-crystal formation via a solvent-free ultrasonic 
approach at ambient temperature using equimolar weights of the physical 
mixture alone, and with addition of 5% water and 5% PEG 8000. In all cases, 
CBZ-SAC 1:1 co-crystal form I was obtained. Characterisation was 
performed using PXRD, DSC, FTIR and HPLC. Dissipated power and 
temperature rise was also measured. 
To quantify the effect of the ultrasound, the top and bottom surfaces of the 
co-crystal tablet obtained from equimolar weights of CBZ-SAC and CBZ-SAC 
with 5% water was examined using Raman spectroscopy. 
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6.2 Crystal structure data 
6.2.1 Carbamazepine, anhydrous form III (CSD Ref: CBMZPN10) 
The crystal structural data (CSD) and PXRD pattern of anhydrous CBZ form 
III was described in detail in section 5.2. 
6.2.2 Saccharin (CSD Ref: SCCHRN)  
The saccharin (SAC) crystal structure (figure 6.1) is a monoclinic and a 
planer crystal and lies in space group P 21/c space group with a = 9.56° Å, 
b=6.91°Å, c=11.82° Å   d β = 1 3.85°. The crystal structure forms a 
centrosymmetric dimer via a N-H----O H-bond between keto oxygen and 
imide nitrogen of the five-membered rings. The hydrogen bond around the 
centre of symmetry forming the six-sided ring and narrow angle at C-S-N 
alleviates the strain from the molecule making it a planar structure (Okaya 
1969). Figure 6.2 illustrates the PXRD patterns for SAC. 
 
Figure 6.1 Crystal structure of SAC (attained from CSD Ref: SCCHRN). 
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Figure 6.2 Calculated PXRD patterns for SAC (adapted from CSD and processed 
in OriginPro 8) 
6.2.3 CBZ-SAC 1:1 co-crystals 
6.2.3.1 CBZ-SAC 1:1 form I (CSD Ref: UNEZAO) 
This triclinic form of CBZ-SAC 1:1 relates to space group P-1 with unit cell 
dimensions: a 7.52(11) Å, b 10.45(15) Å, c 12.68 18) Å,   d   g  s: α= 
83. 4  ) , β= 85.7   ) ,   d γ= 75.41  ) ° (CSD Ref: UNEZAO).  As shown 
in figure 6.3, the crystal packing consists of homosynthons between two CBZ 
carboxamide groups. An additional hydrogen bonded homodimer is present 
between SAC N-H and CBZ carboxyl group, and anti-NH of CBZ urea with 
S=O of SAC (Porter III et al. 2008). The crystal structure and PXRD pattern 
data is depicted in figures 6.3 and figure 6.4 respectively.  
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Figure 6.3 Crystal structure of CBZ-SAC 1:1 form I (CSD Ref: UNEZAO)  
 
2 4 6 8 10 12 14 16 18 20 22 24 26 28 30
0
4000
8000
12000
In
te
ns
ity
2 Theta(
0
)
 
Figure 6.4 Calculated PXRD patterns for CBZ-SAC 1:1 form I (adapted from CSD 
Ref: UNEZAO)  
6.2.3.2 CBZ-SAC 1:1 form II (CSD Ref: UNEZAO01)  
This monoclinic form lies in the space group C2/c with unit cell dimensions: 
 = 35.7  1 ) Å, b=  .84  ) Å, c=1 .11 5) Å   d β = 98. 3  )   CSD R f: 
UNEZAO01). As shown in figure 6.5 a hetersynthon formation takes place 
via H-bonding of CBZ (C=O) with SAC (N-H) and SAC (N-H) with CBZ 
(C=O). Also, further H-bonding formed between anti N-H of CBZ urea with 
S=O of SAC (Porter III et al. 2008). The crystal structure and calculated 
PXRD pattern are shown in figures 6.5 and figure 6.6, respectively.     
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Figure 6.5 Crystal structure of CBZ-SAC form II (CSD Ref: UNEZAO01) 
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Figure 6.6 Calculated PXRD patterns for CBZ-SAC form II (adapted from CSD 
Ref: UNEZAO01) 
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6.3 Results of CBZ-SAC co-crystals processed at RT and 
100% power  
6.3.1 DSC results 
All samples obtained from the ultrasonic method were ground by mortar and 
pestle to get uniform particle size. DSC analysis of experimental batches was 
carried out as described in section 3.5.1. 
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Figure 6.7 DSC thermograms of CBZ-SAC CC processed at RT and 100% power 
[CBZ, SAC, CBZ-SAC PM, CBZ SAC CC processed at A) 20 sec, B) 40 sec, C) 60 sec and 
CBZ-SAC CC (reference)] 
The DSC profile of CBZ-SAC co-crystal (reference) produced a distinctive 
peak at 177°C which was different from the individual component’s melting 
points; CBZ (175°C, 191°C) and SAC (226°C), their physical mixture 
(156°C), and sonicated co-crystal (173.8°C). DSC thermogram of CBZ-SAC 
co-crystal processed at 20 sec (batch A) had two endothermic peaks at 
155.9°C and 173.4°C, which represented the eutectic melting point and co-
crystal melting points respectively. Therefore, the co-crystal obtained was not 
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a pure form. At 40 and 60 sec of exposure time (batches B and C), the DSC 
thermograms exhibited a broad exothermic peak at 72-96°C, and broad 
individual peaks at 172.5°C and 171.5°C, respectively. Therefore as the 
exposure time increased, partially amorphised CBZ-SAC co-crystal form I 
was obtained. In order to retard amorphisation, improve crystallinity and 
prevent degradation, 5% of water was added to equimolar weight of CBZ and 
SAC and subjected to maximum level of power to observe any effect on the 
quality of co-crystal obtained. 
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Figure 6.8 DSC thermograms of CBZ-SAC CC processed with the addition of 5% 
water at RT and at 100% power 
[CBZ-SAC PM-5%H20, ultrasonicated CBZ-SAC co-crystal at D) 20 sec, E) 40 sec and F) 
60 sec] 
In figure 6.8, DSC thermograms of CBZ-SAC PM mixed with 5% water 
illustrated a broad endothermic peak between 55-75°C, indicating water loss, 
followed by an eutectic peak at 155°C and a co-crystal peak at 174°C. The 
obtained co-crystals batches (D and E) subjected to ultrasound at 20 and 40 
sec had similar results which indicated that co-crystals were not pure and 
contained residual water. At 60 sec of exposure time (batch F), the DSC 
thermogram depicted a single endothermic peak with the absence of a water 
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peak around 70°C. This confirms that the localised temperature generated by 
the ultrasound probe liberated water molecules from the sample, producing a 
dehydrated co-crystal form I.  
Figure 6.9 shows DSC thermograms of CBZ-SAC co-crystal obtained with 
the addition of 5% PEG 8000 to pre-processed CBZ-SAC PM.  
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Figure 6.9 DSC thermograms of CBZ-SAC CC processed with the addition of 5% 
PEG 8000 at RT and 100% power. 
[PEG 8000, CBZ-SAC-PM-5% PEG 8000, processed CBZ-SAC CC at H) 20sec, I) 40sec 
and J) 60sec]. 
The DSC curve of PEG 8000 displayed a endothermic melting peak at ~60°C 
which was shifted to 55°C as the consequence of CBZ-SAC co-crystal 
formation (Jayaramudu et al. 2016). The DSC thermogram of CBZ-SAC PM 
with 5% PEG 8000 had endothermic melting peaks at 55°C, 155°C and 
174°C, attributed to PEG 8000, eutectic point of CBZ-SAC PM, and co-
crystal, respectively. Ultrasonicated CBZ-SAC co-crystals at different 
sonication times (Batches G, H and I) showed endothermic peaks at 55°C, 
155°C and 174°C. This explains the presence of PEG molecules dispersed 
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within the co-crystal molecules alongside the presence of a small amount of 
unreacted CBZ. 
6.3.2 PXRD Results 
All samples obtained from ultrasonic method were ground by mortar and 
pestle prior to PXRD analysis of experimental batches, which was carried out 
as described in section 3.5.2. 
PXRD patterns of CBZ, SAC and ultrasonicated samples of equimolar CBZ 
and SAC are shown in figure 6.10  
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Figure 6.10 PXRD patterns of CBZ-SAC CC processed at RT and 100% power 
[CBZ, SAC, CBZ-SA PM, obtained CBZ-SAC Form I CC at A) 20 sec, B) 40 sec, C) 60 sec 
and CBZ-SAC Form I CC (reference)] 
The characteristic diffraction peaks of P-monoclinic CBZ III were at 2θ= 
13.1°, 13.4° and 15.3° (Li et al, 2014). Key characteristic peaks of SAC 
originated at 2θ= 9.8°, 16.3° and 25°. 
Through the solvent crystallisation approach described in section 3.4.5, the 
new crystalline material formed indicated the unique feature of CBZ-SAC co-
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crystal form I as depicted by the PXRD peaks at 2θ =7° and 14° which are in 
good agreement with the CSD data (figure 6.4).   
At 20 sec of ultrasonication, transformation to the co-crystalline phase  was 
observed as indicated by a diffraction peak at 2θ =6.8° which is unique to 
CBZ-SAC form I co-crystal (Hickey et al. 2007; Porter III et al. 2008; 
Tomaszewska et al. 2013; Qiu and Li 2015) confirmed by PXRD patterns of 
CBZ-SAC CC (reference and CSD). However, unreacted SAC and CBZ at 
2θ= 25.0° and 13.3° respectively, was also present as indicated by the 
arrows in figure 6.10; PXRD patterns of batches B and C at exposure times 
of 40 and 60 sec respectively, showed low intensity co-crystal peaks which 
indicated the possible amorphisation of the samples. The PXRD patterns 
were also in agreement with the DSC results shown in figure 6.7.  
Figure 6.11 represents PXRD patterns of CBZ-SAC form I co-crystal 
obtained from the addition of 5% water and 100% applied power at room 
temperature. 
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Figure 6.11 PXRD patterns of CBZ-SAC CC processed with addition of 5% water 
at RT and 100% power 
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[CBZ-SAC PM, CBZ-SAC PM-5% H2O, ultrasonicated CBZ-SAC CC obtained at D) 20sec, 
E) 40 sec, F) 60 sec and CBZ-SAC CC (reference)] 
The PXRD patterns of PM of CBZ and SAC alone and with addition of 5% 
water produced similar PXRD patterns with peaks at 13.3° and 25.0° which 
are characteristic peaks of the p-monoclinic form of CBZ and SAC indicated 
by arrows. This confirms that the above physical mixtures failed to produce 
co-crystals during physical mixing with 5% water.  At 20 and 40 sec of 
exposure time (batches D and E), the x-ray diffraction showed peaks at 7° 
and 14°, which are characteristic peaks of co-crystal form I, while the peaks 
at 13.3° and 25.0° were characteristic peaks of CBZ and SAC, respectively. 
This shows the presence of unreacted CBZ and SAC in the ultrasonicated 
samples.  The ultrasonic co-crystallisation batch F taken at 60 sec exposure 
time generated a prominent co-crystal peak at 7° along with the suppression 
of ch   c    s  c p   s of CBZ   d S C     θ=13.3°   d  5. °, indicating  
the presence of  CBZ-SAC form I with no amorphisation. The PXRD patterns 
of CBZ-SAC form I co-crystal (reference) and DSC results (figure 6.7), 
support these findings. Presence of water provides a medium for transmitting 
ultrasound energy as well as medium for crystal growth resulting in better 
quality co-crystals. 
The PXRD patterns of PEG 8000, CBZ-SAC PM with 5% PEG and CBZ-
SAC co-crystals obtained with 5% PEG 8000 at 100% applied power are 
shown in figure 6.12. PEG 8000 was observed to show major peaks at 2θ = 
19.31° and 23.32° (Jayaramudu et al. 2016). The addition of PEG 8000 to 
CBZ-SAC PM produced peaks similar to the PM, indicating no interaction of 
PEG 8000 with the components. CBZ-SAC co-crystal batches (G-I), clearly 
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show that PEG 8000 molecules were well distributed between the co-crystal 
molecules confirmed by the broadening of the peak at 2θ= 23.3°.    
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Figure 6.12 PXRD patterns of CBZ-SAC CC obtained with the addition of 5% PEG 
800 at RT and 100% power 
[PEG 8000, CBZ-SAC PM-5% PEG 8000, processed CBZ-SAC CC obtained at G) 20sec, 
H) 40sec and I) 60sec] 
All PXRD patterns of CBZ-SAC co-crystals obtained at different sonication 
times of 20, 40 and 60 sec (G, H and I)  show a unique characteristic peak at 
 θ=  .8°,   p  s     g CBZ-SAC form I co-crystals followed by peaks at 
15.3° and 25.1° indicating the presence of un-reacted CBZ and SAC. The 
observation of sharp crystalline peaks confirms that the addition of 5% PEG 
8000 inhibits amorphisation; however, the co-crystals formed were not pure. 
This can be due to ultrasound induced melting/ softening of PEG 8000 
molecules leading to its distribution between the CBZ and SAC molecules. 
Similar to water, the molten PEG or solution of drug and co-former in molten 
PEG serves as medium for propagation of ultrasound energy.  
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6.3.3 FTIR Results 
IR spectroscopy is a technique used to characterise hydrogen bonding, 
because the change in hydrogen bonding at the intermolecular level results 
in a distinct vibrational frequency shift. Ground batches were investigated 
under the FTIR method described in detail in section 3.5.4. Significant 
changes in FTIR spectra were observed due to the difference in hydrogen 
bond interactions between CBZ, SAC and CBZ-SAC co-crystal (figure 6.13). 
The IR spectrum of CBZ, SAC, CBZ-SAC PM and CBZ-SAC co-crystal 
prepared by the solution method are shown in figure 6.13  
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Figure 6.13 IR spectrum of CBZ, SAC, CBZ-SAC PM and CBZ-SAC CC 
(reference) 
The IR spectrum of CBZ form III in figure 6.13 shows main characteristic 
peaks at 3463, 3157 and 1674 cm-1 which link to the free anti-NH, hydrogen 
bonded syn-NH and carbonyl stretch, respectively. The spectrum of pure 
SAC also shows peaks attributed to NH and C=O stretch of the secondary 
amide at 3091 and 1715 cm-1. Additionally, peaks at 1332 and 1175 cm-1 
corresponding to asymmetric and symmetric stretching of –SO2 were also 
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observed.  The IR spectra of CBZ-SAC physical mixture resulted in peaks for 
CBZ III at 3463 and 1674 cm-1 and SAC at 1715, 1332 and 1175 cm-1. No 
peak shift was observed, therefore, suggesting that no hydrogen bonding 
occurred in the physical mixture state. The carbonyl, amide and –SO2 
regions indicated hydrogen bond formation between CBZ and SAC which 
was observed in the co-crystal spectra. The spectra of co-crystal exhibited a 
shift in carbonyl stretching of CBZ at 1644 and a shift in the primary –NH 
group of CBZ at 3498 cm-1. Similarly, the free carbonyl group of SAC shifted 
from 1715 to 1724 cm-1 along with the shift of asymmetric stretch of –SO2 in 
SAC from 1332 cm-1 to 1320 cm-1. All these changes in IR spectra pointed 
out the interaction between CBZ and SAC molecules in their solid state 
forming co-crystal (Wang et al. 2013a). These IR peak identities of CBZ, 
SAC and CBZ-SAC PM and CBZ-SAC co-crystals are summarised in table 
6.1. 
Table 6.1 Summary of IR peak identities of CBZ, SAC, CBZ-SAC PM and CBZ-
SAC CC 
Compound Peak position (cm-1) Assignment 
CBZ III 
 
SAC 
 
 
CBZ-SAC PM 
 
 
3463 
 
1674                                       
1715 
1332 and 1175 
3091 
 
3463 
1674 
1715 
 
1332 and 1175                                             
-NH2 
 
-(C=O)- 
-(C=O)- 
-SO2- 
-NH- 
 
-NH2 of CBZ 
-(C=O) of CBZ 
-(C=O) of SAC 
-SO2- of SAC 
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CBZ-SAC co-crystals 
 
 
3498 
1644 
1320 
 
N-H of CBZ 
-(C=O) of CBZ 
O=S=O of CBZ 
 
   
FTIR results of CBZ-SAC co-crystals obtained from equimolar ratio of CBZ-
SAC, CBZ-SAC with 5% water and CBZ-SAC with 5% PEG 8000 are shown 
in figures 6.14, 6.15 and 6.16, respectively. Figure 6.13 shows peak shifts in 
the regions that are responsible for hydrogen bonding interaction in their co-
crystal structure. Therefore, the region from 3400 to 3600 cm-1 was chosen 
because it shows the important peak shift corresponding to NH stretch of the 
amide and–NH hydrogen bonding formed in the co-crystal at 3498 cm-1. 
Figure 6.14 depicts the FTIR spectra in the selected region 3400-3600 cm-1 
for CBZ-SAC processed at different sonication times. The IR spectrum of 
sample exposed to 20 sec of ultrasound shows peaks at 3464 and 3498 cm-1 
corresponding to NH stretch of unreacted CBZ and CBZ-SAC co-crystal, 
respectively.  
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       Figure 6.14 IR spectra of CBZ-SAC co-crystal processed at RT and 100% 
power 
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[Processed CBZ-SAC CC obtained at A) 20 sec, B) 40 sec and C) 60sec] 
At 40 and 60 sec of exposure time (batches B and C), the IR spectrum 
showed a single peak at 3498 cm-1 for the co-crystal. 
Figure 6.15 represents the IR spectrum of equimolar CBZ-SAC mixture with 
5% water processed at RT and 100% power, at sonication times of 20, 40 
and 60 sec. IR spectra of batches D and E (at 20 and 40 sec of sonication 
times) showed broad peaks between 3400-3500 cm-1; indicative of O-H 
stretch of water. The broad absorption band exists due to the hydrogen 
bonding between water molecules that inhibit N-H stretching at 3498 cm-1. 
This is in agreement with a reported study, where the strong O-H band 
absorption intensity and broad peak of methanol solvent and water solvent 
mixtures at 3400 cm-1 suppressed the major peaks for CBZ, SAC and CBZ-
SAC co-crystals (Wang et al. 2013a).  
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   Figure 6.15 IR spectra of CBZ-SAC CC processed with 5% water at RT and 
100% power 
[CBZ-SAC – 5% water processed at D) 20 sec, E) 40 sec and F) 60 sec] 
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At 60 sec (batch F), O-H stretch was observed which was due to the 
evaporation of water leading to a low intensity peak, and the N-H stretch at 
3498 cm-1 confirmed the co-crystal formation.   
Figure 6.16, IR spectra of equimolar CBZ-SAC physical mixture with 5% 
PEG 8000 processed at RT and 100% power at sonication times of 20, 40 
and 60 sec. 
Batch G showed peaks at 3463 and 3498 cm-1, representing N-H stretch of 
CBZ and N-H stretch of co-crystals, respectively. This confirms that the co-
crystal formed was not a pure form. With the increase of sonication times 
from 40 to 60 sec, (batch F and G), the IR spectra showed a single 
prominent peak at 3498 cm-1, representing N-H stretch of co-crystal. 
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Figure 6.16 IR spectra of CBZ-SAC CC with 5% PEG 8000 processed at RT and 
100% power 
[CBZ-SAC – 5% PEG 8000 processed at G) 20 sec, H) 40 sec and I) 60 sec] 
The FTIR data showed in figures 6.14, 6.15 and 6.16, support the findings 
from the DSC results (figure 6.7, 6.8, 6.9) and PXRD results studies (figure 
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6.10, 6.11 and 6.12), where explained the effect of addition of water, without 
water and PEG in co-crystal formation. 
6.3.4 Measurement of temperature and power  
The final temperature rise and energy dissipated under the effect of 
ultrasound were carried out as described in detail in section 3.3.2.  
Table 6.2 Measured final temperature rise, dissipated power and total energy input 
for CBZ-SAC processed with ultrasound at RT and 100% power.  
Components Batch 
code 
Exposure Time 
(sec) 
Measured 
Final Temp 
(°C) 
Average 
Power   
Input 
 (W) 
Total 
Energy 
Input 
(KJ) 
CBZ-SAC 1:1 
PM 
A 20 28 94 1.9 
B 40 32 129 5.2 
C 60 42 134 8.0 
CBZ-SAC-5% 
water 
D 20 30 102 2.0 
E 40 30 98 3.9 
F 60 26 95 5.7 
CBZ-SAC-5% 
PEG 8000 
G 20 29 92 1.8 
H 40 30 115 4.6 
I 60 33 126 7.6 
 
For the physical mixture alone, the maximum temperature and average 
power input increased when exposure time increased. High local 
temperature induced by ultrasound had a strong effect on CBZ-SAC alone 
and was confirmed by melting of the sample. This suggested that the melting 
which was caused by the localised heating during the process played a vital 
part in co-crystal formation. When 5% of water was used, the measured final 
temperature and average power input decreased when the exposure time 
increased. This may have resulted from water molecules evaporating upon 
prolonged exposure to ultrasound. No melting was observed and the local 
temperature caused by high ultrasound power was affected by the addition of 
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5% water. When 5% PEG 8000 was used, the measured final temperature 
did not increase as much as compared to the physical mixture when the 
exposure time was increased.  
6.3.5 Chemical stability  
The use of ultrasound processing at RT and application of 100% power for 
the synthesis of CBZ-SAC form I co-crystals induced degradation in the 
samples, as observed by the change in colour. Water, polymer and exposure 
time influenced the amount of degradant produced. Within the United States 
Pharmacopeia (USP) standards for drug preparations and chemical 
substances, the limit set for CBZ related impurities is not more than 0.2% 
(Convention 2015). The impurity inspected during this study is a CBZ 
degradation product, iminostilbene. The degradation into iminostilbene of 
ultrasonicated product was examined using the HPLC method described in 
detail in section 3.5.7. A calibration curve was constructed to determine the 
degraded products as shown in figure 6.17. 
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Figure 6.17 Calibration curve for iminostilbene concentration against the peak 
area obtained from HPLC analysis 
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Figure 6.18 Chromatogram for CBZ and iminostilbene showing peak elution at 8.2 
and 11.3 minutes, respectively 
As shown in figure 6.18, the HPLC method for separation and identification 
of CBZ and iminostilbene peaks was developed with two well separated 
peaks at retention times of 8.2 and 11.3 mins, respectively. The average 
iminostilbene impurity in each sample was calculated after obtaining their 
peak area values.    
Table 6.3 Degradation results: percentage iminostilbene in ultrasonicated CBZ-
SAC CC processed at RT and 100% power. 
Component Batch Code Exposure 
Time (sec) 
Iminostilbene 
(%) 
Standard 
Deviation (SD) 
CBZ-SAC 
1:1 PM 
A 20 0.2544 0.3420 
B 40 0.2849 0.0024 
C 60 0.3499 0.0173 
CBZ-SAC-
5% water 
D 20 NONE NONE 
E 40 0.0198 0.0006 
F 60 0.1200 2.1337 
CBZ-SAC-
5% PEG 
8000 
G 20 0.0206 0.0002 
H 40 0.1545 0.0085 
I 60 0.3038 0.0104 
   
The HPLC results show the presence of iminostilbene in all ultrasonicated 
CBZ-SAC CC samples except in batch D, where the sample was exposed to 
20 sec of sonication with the presence of 5% water. The % impurity of CBZ-
 178 
 
SAC co-crystal formed without addition of any additives (batches A, B and C) 
was highest and above the USP standard level. These impurities increased 
with the increase in exposure time. The addition of 5% PEG 8000 assisted in 
CBZ degradation and % impurity was above the limit, which increased with 
the increase in exposure time. In all batches, at the highest exposure time of 
60 sec, the % impurity was above the USP limit of 0.2%. One explanation of 
iminostilbene degradation presented within CBZ-SAC co-crystals batches 
would be the heating (localised temperature) caused by sonication at 
maximum power level even at shorter sonication time. 
6.3.6 SEM Results 
Scanning Electron Microscopy (SEM) was used to study the surface 
morphology of starting materials CBZ, SAC compared to CBZ-SAC co-
crystals prepared by the reference and ultrasound methods. The method was 
described in detail in experimental section 3.5.6. 
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 Figure 6.19 SEM of starting materials and CBZ-SAC co-crystals 
A) CBZ (100X), B) SAC (500X), C) CBZ-SAC co-crystal prepared by solution method (100x) 
and D) CBZ-SAC co-crystal prepared by ultrasound (1000x) 
The crystal shape of CBZ was flaky or thin plate-like (Nokhodchi et al. 2005). 
The crystal shape of untreated SAC was block-shaped particle morphology 
(figure 6.19B). In contrast the shapes of the CBZ-SAC co-crystals (reference, 
figure 6.19C) and ultrasonicated co-crystals (figure 6.19D) were block-
shaped and agglomerated rod-like, respectively. These changes of the 
shapes can be explained by the interaction of CBZ and SAC molecules 
which result in the modification of the CBZ crystal faces and hence the 
crystal morphology. 
A B 
C D 
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6.4 Results of CBZ-SAC co-crystals tablets 
To check the effect of the ultrasound on the top and bottom surface of the 
co-crystal tablet obtained from equimolar weights of CBZ-SAC and CBZ-SAC 
with 5% water was examined using Raman spectroscopy.     Nnn                         
b    This is an alternative method which can be used to identify the crystalline 
arrays of pharmaceutical drugs. It is a rapid, non-destructive technique and 
has lower detection limits when compared to PXRD and DSC. Moreover, the 
water does not show a strong spectrum and thus does not obscure the 
spectral signatures of analytes of interest in the wet matrices, which can be 
an issue in infrared spectroscopy (Aaltonen et al. 2008; De Beer et al. 2011). 
This is why Raman was chosen to investigate co-crystal formation on the top 
and bottom surfaces tablets.  
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 Figure 6.20 CBZ-SAC co-crystal tablets with 5% water: top and bottom surfaces  
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Figure 6.21 CBZ-SAC co-crystals tablets without 5% water: top and bottom 
surfaces 
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6.4.1 Raman spectroscopy results 
The Raman spectra of CBZ, SAC, physical mixture and intact co-crystal of 
CBZ-SAC (reference) are represented in figure 6.22 with their spectral data 
shown in table 6.4. Since the co-crystal was formed between CBZ and SAC 
after slow evaporation, a significant Raman spectral difference should be 
noticed between the physical mixture and intact co-crystal of CBZ-SAC.  The 
Raman spectrum of SAC showed five sharp peaks; a peak at 1697cmˉ1 
depicting C=O stretching vibration, peaks at 1593, 1017 and 702 cmˉ1 
representing C-C stretching and C-C-C bending vibration, and a peak at 
1177 cmˉ1 attributed to the SO2 stretching vibration (Lin et al. 2013).  
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Figure 6.22 An overlay of Raman spectra for CBZ, SAC, CBZ-SAC PM and CBZ-
SAC CC 
The Raman spectrum of CBZ-SAC physical mixture overlapped both 
characteristic peaks of CBZ III and SAC suggesting that there was an 
interaction between them. On the other hand, the Raman spectrum of CBZ-
SAC form I co-crystals contained a single peak at around 1725 cm-1, which 
differs from S C’s stretching frequency at 1697 cm-1. The pattern of 
spectrum in the ranges of 2950-3500 cm-1 was different from those of the 
physical mixture (Rager and Hilfiker 2010). Significant differences among the 
1697 cm
-1
 
1697 cm
-1
 
1725 cm
-1
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Raman spectra of CBZ III, SAC, CBZ-SAC co-crystals and the physical 
mixture demonstrates that CBZ-SAC co-crystals are not just a physical 
mixture of the two components; rather, a new solid-state formation was 
generated.  
Table 6.4 Raman peaks for CBZ III, SAC, CBZ-SAC PM and CBZ-SAC co-crystal 
Compound Peak position (cm-1) Assignment 
CBZ III double peaks at 272 and 
253 
 
1040, 1025 
 
triple 3020, 3042 and 
3071 
 
 
 
lattice vibration 
 
C-H bending 
 
non-aromatic C-H stretch 
aromatic C-H stretch 
aromatic asymmetric 
stretch 
SAC 
 
CBZ-SAC PM 
 
1697 
 
1040, 1025 
1697 
triple 3024, 3050 and 
3077 
 
C=O stretch 
 
C - H bending 
C=O stretch 
Non-aromatic C-H stretch 
Aromatic C-H stretch 
Aromatic asymmetric 
stretch 
 
CBZ-SAC co-crystals 1725 C=O stretch 
 
The displayed spectra showed a pronounced difference over the entire 
spectra but the strongest band difference lie in the range of 1697-1730 cm-1, 
where the C=O stretch of CBZ-SAC co-crystal is represented at 1725 cm-1 
(figure 6.22). Therefore, this selected region was used to detect co-crystal 
formation on the top and bottom surfaces of CBZ-SAC co-crystal tablets 
obtained at different sonication times. Figure 6.23 represents Raman spectra 
of the top and bottom surfaces of CBZ-SAC CC co-crystals obtained at 20 
sec of exposure time with and without addition of 5% water.     
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Figure 6.23 Raman spectra of the top and bottom surface of CBZ-SAC CC 
processed at 20 sec 
[20s – 5% water-top surface (green colour), 20s – 5% water – bottom (blue colour), 20s – 
top (red colour) and 20s – bottom (black colour)] 
The main peak at 1725 cm-1 represents CBZ-SAC form I co-crystal.  Raman 
spectra of CBZ-SAC co-crystals bottom surfaces processed at 20 sec of 
exposure time with and without addition of 5% water showed a single 
characteristic peak at 1697 cm-1 indicative of free SAC molecules present 
(blue and black colour), hence, no co-crystal was formed. Raman spectra of 
the top surface of the sample (red colour) processed without water showed a 
strong characteristic peak at 1725 cm-1, and a low intensity peak at 1697 cm-
1. This indicated that the top surface consisted of a mixture of co-crystal and 
SAC with the amount of co-crystal being prominent. Raman spectra of the 
top surface of the sample (green colour) processed with the addition of 5% 
water showed a less intense peak at 1725 cm-1 and a strong intensity peak 
at 1697 cm-1 indicating the presence of free SAC with low amounts of co-
crystal.   
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Figure 6.24 shows the Raman spectra of the top and bottom surfaces of the 
co-crystal tablets processed with and without the addition of 5% water 
exposed to 40 sec and 100% applied power. 
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Figure 6.24 Raman spectra of the top and bottom surfaces of CBZ-SAC CC 
processed at 40 sec 
[40s – 5% water-top surface (green colour), 40s – 5% water – bottom (blue colour), 40s – 
top (red colour) and 40s – bottom (black colour)] 
After the addition of 5% water, the top surface (green colour) showed a high 
intensity peak at 1725 cm-1 and a less intense peak at 1697 cm-1, confirming 
the co-crystal formation on the top surface compared to the bottom surfaces 
(blue colour) which only produced a prominent peak at 1697cm-1 for SAC. 
Without the addition of water, Raman spectra of the top surface (red colour) 
generated a single peak at 1725 cm-1, and the spectra at the bottom (red 
colour) produced a peak at 1697 cm-1. This confirms that pure co-crystals 
were only formed at the top surface due to excessive penetration of 
ultrasound waves at the top surface which aided co-crystal formation. 
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Figure 6.25 represents Raman spectra of the top and bottom surfaces of the 
co-crystal tablets processed with and without the addition of 5% water 
exposed to 60 sec and 100% applied power. 
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Figure 6.25 Raman spectra top and bottom surface of CBZ-SAC CC processed at 
60 sec 
[60s – 5% water-top surface (green colour), 60s – 5% water – bottom (blue colour), 60s – 
top (red colour) and 60s – bottom (black colour)] 
As shown in figure 6.25, Raman spectra of CBZ-SAC CC top surfaces 
processed with 5% water and exposed to 60 sec of ultrasound (green line) 
showed less intense peak at 1725 cm-1 and higher intense peak at 1697 cm-
1, whereas the bottom surface (blue colour) showed only a strong intense 
peak at 1697 cm-1, indicating that no co-crystal formed on the bottom. 
Raman spectra of top surface (red colour) processed without water showed 
only a strong characteristic peak at 1725 cm-1 which indicating that co-crystal 
was prominent on the top, while the bottom surface (black colour) showed 
only a strong characteristic peak at 1697 cm-1, indicating that only SAC was 
present. These results suggest that ultrasound had greater influence on co-
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crystal formation on the top surface than the bottom surface of CBZ-SAC co-
crystal tablets, especially when processed without addition of water. In the 
presence of 5% water, the co-crystal peak on the top surfaces was evident 
with low intensity and along with a high intensity of SAC peak. No co-crystal 
peak was present for the bottom surface of the tablet at different sonication 
times of 20, 40 and 60 sec. The water appeared to hinder formation of co-
crystal on the top surface of the tablet because of mismatch ultrasound 
energy dissipation. In general, on both top and bottom surfaces of co-crystal 
tablets, the increase in the peak intensity at 1725 cm-1 and the decrease in 
peak intensity at 1697cm-1 was observed as the sonication time was 
increased, which could be explained by progressive co-crystal formation 
between CBZ and SAC. This strongly suggests that gradual increase in 
sonication time may gradually induce co-crystal formation between CBZ and 
SAC and this was confirmed using Raman spectroscopy for qualitative 
detection. To investigate this further, Raman spectroscopy could be used to 
quantify the co-crystal concentration on the top and bottom surfaces (see 
further work section 9.2).    
6.4.2 PXRD Results 
Material scraped off the top and bottom surfaces of CBZ-SAC CC tablets 
were placed on a simple zero order holder to determine crystallinity using 
PXRD. Due to the small amount of material taken from the tablet surfaces, 
and considering the preferred orientation phenomena, the intensity of the 
PXRD peaks were relatively low and were difficult to interpret.  
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Figure 6.26 PXRD patterns of CBZ-SAC CC tablets top surfaces processed with 
5% water 
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Figure 6.27 PXRD patterns of CBZ-SAC CC tablets bottom surfaces processed 
with 5% water 
Figures 6.26 and 6.27 represent PXRD patterns of the top and bottom 
surfaces of CBZ-SAC co-crystal tablets obtained with addition of 5% water at 
sonication times of 20, 40 and 60 sec.  At the different sonication times used, 
peaks associated with the co-crystal appeared with low intensities and 
confirm the results obtained from Raman spectroscopy. 
PXRD patterns of CBZ-SAC co-crystal top surface material, processed 
without water at sonication times of 20, 40 and 60 sec (figure 6.28), depicted 
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co-crystal peaks at 2θ = 6.8° for 20 and 40 sec batches. For 60 sec 
sonication time, the co-crystal peaks disappeared confirming that 
amorphisation may have occurred. 
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Figure 6.28 PXRD patterns for CBZ-SAC CC tablet top surface processed without 
water 
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Figure 6.29 PXRD patterns for CBZ-SAC CC tablets bottom surfaces processed 
without water 
As shown in figure 6.29, PXRD patterns of the material from the bottom 
surfaces processed without water had prominent peaks at 2θ = 13.3° and 
25° which indicated that unreacted CBZ and SAC was present and no co-
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crystal peaks were apparent. These results were in agreement with the 
Raman spectra results (figure 6.23, 6.24 and 6.25).  
6.4.3 DSC Results 
The DSC technique described in detail in section 3.5.1 was used to 
determine the crystallinity of material from the top and bottom surfaces of the 
CBZ-SAC co-crystal tablets. Figure 6.30 shows DSC thermograms for the 
top surface material of the obtained co-crystal tablets processed at RT with 
5% water at sonication times of 20, 40 and 60 sec and with 100% applied 
power. DSC thermograms of the top surface – 5% water at 20 and 40 sec 
exposure times had two endothermic peaks at 155°C (fusion of eutectic 
mixture) and 174°C (fusion of co-crystal).  
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Figure 6.30 DSC thermograms for CBZ-SAC CC tablets top surfaces processed 
with 5% water 
At 60 sec exposure time, the top surface sample showed a single 
endothermic peak at 172°C, representing CBZ-SAC form I co-crystal. 
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Figure 6.31 DSC thermograms for CBZ-SAC CC tablets bottom surfaces 
processed with 5% water 
DSC thermograms of the tablet bottom surfaces processed with 5% water 
and exposed to ultrasound at 20 and 40 sec, figure 6.31 showed a broad 
endothermic peak between 55-75°C, and endothermic peaks at 155°C and 
174°C, which illustrates the loss of water, eutectic point of physical mixture 
and melting point of co-crystal, respectively. With an increase of exposure 
time to 60 sec, the water peak disappeared and the peaks at 155°C and 
174°C were present. All bottom surfaces were composed of unreacted SAC 
or CBZ-SAC physical mixture, also confirmed by the Raman results.  
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Figure 6.32 DSC thermograms for CBZ-SAC CC tablets top surface processed 
without water 
DSC thermograms of CBZ-SAC co-crystal tablets top surface material 
processed without water at 100% power was applied at different sonication 
times of 20, 40 and 60 sec are shown in figure 6.32. At 20 sec, the top 
surface material showed a small endothermic peak at 155°C followed by an 
endothermic peak at 174°C. This confirms that a small amount of unreacted 
physical mixture was converted into co-crystal upon heating. The top surface 
materials exposed to 40 and 60 sec ultrasound displayed an endothermic 
peak at 174°C (co-crystal peak), however at 60 sec there was also an 
exothermic peak at 80°C, which could be an amorphous crystallisation peak. 
The DSC results provide agreement with the Raman spectroscopy analysis 
shown in figures 6.23, 6.24 and 6.25.  
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  Figure 6.33 DSC thermograms for CBZ-SAC CC tablets bottom surfaces 
processed without water 
DSC thermograms of CBZ-SAC co-crystal tablets bottom surface material 
processed without water at 100% power at sonication times of 20, 40 and 60 
sec (figure 6.33) displayed broad endothermic peaks at 155°C and 160°C 
and an endothermic peak at 174°C which was attributed to  fusion of eutectic 
mixture and co-crystal, respectively. This confirms that the bottom surface 
material consisted of unreacted physical mixture which upon heating was 
converted to the co-crystal form. These results were accordance with the 
PXRD and Raman spectroscopy results. 
6.4.4 SEM Results 
Scanning Electron Microscopy (SEM) was used to study the surface 
morphology of ultrasonicated CBZ-SAC co-crystals tablets (top and bottom 
surfaces) processed with and without addition of 5% water at application of 
100% power level at sonication times of 60 sec (figure 6.34). The method 
was described in detail in section 3.5.6. 
 195 
 
 
Figure 6.34 SEM images of CBZ-SAC co-crystals tablets (top and bottom 
surfaces) processed with and without addition of 5% water 
A) CBZ-SAC CC tablet top surface (100x), B) CBZ-SAC CC tablet bottom surface (1000x), 
C) CBZ-SAC CC tablet top surface-5% water (1000x), D) CBZ-SAC CC tablet bottom 
surface- 5% water (1000x)) 
As shown in figure 6.34A, the CBZ-SAC co-crystals top surface without water 
exhibited a large block particle with many crystal features such as rough 
surfaces and irregular edges, while the bottom surface (B) exhibited a clear 
rod-like morphology. However as shown in figure 6.34C, the CBZ-SAC co-
crystals top surface with added 5% water crystallised in agglomerated 
particles and its shape is rod-like with smooth surface. In addition the shape 
of  bottom surfaces (D) crystals appeared as a thin tabular-like morphology, 
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similar to the morphology of CBZ-SAC co-crystals prepared by the sonic 
slurry method (Tomaszewska et al. 2013). 
6.4.5 Chemical stability  
CBZ-SAC co-crystal tablets were obtained by subjecting the 1:1 CBZ-SAC 
physical mixture to 100% power at room temperature with and without the 
addition of 5% water. When no water was added, degradation occurred in 
the obtained tablets evidenced by change in colour of the top and bottom 
surfaces was observed (figure 6.20 and 6.21). Regarding the United States 
Pharmacopeia (USP) standards for drug preparations and chemical 
substances, the limit set for CBZ related impurities is 0.2% w/w (USP 
Convention 2015). The impurity inspected during this study was a CBZ 
degradation product, iminostilbene. The presence of iminostilbene in the 
ultrasonicated tablets (top and bottom surface material) was examined using 
a HPLC method. A calibration curve was constructed to determine the 
degraded products as shown previously in figure 6.17. The HPLC method for 
the separation and identification of CBZ and iminostilbene peaks was 
developed with two well separated peaks at retention times of 8 and 11 mins, 
respectively (figure 6.18). The average iminostilbene impurity in each top and 
bottom surface material of obtained tablet was calculated after obtaining their 
peak area value.   
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Table 6.5 Degradation results: percentage iminostilbene in CBZ-SAC CC tablets 
(top and bottom surface) processed at RT and apply 100% power 
Component Batches Iminostilbene 
(%) 
Standard Deviation 
(SD) 
 
 
CBZ-SAC PM 
1:1 
20s – top surface 0.0379 0.0382 
20s – bottom surface 0.0061 0.0031 
40s – top surface 0.1474 0.0955 
40s – bottom surface 0.0545 0.0999 
60s – top surface 0.1429 0.1409 
60s – bottom surface 0.0915 0.1540 
 
 
 
 
CBZ-SAC PM – 
5% water 
20s – top surface – 
5% water 
0.0043 2.1127 
 
20s – bottom surface 
– 5% water 
0.0043 2.0002 
 
40s – top surface – 
5% water 
0.0057 0.0014 
40s – bottom surface 
– 5% water 
0.0045 
 
2.6502 
 
60s – top surface – 
5% water 
0.1162 0.1119 
60s – bottom surface 
– 5% water 
0.0045 2.0007 
 
Although the % iminostilbene on the top and bottom surfaces of the obtained 
tablets without addition of 5% water increased with increase in exposure 
time, HPLC detected the presence of iminostilbene which was not above the 
limit of US pharmacopeia (0.2%). With the addition of 5% water, the % of 
iminostilbene in the top and bottom surfaces of the CBZ-SAC co-crystal 
tablets was roughly the same for both surfaces and was below the US 
pharmacopeia limit (0.2% w/w). From these results, it was concluded that the 
addition of water played an important role in suppressing degradation, 
particularly on the top surface of the obtained tablets. These results 
coincided with a study which reported that sonic slurry and anti-solvent 
crystallisation batches of CBZ-SAC co-crystals, in different solvents, found 
that the final product iminostilbene concentration was less than 0.2% w/w 
(Apshingekar 2014) 
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6.5 Summary 
The solvent free ultrasonic approach succeeded in the formation of CBZ-
SAC co-crystals form I and the presence of additives such as water and PEG 
8000 had a significant influence on the co-crystal formation. The presence of 
the degraded product iminostilbene, in all ultrasonicated CBZ-SAC co-
crystals prepared with CBZ-SAC PM alone, with addition 5% water and 5% 
PEG generally increased with increase of exposure time. The highest level of 
iminostilbene was present in CBZ-SAC PM samples compared 5% PEG and 
5% water samples. The CBZ-SAC 5% water samples had the lowest 
concentration of iminostilbene.   
Raman spectroscopy found to be a useful, qualitative technique for the 
determination of the presence of CBZ-SAC co-crystals in the formed tablets. 
It was found that the co-crystal was more abundant in the top surface of the 
tablets, compared to the bottom surfaces, particularly in the absence of 
water. The Raman spectroscopy results complemented the DSC and PXRD 
results. 
   
  
 
 
 
 
 
 
 
CHAPTER 7 ULTRASOUND-ASSISTED 
PARACETAMOL TABLETABILITY
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7.1 Introduction  
Paracetamol (PAR) is a non-steroidal anti-inflammatory drug (NSAID) 
generally used in treatment for its analgesic (pain killing) and antipyretic 
(fever suppressant) properties and is a popular drug and commonly used 
drug (Nayak 2010). Paracetamol appears in different polymorphic forms. 
Form I (monoclinic) is the commercially available form; it is 
thermodynamically stable at room temperature and pressure. However, it 
has become a challenging model drug, due to poor biopharmaceutical 
properties such as compressibility, flowability and compactability. In contrast, 
form II (orthorhombic) under compression undergoes plastic deformation; 
therefore it can be used for direct tablet compression, conversely, this form 
was proved to be suitable only at laboratory scale (Giordano et al. 2002; 
Kaialy et al. 2014). Form III which is thermodynamically unstable at room 
temperature and pressure meaning that it is not possible to determine its 
crystal structure. This form is not suitable for direct compression (Di Martino 
et al. 1996). The paracetamol powder suffers from poor compression 
properties, this is because during compression there is reduced plastic 
deformation leading to soft tablets which have a high capping tendency 
(Hong-Guang and Ru-Hua 1995). To improve the plasticity, binders were 
added to the tablet formulation and thus increased interparticulate bonding 
strength within the tablet. PEG 8000 is a synthetic polymer which is used as 
binding agent and is useful for achieving various tablet mechanical strengths 
and drug release properties for different pharmaceutical purposes 
(Enauyatifard et al. 2012; Shailendra 2012). Paracetamol tablets are of poor 
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quality when produced using direct compression, therefore pharmaceutical 
companies are looking for alternative methods to replace or improve direct 
compression for obtaining good paracetamol tabletability. An example of this 
is the engineering of paracetamol form I crystals using anti-solvent 
crystallisation in the presence of various hydrophilic additives such as PEG 
for direct compression (Kaialy et al. 2014). Recently, a combination of  
ultrasonication and fast precipitation produced micro-sized crystals of PAR 
form I with significantly improved compaction behaviour (higher plastic 
deformity and cohesive interaction between particles) which could be used 
for direct compression  Buč        .   15). Direct compression of PAR 
formulation can be carried out using a binding agent such as hydroxyl propyl 
cellulose (HPC) for improving tabletability (Govedarica et al. 2011). Co-
crystallisation of PAR form I with different formers was a feasible method to 
generate layered solid forms of PAR form I, exhibiting tablet-forming 
properties resembling those of form II (Karki et al. 2009). There have been 
many studies conducted where ultrasound has been simultaneously applied 
with mechanical pressure, with the objective of improving compactability of 
low compressible materials (Rodriguez et al. 1997; Rodriguez et al. 1998; 
Levina and Rubinstein 2000). The aim of this study was to explore the 
application and direct use of ultrasonic energy for aiding the compression of 
poorly compressible crystals of PAR form I and to find an alternative method 
used for production of tablets instead of direct compression. This method 
also used 5% and 10% (w/w) PEG 8000; this was at very low amounts 
compared to the amount of PAR used in the preparation of conventional 2g 
and 3g tablets. The effect of power and sonication time on the properties of 
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the obtained PAR tablets was investigated. Figure 7.1 and 7.2 depicted the 
solid forms of ultrasonicated-PAR tablets, top and bottom surfaces, obtained 
by applying maximum power at different sonication times 20, 40 sec. The 
uniformity and shape of the obtained tablets clearly improved as sonication 
time increased, particularly for the bottom surfaces. Also, the same amount 
of PAR and PEG and the same conditions without apply of US did not form 
tablets and the products were powder form. 
 
Figure 7.1 Sonicated-PAR tablets processed with 5 and 10% PEG 8000 in total 2g  
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Figure 7.2 Ultrasonicated-PAR tablets processed with 5 and 10% PEG 8000 in 
total 3g  
As shown in figure 7.1 and 7.2, direct use of ultrasound can be used to 
obtain good tabletability of PAR form I.  Plastic deformation of the particles is 
achieved by transmitting energy at an ultrasonic frequency where the rate is 
higher than elastic relaxation of the material. Moreover, when one of the 
components in the mixture is thermoplastic (in this case PEG 8000), the 
applied energy can cause transition of the polymer and the final tablets have 
an external glassy appearance and higher density (solidified). These results 
were in agreement with a study where ultrasound assisted a tableting 
machine for obtaining theophylline tablets with use of thermoplastic materials 
among pharmaceutical excipients (Rodriguez et al. 1998). 
 
 
 203 
 
7.2 Crystal structure data  
7.2.1 Paracetamol form I (CSD Ref: HXACCAN06) 
Paracetamol (PAR) form I (figure 7.3) is a monoclinic form and lies in space 
group P 21/a with unit cell dimensions cell length a=12.763° Å   b= 9.250° Å 
c= 7.082° Å   d c      g      α 9 .    β= 115.5     d γ= 9 .   . Th  
crystal structure has pleated sheets stacked along the b axis; making a stiff 
construction of molecules inside the crystal and resulting in poor compassion 
with high capping properties figure 7.1) (Joiris et al. 1998). Figure 7.3 and 7.4 
represents the crystal structure of PAR and computationally calculated 
PXRD pattern of PAR form 1 (monoclinic). 
 
 
Figure 7.3 Crystal structure of PAR form I attained from CSD Ref: HXACCAN06   
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 Figure 7.4 Calculated PXRD pattern for PAR form I (adapted from CSD and 
processed in OriginPro 8) 
7.2.2 Paracetamol form II (CSD Ref: HXACCAN08) 
The paracetamol (PAR) form II (figure 7.5) is orthorhombic and lies in space 
group p b c a with cell length a= 17.666° Å, b= 11.777° Å and c= 7.212° Å. 
C      g  s    α 9 .   , β= 9 .      d γ= 9 .   . Th  c  s    s  uc u   h s 
parallel hydrogen-bonded sheets along the c axis giving slide planes which 
are responsible for an increase in crystal plasticity (Joiris et al. 1998; Nichols 
and Frampton 1998). 
 
Figure 7.5 Crystal structure of PAR form II attained from CSD Ref: HXACCAN08  
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Figure 7.6 represents the calculated PXDR pattern of PAR form II 
4 6 8 10 12 14 16 18 20 22 24 26 28 30
0
2000
4000
6000
8000
10000
In
te
n
si
ty
2 Theta (
0
)  
 
Figure 7.6 Calculated PXRD pattern for PAR form II (CSD Ref: HXACCAN08)  
7.3 Results 
This section include the DSC characterisation results, PXRD characterisation 
results, FTIR characterisation results, measurement of final temperature rise 
and average power and total dissipated energy input, measurement of 
diameter, thickness and hardness of the obtained tablets, dissolution studies, 
chemical stability studies and SEM characterisation for ultrasonicated PAR 
tablets prepared using different conditions .  
7.3.1 DSC Results 
The top surfaces of obtained PAR tablets batches were scraped and the 
resulting material was subjected to DSC using the method described in 
details in section 3.5.1. DSC was used to investigate any changes in the type 
of polymorph occurring as results of the application of ultrasound. Figure 7.7 
represented DSC thermograms of untreated PAR, PEG 8000 and PAR-PEG 
PM. 
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Figure 7.7 DSC thermograms of untreated-PAR, PEG 8000 and PAR-PEG PM 
The thermogram of PAR exhibited a single endothermic peak at around 
171°C with an enthalpy 154.2 J/g. The thermogram for PEG 8000 had an 
endothermic peak at 60°C-63°C with an enthalpy of 163 J/g. These 
endothermic peaks have been reported in the literatures (Nichols and 
Frampton 1998; Majumdar et al. 2010). The thermograms for the physical 
mixture of paracetamol with 5 and 10% PEG 8000 showed two endothermic 
peaks related to the fusion of PEG 8000 and melting of PAR respectively 
59°C, 12.49 J/g, 170.5°C, 121.9J/g. This data revealed that the physical 
mixture did not exhibit any changes in thermal behaviour compared to the 
pure components. The DSC thermograms of untreated PAR and all 
sonicated PAR tablets in the presence of 5 and 10% PEG 8000 at sonication 
times of 20 and 40 sec and total weights 2g and 3g (w/w) are shown in 
figures 7.8 and 7.9, respectively. The enthalpy and melting point of all 
samples are reported in table 7.1. The results showed that all US-PAR 
tablets showed two endothermic peaks related to the fusion of PEG 8000 
and melting of PAR form I. This indicated that PEG molecules may have 
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been melted and entrapped or distributed between PAR molecules during 
the ultrasonication process. It is clear from table 7.1 that as more PEG was 
added and the sonication time increased from 20 to 40 sec during direct use 
of ultrasound to prepare paracetamol tablets, the enthalpy of the 
paracetamol peak decreased which could be due to the strong interaction 
between dissolved PEG 8000 molecules and PAR molecules. This could be 
the main reason why the paracetamol melting point is slightly shifted to lower 
temperature for these samples.  
       Table 7.1 Thermal behaviour of Ultrasonicated-PAR tablets   
Sample Sonication 
time (sec) 
Melting point (°C) Enthalpy (J/g) 
PAR untreated 171.0 154 
PAR-PEG PM untreated 171.0 118 
PAR-5% PEG (2g) 20 170.2 136 
40 170.2 135 
PAR-10% PEG (2g) 20 169.6 119 
40 169.6 118 
PAR-5% PEG (3g) 20 170.3 142 
40 170.5 142 
PAR-10% PEG (3g) 20 170.5 131 
40 170.5 130 
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Figure 7.8 DSC thermograms of US-PAR tablets processed with addition of 5 and 
10% PEG 8000 in total 2g (w/w) 
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Figure 7.9 DSC thermograms of US-PAR tablets processed with addition of 5 and 
10% PEG 8000 in total 3g (w/w) 
It is noticeable that the melting peak of PEG 8000 in the ultrasonicated 
tablets of PAR is not around 63°C as expected, but 59°C. This may be 
because the high concentration of PAR depressed the melting point of PEG. 
All this data indicated that no polymorphic modification occurred during direct 
use of ultrasound to PAR form I. 
7.3.2 PXRD results 
In order to test the possible effect of direct use of maximum power 
ultrasound and addition of PEG on the crystal structure of the obtained 
tablets, the top surfaces were scraped and the resulting material was 
characterised by x-ray diffraction using the method described in detail in 
section 3.5.2. Figure 7.10 shows PXRD pattern of untreated-PAR, PEG 8000 
and PAR-PEG PM.  
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Figure 7.10 PXRD patterns of PAR, PEG 8000 and PAR-PEG PM  
It was observed in the PXRD diffractograms (figure 7.10) that pure PAR is 
c  s              u   show  g ch   c    s  c p   s     θ= 1 .1° 13.48°   d 
24.37° of form I. This is accordance with the results obtained by  (Nichols 
and Frampton 1998; Wang et al. 2011), PEG is semi crystalline showing two 
intense peaks at 2θ=19.31° and 23.32° (Jayaramudu et al. 2016). PAR-PEG 
PM showed discernible peaks of PAR with broadening of the peaks at 19.3° 
and 22.32° confirming that no hydrogen bond occurred between PAR and 
PEG during physical mixing and suggested no chemical interaction between 
two components. Figures 7.11 and 7.12 depict PXRD patterns of all 
ultrasonicated PAR tablets in the presence of 5 and 10% PEG 8000 at 
sonication times of 20 and 40 sec and total weights of 2g and 3g (w/w), 
respectively.    
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Figure 7.11 PXRD diffractograms of US-PAR tablets processed with addition of 5 
and 10% PEG 8000 in total 2g (w/w) 
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Figure 7.12 PXRD diffractograms of US-PAR tablets processed with addition of 5 
and 10% PEG 8000 in total 3g (w/w) 
The PXRD patterns of all ultrasonicated-PAR tablets confirmed the crystal 
form I, i.e., monoclinic PAR and agreed well with PXRD data of previous 
studies, (Di Martino et al. 1996; Nichols and Frampton 1998; Reis et al. 
2014) by showing peaks unique to the monoclinic form I such as 2θ = 12.02°, 
15.4°, and 26.4°. The presence of simple zero order and overlapping of PEG 
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8000 peaks with PAR peaks at 2θ= 19.3° and 22.3° made it difficult to detect 
PEG molecules in ultrasonicated tablets. PXRD measurements showed that 
ultrasonicated tablets consisted exclusively of form I crystals. 
7.3.3 FTIR Results 
Fourier transform infrared spectroscopy (FTIR) studies were performed to 
assist with the evaluation of any possible chemical (functional group) 
interactions between PAR and PEG 8000. The interaction between drug and 
polymer in the intact tablet or physical mixture would result in a distinct 
vibrational frequency (band) shift compared to the spectra of the drug and 
polymer (Bassler et al. 1991). The top surfaces of obtained PAR tablets 
batches were scraped and the resulting material was investigated using the 
method described in detail in section 3.5.4. The FTIR spectra in the range of 
600-4000 cm-1 are given in figure 7.13, for PAR, PEG 8000, PAR-PEG PM, 
PAR tablet (Ultrasonic) and PAR tablet (IR method, reference). The FTIR 
characteristic bands of PAR form I represented N-H amide group stretching 
at 3325 cm-1, C-OH group stretching at 3160 cm-1 and broadening of C-OH 
peak in powdered PAR, which is an indication of hydrogen bonds. The 
asymmetric N-C=O was represented by high intensity peaks at 1650 and 
1610 cm-1. The prominent peak at 1560 and 1510 cm-1 are characteristic of 
aromatic C-C stretching bands. The methyl (CH3) group was characterised 
by a vibration at 1432 cm-1 and the C-N stretching band was detected at 
1220 cm-1 (Ivanova 2005; Zaki 2011). Analysis of the spectra for PEG 8000 
showed specific absorption bands at 2882 cm-1 and 1110 cm-1 corresponding 
to C-H stretching of the CH2 group and C-O-C stretching bonds respectively 
(Alemdar et al. 2005). PAR-PEG PM spectra showed absorption bands 
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associated with PAR and PEG. The ultrasonicated and IR PAR (reference) 
showed FTIR bands similar to the FTIR bands of untreated PAR and specific 
absorption band at 1110 cm-1, indicating the C-O bond of PEG 8000. This 
confirms that no band shifting occurred and the PEG molecules were 
distributed between the PAR molecules. The FTIR spectra of PEG 8000 in 
ultrasonicated-PAR tablets were not easily differentiated because of 
overlapping bands and the low quantity of PEG loading.  
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Figure 7.13 FTIR spectra of PAR, PEG 8000, PAR-PEG PM, PAR tablet 
(Ultrasonic) and PAR tablet (IR method) 
Figures 7.14 and 7.15 depict FTIR spectra for US-PAR tablets obtained with 
addition of 5 and10% PEG 8000 in total weights of 2 and 3g (w/w) exposed 
to 20 and 40 sec at 100% power, respectively.  
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Figure 7.14 FTIR spectra of US-PAR tablets processed with addition of 5 and 10% 
PEG 8000 in total 2g (w/w) 
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Figure 7.15 FTIR spectra of US-PAR tablets processed with addition of 5 and10% 
PEG 8000 in total 3g (w/w) 
FTIR bands representing the functional groups of pure PAR (figure 7.13) 
were found to be in ultrasonicated-PAR tablets obtained at different 
conditions (figures 7.14 and 7.15). In addition the presence of absorption 
band at 2882 cm-1 and 1110 cm-1 confirmed that PEG molecules distributed 
between PAR crystals of formed sonicated tablets. This indicated that 
ultrasonicated-PAR tablets did not undergo structural conversion compared 
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to untreated or monoclinic PAR. Therefore, the obtained PAR tablets still 
exhibited the PAR form I crystal structure. 
7.3.4 Measurement of temperature and power 
The increase in temperature and energy dissipation under the effect of 
ultrasonication was measured as described in detail in section 3.3.2. 
Table 7.2 Measured final temperature and dissipated power for PAR mixed 
with 5 and 10% PEG 8000 with ultrasound at RT and 100% power. 
Components and 
Quantity 
Sonication  
Time 
 (sec) 
Measured Final 
Temp    (°C) 
Average 
Power     
Input 
(W) 
Total  
Energy 
Input 
(KJ) 
PAR-5% PEG (2g) 20 26 91 1.8 
40 30 96 3.8 
PAR-10% PEG (2g) 20 30 103 2.1 
40 35 110 4.4 
PAR-5% PEG (3g) 20 23 90 1.8 
40 25 90 1.8 
PAR-10% PEG (3g) 20 23 88 1.8 
40 25 94 3.8 
 
From the results shown in table 7.2, the dissipation of ultrasound energy 
increased as the amount of polymer was increased from 5 to 10%, 
particularly for 2g w/w tablets. No difference in energy dissipation was 
observed with the 3g w/w tablets, especially for the tablets containing 5% 
PEG 8000. This was mainly due to a high amount of PAR which made it 
difficult for the ultrasound energy to penetrate or transmit into the tablet.  
Propagation of ultrasound energy through the bed of solid particles easily 
limited but addition of low melting polymer PEG enables fast propagation by 
providing a molten phase at low temperature. This result was in agreement 
with results of compacted theophylline tablets using ultrasound-assisted 
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apparatus, where one of the components in the mixture to be compacted 
was thermoplastic (Eudragit®). US energy caused the final tablets to have an 
external glassy appearance and higher density (Rodriguez et al. 1998). Also, 
as the sonication time and added polymer was increased, the measured final 
temperature increased.   
7.3.5 Measurement of Diameter, thickness and hardness 
The diameter, thickness and hardness of the obtained ultrasonicated-PAR 
tablets were measured using a tablet hardness tester which was described in 
detail in section 3.8.1. 
Table 7.3 Measured diameter, thickness and hardness of ultrasonicated-
PAR tablets 
Components and 
Quantity 
Sonication time 
(sec) 
Diameter      
(mm) 
Thickness 
(mm) 
Hardness 
(kgf) 
PAR-5% PEG (2g) 20 22.16 4.4 13 
40 22.27 4.3 14 
PAR-10% PEG (2g) 20 22.26 4.3 14 
40 22.42 4.2 15 
PAR-5% PEG (3g) 20 22.31 7.7 13 
40 22.32 7.0 14 
PAR-10% PEG (3g) 20 22.32 7.4 17 
40 22.35 7.0 18 
 
As shown in table 7.3, due to using the same cell, all ultrasonicated tablets 
obtained at different sonication times and different weights (2g and 3g w/w) 
had the same diameters. The properties of the ultrasonicated powder mixture 
of PAR with 5 and 10% PEG 8000 (total 3g w/w) exhibited a greater crushing 
strength which correlated with the exposure time and maximum power. 
These conditions ensured that more energy dissipated to enhance the 
bonding between particles of PAR and PEG. In addition, the similarities 
between small particle size and high specific area, assured new contact 
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areas and bonding between particles when maximum power was used. 
There was no significant difference in the breaking force during addition of 
the same amount of PEG and using different sonication times. The 
improvement in the compatibility of the obtained PAR-tablets could be due to 
the regular distribution of PEG molecules between PAR molecules leading to 
an increase in interparticle contact points and hydrogen bonding between 
them which increased the degree of solidification during ultrasonication. The 
hydrogen bond formed between PEG and the crystal surface of PAR through 
oxygen atoms on the PEG backbone may have brought the PEG chains 
closer to the crystal surface. Also, the high flexibility  of PEG can lead to 
PEG chains covering a large area of the crystal surface (Wen et al. 2005). 
Considering this, the use of 5% and 10% PEG 8000 with a large amount of 
PAR produced good compatible tablets when assisted with ultrasound. 
However when PAR sonicated without addition of PEG molecules at the 
same conditions, there was no appearance of any feature of tablets. 
7.3.6 Dissolution study 
7.3.6.1 Calibration curve of Paracetamol 
Drug concentration was measured and determined in solution via a 
spectrophotometric technique using a quartz cuvette. For the calibration 
curve of PAR, a stock solution of PAR was prepared at 100mg/100ml in a 
saline phosphate buffer (pH 5.8). The linear fit was calculated using a 
calibration curve, the slope of the equation was 0.0601, constant 0.0017 and 
Coefficient of Determination R2=0.998 was obtained in a concentration range 
of 1µg/ml to 5µg/ml by a UV-Visible spectrophotometer at 243 nm (figure 
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7.16). There was good linearity found between the concentration and 
absorbance. 
 
Figure 7.16 Calibration curve of paracetamol in phosphate buffer by UV-
spectrophotometry. Data are expressed as mean and error bars show ± (S.D, n = 3) 
7.3.6.2 Dissolution results 
The dissolution test is an in-vitro tool used to evaluate and provide 
information about the drug release kinetics of a dosage form. It is employed 
as a primary aid in the characterisation of formulations. Therefore, it is one of 
the most used quality control methods for solid pharmaceutical dosage 
forms. The dissolution test and apparatus used was described in section 
3.8.2. The dissolution profiles of paracetamol from the ultrasonicated-PAR 
tablets prepared in 2g and 3g w/w are shown in figures 7.17 and 7.18, 
respectively. The release profile for powdered PAR showed rapid dissolution 
during the first 30 mins. It was observed that drug release from IR-tablets 
had a slower dissolution rate compared to pure PAR and the ultrasonicated 
tablets. This can be ascribed to the high compression force applied which 
produced a strong interaction between the PAR molecules and PEG 8000 
 218 
 
molecules resulting in a material which was difficult to disintegrate.  In 
ultrasonicated-PAR tablets, 2g and 3g (w/w), with the weight ratio of PEG 
8000 5 and 10%, the drug release was not affected by the content of PEG 
8000. Both formulations produced a very similar release profile, particularly 
at 5 and 15 min. All ultrasonicated-PAR tablets showed slower drug release 
within one hour compared with powdered PAR (figure 7.17 and 7.18). 
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Figure 7.17 Percentage cumulative drug release of PAR from ultrasonicated-PAR 
tablet (2g w/w). Data are expressed as mean error bars show ± (S.D, n =2) 
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Figure 7.18 Percentage cumulative drug release of PAR from ultrasonicated-PAR 
tablet (3g w/w). Data are expressed as mean error bars show ± (S.D, n =2) 
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However, when using sonication times of 20 and 40 sec, the dissolution rate 
decreased as the sonication time increased.  The compaction of paracetamol 
increased with increasing exposure to ultrasound energy. It would have also 
resulted in more penetration of melt binder causing formation of compact 
tablet.  
7.3.7 Chemical stability 
PAR yields 4-amino phenol as a degradation product when heated or 
extruded at high temperatures (Bhimavarapu et al. 2011). The localised heat 
and induced temperatures generated by ultrasound may cause degradation 
of PAR, therefore, the obtained PAR tablets were subjected to the HPLC 
method described in detail in section 3.8.3  to investigate whether they had 
degraded or not. This method was stability indicating and can be used to 
determine paracetamol in the presence of its degradants.  
 4-aminophenol calibration 
The calibration curve for 4-aminophenol was linear over the concentration 
range 10-150mg/ml. the linearity equation was calculated using a calibration 
curve, the slope of the equation was 0.5782, constant 51421 and R2= 0.998 
(figure 7.19). The calibration equation was used to calculate the unknown 
amount of 4-aminophenol present in ultrasonicated-PAR processed tablets. 
The solvent media which was used to dissolve the sample was acetonitrile.  
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Figure 7.19 Calibration curve plot for 4-aminophenol concentration against the 
peak area obtained from HPLC analysis (n=1) 
 
Figure 7.20 Chromatogram for PAR and 4-aminophenol showing peak elution at 
1.2 and 6.5 minutes, respectively 
 Figure 7.20 displays a chromatogram of the elution peaks of PAR and 4-
aminophenol; it confirms the sensitivity of the method developed.  
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Figure 7.21 Chromatogram showing separation of sonicated PAR tablets   
Based on the HPLC analysis, all sonicated PAR-tablets produced only 
chromatogram of elution peak of PAR. This confirms all sonicated PAR 
tablets did not have any degradation.  
7.3.8 SEM Results 
Scanning Electron Microscopy (SEM) was used to study the surface 
morphology of ultrasonicated-PAR tablets and the method was described in 
detail in section 3.5.6. Figure 7.22 shows the SEM images for pure PAR, 
PEG 8000, PAR-PEG PM, PAR tablets prepared by IR method and 
ultrasonicated PAR tablets produced with assistance of ultrasound. The 
typical morphology of PAR (figure 7.22A) is an elongated needle like 
structure. PEG 8000 (figure 7.22B) existed in crystalline mixtures of smooth 
irregular spherical particles. In the physical mixture, both PAR and PEG 8000 
maintained their original shape (figure 7.22C).     
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               (A). PAR 150X (left)                       PAR 1000X (right)  
 
  
(B) PEG 8000 100X (left)                    PEG 8000 400X (right) 
  
(C) PAR-PEG PM 100X (left)          PAR-PEG PM 500X (right) 
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(D) PAR-IR tablet 100X (left)           PAR-IR tablet 500X (right) 
  
(E) US-PAR tablet 100X (left)       US-PAR tablet 500X (right) 
    
(F) US-PAR tablet fragment 100X (left) US-PAR tablet 500X (right) 
Figure 7.22 SEM images of PAR, PEG 8000, PAR-PEG PM and PAR tablets 
(reference and ultrasonicated) at different magnifications 
The characteristic morphology of the PAR tablets prepared by the IR method 
(figure 7.22D) and ultrasonicated PAR tablets (figure 7.22E and F) appeared 
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as agglomerated particles but still had more crystal like morphology. SEM 
pictures of US-PAR tablets suggested that individual surface properties of 
PAR and PEG were lasting during the application of high pressure and 
ultrasound. This could lead to induced melting on the top surface of the 
tablets during sonication.  
7.4 Summary 
The obtained ultrasonicated-PAR tablets were form I as confirmed by solid 
state techniques: DSC, PXRD and FTIR. The results of the physical and 
mechanical properties of the ultrasonicated-PAR tablets, obtained by the 
direct application of ultrasound, indicated that the input power level, 
exposure time and use of binding agent, such as PEG 8000, were essential 
parameters to produce PAR monoclinic form tablets with desired mechanical 
characteristics for specific purposes. The HPLC analysis did not reveal any 
decomposition of PAR after ultrasonication. It can thus be reasonably 
assumed that the ultrasound method can be safely used for the compaction 
of PAR tablets. Also, the direct use of ultrasound could be used as scalable 
method for improving the tabletability of poorly compressible pharmaceutical 
drugs. 
  
 
 
 
 
 
 
 
 
CHAPTER 8 GLOBAL DISCUSSION 
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Previous chapters have shown results of co-crystals synthesis and 
paracetamol tabletability using solvent-free ultrasound approach. The overall 
findings will be discussed in the context of the original aims and previously 
reported work.  Melt-based methods for synthesising co-crystals, such as hot 
melt extrusion, typically require processing temperatures to be above the 
eutectic temperature of the physical mixture to optimise co-crystallisation. 
Additionally, high shear mixing zones under elevated temperatures in an 
extruder can cause degradation and polymorphic transformations to occur 
(Joshi, 2012). For this project, a solvent-free ultrasonic approach for co-
crystal synthesis was used.  This technique was applied with wide range of 
temperatures and different power levels. The effect of changing these 
parameters on the co-crystal yield was investigated. IBU-NIC co-crystal 
synthesis was attempted using temperatures of 50, 60 and 70°C and 
different power levels of 25, 50, 75 and 100% power. The sonication time 
was directly dependent on the processing temperature and power level used. 
As the set temperature and level of power were increased, a shorter 
sonication time was required for co-crystallisation to occur. For example, 
using the processing conditions of 70°C and 100% power required a 4 sec 
exposure time to obtain the pure co-crystal form. 
Using the solvent-free ultrasonic technique, CBZ-NIC co-crystal was also 
investigated to observe the effect of processing temperature and power level 
on the co-crystal yield. When using processing temperatures near to the 
eutectic point of the physical mixture and different levels of power; it was 
found that using a high power level and a processing temperature close to 
the eutectic point, required a shorter sonication time to generate pure CBZ-
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NIC co-crystal form I. In addition, CBZ-NIC was processed at room 
temperature and a constant maximum power of 100% was applied. It was 
found that under these conditions, with a long exposure time (80 sec), the 
resulting material was pure co-crystal with partial amorphisation. DSC and 
PXRD characterisation confirmed this (figures 5.25, 5.28). Although the 
samples were processed at room temperature, the excessive ultrasound 
energy led to high levels of collisions between molecules and between the 
molecules and the static cell wall, causing the amorphous phase to form. 
Using the same conditions, 5%, 10% and 15% water was added to equimolar 
CBZ-NIC physical mixture; the presence of water was successful in 
preventing amorphisation of the sample. Adding water also enhanced co-
crystal formation, produced a higher co-crystal yield (figure 5.31), and 
prevented degradation from occurring. These results suggested that the 
water acted as a medium for transmitting ultrasound energy as well as 
medium for crystal growth resulting in the better quality of co-crystals. Also, 
the localised temperature may have decreased in the presence of water (the 
measured final temperature was not above 57°C, table 5.4). 
In the case of CBZ DH, the attached water molecules did not appear to help 
the ultrasound energy to dissipate easily, this is because CBZ DH less dense 
material and porous appeared between particles and fluffy texture caused a 
mismatch of ultrasound of ultrasound energy dissipation. The co-crystal form 
I was obtained with a relatively high yield.  
Ultrasound can cause hot localised temperatures which may cause 
degradation to the material; it was therefore beneficial to add 5% water to 
both CBZ-NIC and CBZ-SAC samples. The localised temperature can cause 
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the water to evaporate and pure co-crystals can be obtained without 
amorphisation occurring, it was also observed that less degradation had 
occurred, compared with no addition of water.  
Additional ultrasound experiments were carried out with the inclusion of 5% 
PEG 8000 to CBZ-SAC. The high energy conditions induced melting and 
softening of the PEG molecules. This caused distribution of energy, which 
reduced shear, and increased the number of collision between molten 
molecules.  
Raman spectroscopy was used to investigate co-crystal distribution was in 
CBZ-SAC co-crystal tablets obtained with and without addition of 5% water. 
The results suggested that the ultrasound technique had a greater influence 
on co-crystal formation on the top surface compared to the bottom surface of 
the CBZ-SAC co-crystal tablets, especially when processed without the 
addition of water. 
In the presence of 5% water, Raman spectra indicated an increased 
presence of SAC and a decreased presence of co-crystal on the top surface. 
No co-crystal was present for the bottom surface of the tablet when different 
sonication times of 20, 40 and 60 sec were used (figures 6.23, 6.24 and 
6.25). The water was thought to hinder co-crystal formation on the top 
surface of the tablet because of a mismatch of the ultrasound energy 
dissipation. As the sonication time was increased, for both the top and 
bottom surfaces of the co-crystal tablets, the co-crystal peak intensity at 
1725 cm-1 increased, and the SAC peak intensity at 1697cm-1 decreased. 
This strongly suggests that gradual increases in sonication time may allow 
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increased co-crystal formation between CBZ and SAC and this was 
confirmed by using Raman spectroscopy as a qualitative characterisation 
technique. In future work, Raman spectroscopy could be used to quantify the 
co-crystal concentration on the top and bottom surfaces of the tablets. 
In recent years, solid state characterisation techniques combined with 
multivariate analysis and chemometrics have been used for pharmaceutical 
co-crystal quantification. PXRD and FTIR combined with multivariate 
analysis have been used to quantify carbamazepine form I, carbamazepine 
form III, saccharin and CBZ-SAC 1:1 co-crystals (Caliandro et al. 2013). 
Evaluation of the purity of IBU-NIC co-crystals, synthesised via solvent 
evaporation was done by using Raman, FTIR PXRD and DSC with partial 
least squares regression combined with chemometric pre-treatment. Raman 
spectroscopy was more accurate, than all other techniques previously 
discussed, and presented lower calibration and prediction error (Soares and 
Carneiro 2014). 
NIR can be used as an in-line PAT tool during the formation of IBU-NIC co-
crystals using hot melt extrusion (Kelly et al. 2012). Identification of key NIR 
bands shifts for carbamazepine-cinnamic co-crystals during extrusion 
succeeded in the determination of where co-crystals were forming (Moradiya 
et al. 2014). The NIR prediction models that were used in this study were 
developed to quantify IBU-NIC and CBZ-NIC co-crystals. The prediction  
models for both co-crystal pairs were made by taking averaged calibration 
and validation samples spectra and were used to compare the measured co-
crystal yield to the PLS regression predicted co-crystal yield (figure 4.12 and 
5.18). Chemometric pre-treatments were also applied with the SNV being 
 229 
 
important for reducing calibration and prediction error values. Different NIR 
regions were used to create the prediction models and the regions with the 
lowest error values were chosen (Table 4.2 and 5.2). To determine the purity 
of IBU-NIC co-crystals produced in this project, the wavenumber region of 
7450-7000 cm-1 provided lowest RMSEC (0.77%), RMSEP (0.95%) and 
correlation coefficient (0.9997) values. For quantifying CBZ-NIC co-crystals, 
the wavenumber region of 9000-8500 cm1- provided lowest RMSEC (1.23%), 
RMSEP (3.53%) and correlation coefficient (0.9992) values. The models 
helped to predict the co-crystal yield and can be used to optimise the 
process used to prepare the co-crystals (Wood et al. 2016). The predicted 
co-crystal yields were in-line with other characterisation techniques such as 
DSC and PXRD. For example, the produced IBU-NIC co-crystal (batch AJ), 
processed at 70°C, and exposed to 4 sec of maximum power 100%, was 
predicted to have 99% co-crystal purity using the prediction model. A single 
endothermic peak at 91°C confirmed this prediction result with DSC, and with 
PXRD, the co-crystal peak at 2θ=2.9° was observed. 
To investigate the change in colour of some samples, caused by using high 
ultrasound energy and high temperatures, HPLC was used. The HPLC 
technique was used to investigate any degradation that had occurred for 
starting materials such as IBU and CBZ. The HPLC results were supported 
by other characterisation techniques.   
In the context of pharmaceutical dosage forms, tablets are the most common 
form. Manufacturing tablets can be done using powder or granules, which 
are typically compressed by tablet punching machines. However, the 
materials must have good compressibility to be able to form a tablet (Mohan, 
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2012). Various pharmaceutical powders such as PAR form I and IBU 
experience plastic and elastic deformation during conventional compression 
techniques for preparing tablets. The application of HPU with compaction 
machines increases the success of obtaining tablets with good 
physicochemical properties. It was found that tablet strength increased when 
mixing IBU with microcrystalline cellulose (MCC). This was due to ultrasound 
induced bonding between IBU and MCC molecules, and an increase in the 
temperature of the tablet surface from 43 to 60°C. These conditions (particle 
rearrangement, interparticulate bonding and incorporation of API into 
thermoplastic material) can also lead to a decrease in the dissolution rate 
(Levina and Rubinstein, 2002).  
In this project the direct use of ultrasound on poorly compressible PAR form 
I, with the addition of a polymer, was found to be a suitable method to form 
PAR tablets. The PAR was processed at RT with addition of 5 and 10% w/w 
PEG 8000 in 2g and 3g tablets with different exposure times at 100% power. 
Although a small amount of PEG 8000 was used, the mechanism behind 
obtaining a suitably compressible tablet could be that PEG melt was 
distributed between the PAR crystals causing melt bonding. The measured 
final temperature and energy dissipation, when using 100% ultrasound 
power, were 26 to 35°C and 91 to 110W respectively (table 7.2). The results 
suggested that as the sonication time and added polymer were increased, 
the measured final temperature and dissipated energy also increased. The 
hardness, or crushing strength, was greater as the sonication time increased 
in both the 2g and 3g tablet batches. However, there was no considerable 
difference in batches which had 5 and 10% PEG 8000 (table 7.3).  
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Tabletting can be defined as a compaction process that involves two steps: 
compression and consolidation. Guaifenesin tablets, used for cough 
treatment, and produced by direct compression, had a greater mechanical 
strength, because at higher compaction forces, the air in the powder bed and 
voids in the individual particles were eliminated. The powder bed densified to 
a greater extent. These results were confirmed by a decrease in the release 
rate, median pore radius and porosity (Crowley et al. 2004). Similar results 
were obtained in this study. The ultrasound energy and mass of the 
ultrasound apparatus weight behave in similar way to the compaction 
process. The ultrasound reduced the bulk volume by eliminating voids and 
bringing particles into closer contact (compression action) and finally led to 
consolidation. This explains its lower dissolution rate compared to the PAR 
powder (figure 7.13 and 7.14). To conclude, a longer exposure time of 40sec 
at 100% power was enough to assure the bonding between PAR and PEG 
8000 molecules. The advantages of use of ultrasound in assisting 
compression of paracetamol were numerous. It was more economical (less 
time, less materials, fewer steps), avoided the use of pressure, heat and 
moisture (as used in direct compression and wet granulation methods). 
These studies have provided a sound understanding of material properties, 
processability, and performance of ultrasound on different co-crystal pairs 
and low compressible materials like paracetamol.  
Although the solvent-free ultrasonic approach, which was developed in this 
project, succeeded in producing different co-crystal pairs and good PAR 
tabletting, this apparatus faces many challenges. For example, it was not 
universal to meet the requirements of different applications. Therefore, the 
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majority of ultrasound experiments have been used at the laboratory scale, 
.i.e. it is difficult to scale up. There may be issues of noise irradiation and 
heating effects, particularly when used in larger scale applications.  Erosion 
of the tip surface of the transducer, or immersed horn, during the processing 
of solids or bends with small amounts of solvents could also be a problem. 
Th    os o  c   b  u  vo d b  ,   d w      duc   h      sduc  ’s   f  sp  . 
The erosion of the probe and the degradation that was caused to the 
products could be avoided in future experiments by covering the static cell 
with heat resistant material.  
The challenges of this technique which have been discussed must be 
overcome before it can be introduced to industry. However, if they can be 
solved, this technology can play a key role in a continuous process for the 
preparation of co-crystals and tablet manufacturing. It could be used in future 
to assist the solvent-free continuous co-crystallisation process, using HME, 
for the production of co-crystals by applying ultrasound at the end of 
extruder. Different parameters such as sonication time, temperature, levels 
of power would have a great influence on the co-crystal yield. This technique 
may also allow for the processing temperature, residence time, shear 
intensity and screw speed to be decreased during HME.  
  
 
 
 
 
 
 
 
 
CHAPTER 9 CONCLUSIONS 
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The aims of the project were to explore the synthesis of co-crystals by using 
a novel solvent-free ultrasonic approach, developing NIR calibration models 
for determining the purity of co-crystals and use of ultrasound to improve 
tabletability of paracetamol. From the experimental work performed, the 
following conclusions could be drawn. 
9.1 Conclusions: 
 A solvent-free ultrasonic co-crystallisation approach was developed, 
and was used to successfully form IBU-NIC, CBZ-NIC and CBZ-SAC 
co-crystals. 
  Different parameters such as temperature, sonication time and 
applied power level were used to optimise the process.  For example 
at 100% power and set processing temperature at 70°C, shorter 
sonication time was required to produce pure IBU-NIC co-crystals. 
 Additives such as water and PEG influenced the rate of co-crystal 
formation and co-crystal stability. Water aided ultrasonic energy 
dissipation in CBZ-NIC co-crystals and inhibited amorphisation and 
degradation. 
 Accurate NIR prediction models were developed for IBU-NIC and 
CBZ-NIC pairs. These were used to determine the purity of the co-
crystals made using the solvent-free ultrasonic approach, which 
enabled monitoring, optimisation and understanding of the co-
crystallisation process. 
 Raman spectroscopy succeeded in detecting CBZ-SAC co-crystals 
formed on the top and bottom surfaces of CBZ-SAC tablets. On both 
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tablet surfaces, the co-crystal yield increased as the sonication time 
was increased from 20 to 60 sec. Co-crystals were found to form more 
readily on the upper surface of the tablets, in contact with the 
sonotrode tip. 
 The ultrasonic approach was also found to be more economical (less 
time, space, materials, personnel, fewer steps) compared to existing 
methods for producing paracetamol tablets. Hardness increased as 
the applied power, sonication time and % of polymer added were 
increased. Drug release of the sonicated paracetamol tablets 
decreased as the sonication time was increased.  
 The solvent-free ultrasonic approach shows good potential for use in 
industrial applications. It is a green technology, due to no solvents 
being required, and was found to be an effective in improving co-
crystal yield and paracetamol tabletability. 
9.2 Future work 
Twin screw extrusion has been used as a solvent-free continuous co-
crystallisation approach for pharmaceutical co-crystals. The main limitation of 
this technology is the harsh processing conditions, which includes high shear 
and high temperatures, restricting the processing of thermolabile drugs, such 
as carbamazepine. Ultrasound assisted extrusion is a novel concept. Future 
research into pharmaceutical co-crystals will focus on developing solvent-
free, ultrasound assisted, twin screw extrusion, for preparing pharmaceutical 
co-crystals. The following ideas could be followed to develop this novel 
technique:   
 235 
 
 To compare properties, such as dissolution rate and mechanical 
strength, of pharmaceutical co-crystals prepared using extrusion and 
ultrasound assisted extrusion. 
 To examine the effect of process variables such as temperature, 
sonication time, and power rate on the co-crystal yield.  
  To develop and monitor the effect of ultrasound assisted extrusion for 
the preparation of solid dispersions of drugs or co-crystals dispersed 
within polymers.  
The following ideas are suggestions for improving the solvent-free ultrasound 
approach used for synthesising pharmaceutical co-crystals:  
 All experiments could be repeated using a transparent static cell to 
visualise the effect of ultrasound and to understand the effect of 
ultrasound on solid state materials.  
 A prediction model to determine CBZ-SAC co-crystal concentration on 
the top and bottom surfaces of tablets could be developed. The 
prediction model could then be compared to the Raman spectroscopy 
and DSC characterisation methods. 
Future work in the area of ultrasound for poorly compressible materials will 
be focused on use of different polymers and process parameters. 
Finally, it would be useful to design a scalable continuous ultrasound 
technique, simultaneously using ultrasound during mixing, HME and press 
tabletting. This would encourage the use of this technology in the 
pharmaceutical industry. 
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Table A 1. Summary of IBU-NIC co-crystals results processed at different process parameters with using solvent-free ultrasound 
Power level 
% of max 
Set temp 
(°C) 
Batch code Exposure 
time (sec) 
Actual 
Temp(°C) 
Average 
power input 
(w) 
Total 
energy 
(KJ) 
DSC 
results 
PXRD 
results 
% NIR 
 
 
 
 
25% 
 
50°C 
A 200 58 47 9.4 ± ± 54 
B 300 56 37 11.1 ± ± 57 
C 400 60 37 14.8 ± ± 60 
60°C D 400 61 35 14 ± ± 61 
 
 
70°C 
E 50 76 32 1.6 ± ± 64 
F 70 77 43 3.0 ± ± 74 
G 90 79 39 3.5 ± ± 83 
H 200 79 41 8.2 ± ± 94 
I 300 77 37 11.1 ± ± 95 
 
 
 
 
 
50% 
 
50°C 
J 50 98 158 7.9 ± ± 93 
K 60 104 171 10.3 ± ± 94 
L 80 109 200 16 √ √ 98 
 
60°C 
M 10 70 112 1.1 ± ± 79 
N 15 74 116 1.7 ± ± 82 
O 20 81 127 2.5 ± ± 98 
P 30 91 133 4.0 √ √ 98 
 
70°C 
Q 5 73 106 0.5 ± ± 76 
R 10 80 113 1.1 ± ± 90 
S 15 90 134 2.0 √ √ 98 
 
 
 
 
 
75% 
 
 
50°C 
T 5 52 102 0.5 ± ± 77 
U 10 67 150 1.5 ± ± 90 
V 15 87 184 1.3 ± ± 98 
W 30 97 207 6.2 √ √ 99 
60°C 
 
X 5 62 124 0.6 ± ± 55 
Y 10 89 198 2.0 √ √ 98 
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 Z 15 76 144 0.7 ± ± 57 
AA 5 91 172 0.2 √ √ 98 
 
 
 
 
 
100% 
70°C 
 
50°C 
AB 10 52 95 0.5 ± ± 85 
AC 5 52 95 0.5 ± ± 92 
AD 10 66 149 1.5 ± ± 98 
 AE 15 77 150 2.3 √ √ 98 
 
60°C 
AF 5 63 95 0.5 ± ± 83 
AG 10 76 155 1.6 √ √ 99 
 
70°C 
AH 1 68 59 0.06 ± ± 93 
AI 2 72 88 0.09 ± ± 94 
AJ 4 74 100 0.1 √ √ 99 
 
Table A 2. Summary of CBZ-NIC co-crystals results using solvent-free ultrasound processed at 100°C with different levels of power 
Component Power 
level 
Set 
Temp 
(°C) 
Batch 
code 
Exposure 
time 
(sec) 
Actual 
Temp (0C) 
Power 
input 
(W) 
Total 
Energy 
(KJ) 
DSC 
results 
PXRD 
results 
% 
Purity 
NIR 
Degradation 
HPLC 
 
 
 
 
 
CBZ:NIC 1:1 
PM 
 
25% 
 
 
 
 
 
100 
A 70 104 50 0.3 ± ± 58 ˉˉ ˉˉ 
B 150 110 40 6 ± ± 65 ˉˉ ˉˉ 
C 300 110 35 11 ± ± 75 ˉˉ ˉˉ 
 
50% 
D 5 104 130 0.6 ± ± 66 ˉˉ ˉˉ 
E 10 110 154 1.5 ± ± 93 ˉˉ ˉˉ 
F 20 150 200 4 √ √ 95 ˉˉ ˉˉ 
G 50 162 220 11 √ √ 95 + + 
 
75% 
H 5 105 120 0.6 ± ± 71 ˉˉ ˉˉ 
I 10 110 158 1.6 √ √ 94 ˉˉ ˉˉ 
J 15 143 220 3.3 √ √ 93 ˉˉ ˉˉ 
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100% K 5 105 130 0.6 ± ± 71 ˉˉ ˉˉ 
L 10 112 156 1.6 √ √ 93 ˉˉ ˉˉ 
 
 
Table A 3. Summary of CBZ-NIC co-crystals with and without addition of water and CBZ DH-NIC co-crystals results using solvent-free 
ultrasound processed at room temperature and 100% power at different sonication times. 
Component Set Temp 
(°C) 
Power 
Level 
(% of 
max) 
Batch 
code 
Exposure 
Time 
(sec) 
Actual 
Temp 
(°C) 
Power 
Input 
(W) 
Total 
Energy 
(KJ) 
DSC results PXRD 
results 
% 
Purity 
NIR 
Degradation 
HPLC 
results 
 
 
CBZ-NIC1:1 
PM 
 
 
 
 
 
 
 
 
 
 
 
 
A 20 22 87 1.7 ± ± 57  -- -- 
B 40 32 107 4 ± ± 84 -- -- 
C 60 63 127 7.6 ± ± 94 -- -- 
D 80 74 137 11 ± ±  -- -- 
E 100 84 160 16 √+ mo phous √+ mo phous  -- -- 
CBZ-NIC_5% F 20 23 108 2.2 ± + water ± + water 94 -- -- 
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water  
 
RT 
 
 
 
100% 
G 40 29 125 5 ±  ±  97 -- -- 
H 60 44 140 8.4 ± ± 94 -- -- 
CBZ-
NIC_10% 
water 
I 20 22 116 2.3 ± + water ± + water 94 -- -- 
J 40 28 125 5 √ √ 98 -- -- 
K 60 52 138 8.3 √ √ 98 -- -- 
CBZ-
NIC_15% 
water 
L 20 24 128 2.6 ± + water ± + water 94 -- -- 
M 40 45 155 6.2 √ + water √ + water 98 -- -- 
N 60 57 160 9.6 √+ water √+ water 98 -- -- 
 
 
CBZ DH-NIC 
1:1 PM 
O 20 20 90 1.8 ± + water ± + water 96 -- -- 
P 40 24 97 3.9 ± ± 97 -- -- 
Q 60 31 108 6.5 ± ± 94 -- -- 
R 80 39 120 9.6 ± ± 98 -- -- 
S 100 42 145 14.5 √ √ 95 -- -- 
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Table A 4. Summary of CBZ-SAC co-crystals with and without addition of 5% water and 5% PEG 8000 processed at RT and 100% power  
 
Components Batch 
code 
Exposure Time 
(sec) 
Actual Temp 
(°C) 
Measured 
Power (W) 
Total 
Energy 
(KJ) 
DSC 
results 
PXRD 
results 
FTIR 
results 
Degradation 
HPLC 
results 
CBZ-SAC 1:1 
PM 
A 20 28 94 1.9  ± ± + + 
B 40 32 129 5.2 Amorphous 
+ √ 
Amorphous 
+ √ 
√ + + 
C 60 42 134 8 Amorphous 
+ √ 
Amorphous 
+ √ 
√ + + 
CBZ-SAC-5% 
water 
D 20 30 102 2 Water + ± ± Water 
+√ 
-- -- 
E 40 30 98 3.9 Water + ± ± Water 
+√ 
-- -- 
F 60 26 95 5.7 Water + ± √ Water 
+√ 
-- -- 
CBZ-SAC-5% 
PEG 8000 
G 20 29 92 1.8 PEG + ± PEG + ± ± -- -- 
H 40 30 115 4.6 PEG + ± PEG + ± √ -- -- 
I 60 33 126 7.6 PEG + √ PEG + ± √ -- -- 
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Table A 5. Summary of CBZ-SAC co-crystals tablets (bottom and top surfaces) results with and without addition of 5% water processed at RT 
and 100% power   
Component Batches Raman 
results 
PXRD results DSC results Degradation 
% iminostilbene 
 
 
CBZ-SAC PM 1:1 
20s – top surface CC√ +SAC √ √ -- -- 
20s – bottom surface SAC ± ± -- -- 
40s – top surface CC √ √ -- -- 
40s – bottom surface SAC ± ± -- -- 
60s – top surface CC Amorphous + √ Amorphous + √ -- -- 
60s – bottom surface SAC ± ± -- -- 
 
 
 
 
CBZ-SAC PM – 5% water 
20s – top surface – 5% water CC + SAC√ ± ± -- -- 
20s – bottom surface – 5% water SAC ± ± -- -- 
40s – top surface – 5% water CC + SAC ± ± -- -- 
40s – bottom surface – 5% water SAC ± ± -- -- 
60s – top surface – 5% water CC + SAC√ ± ± -- -- 
60s – bottom surface – 5% water SAC ± ± -- -- 
 
± Impure co-crystal 
√ Pu   co-crystal 
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                    Figure A1. NIR Second Derivatives of IBU-NIC calibration curve in the region between (7000-7500 cm-1) 
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Figure A2. NIR Second Derivatives of CBZ-NIC calibration curve in the region between (8500-9000 cm-1) 
 
